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Abstract
The present work contributes to the field of process development and optimization for
the manufacturing of recombinant proteins. Recombinant proteins are biological macro-
molecules, which are produced using genetically modified organisms (GMOs). In addition
to the food industry and for the synthesis of organic compounds, industrially produced
proteins are mainly used in the field of medicine. There, they make a decisive contribution
to the diagnosis, prevention and treatment of various human diseases. The production
of protein-based drugs (biopharmaceuticals) and their provision in a stable and bioavail-
able dosage form (formulation) are a challenge due to the size and complexity of these
molecules. On the way to the final drug product, the target protein undergoes a long and
complex processing chain consisting of GMO cultivation (upstream processing), purifi-
cation operations (downstream processing) and formulation steps. The reaction medium
for the entire manufacturing process is mainly based on aqueous solutions. Some of the
process steps used require extreme conditions such as unphysiological salt concentrations
(e.g. in chromatographic purification) or acidic pH values (e.g. virus inactivation); all of
which are potential stress factors for the protein integrity. Resulting irreversible changes
in protein structure and physical instabilities, e.g. aggregation can affect both drug safety
and efficacy. In order to ensure the product quality during the entire manufacturing pro-
cess, the development of strategies for the stabilization of proteins in aqueous solutions
is of paramount importance. From an economic perspective, short development times are
desirable in order to reduce the ‘time to market’ of a drug product. Standardized pro-
cedures are of great interest for shortening the development times of stabilized protein
products and are therefore the subject of this dissertation.
The aim of this work was the development and optimization of methods for the eval-
uation and implementation of stabilization strategies for proteins in aqueous solutions.
The work is composed of an introduction and motivation, followed by six publications/
manuscripts, in which different stabilization strategies for proteins as well as their pro-
cessing are investigated. Due to the desire for fast, reproducible and cost-efficient meth-
ods, high-throughput screenings (HTS) as well as computer-based (in silico) methods
have been used. In case of HTS, robot-based pipetting platforms were used for the auto-
mated and parallelized experimentation in microlitre scale. This approach generates large
I
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volumes of data and consequently highly sophisticated analytical methods that simulta-
neously provide a sufficiently high sample throughput and data quality are required. For
the in silico process development, mechanistic chromatography models were used and
solved using numerical methods. All methods presented in this work have been devel-
oped using model proteins.
In the first publication1, the effect of solution additives on the conformation and the
aggregation behavior of proteins is examined. For this purpose, an automated high-
throughput method was established for the generation of ternary phase diagrams con-
sisting of protein, precipitant and the respective additive. For the analysis of the protein
conformation, Fourier-transformed-infrared (FT-IR) spectroscopy was applied. FT-IR
can provide insight into the secondary structure of the measured protein sample. Glyc-
erol, glycine and PEG 1000 (polyethylene glycol having a molecular weight of 1 kDa)
were used as sample additives. The results of this study indicate that the additives had
a decisive influence on the process-relevant parameters conformation, solubility and ag-
gregation behavior of the investigated protein lysozyme. The additive effect was found
to depend on the pH value and the associated conformational stability of lysozyme. At
pH values with low conformational protein stability in the unmodified system, glycine
enhanced the unfolding and aggregation of the protein, while PEG 1000 and glycerol
increased the conformational stability of the protein and altered the protein aggregation
behavior. However, no change in the protein solubility was observed. For pH values where
the protein conformation was stable in the unmodified system, the investigated additives
had no effect on the protein structure, but they affected the solubility, phase transition,
crystal size, and morphology. In summary, the presented method provides an efficient
tool for selecting suitable solution additives to prevent unwanted phase transitions and
instabilities.
The observed stabilization of lysozyme by solution additive initiated the investigation on
how the covalent attachment of non-polypeptides to the protein (protein conjugation)
influences its aggregation behavior and solubility. The covalent linkage of proteins and
synthetic materials produces novel hybrid molecules with combined properties of both
reactants. In the pharmaceutical industry, polyethylene glycol (PEG) is state of the art
for protein conjugation. The currently used reaction mechanisms utilize naturally occur-
ring binding sites (amino acids) on the protein surface. Since the individual amino acids
occur repeatedly in a protein, these approaches result in heterogeneous product mixtures
of proteins with different number (conjugation degree) and position (isoforms) of bound
polymers. For a fast and material-efficient identification of the different conjugate species
1Galm et al., Int. J. Pharm., 494/1 (2015): 370-380.
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and reaction monitoring a fast and robust analytical method is required.
In the second publication2, the development of an analytical method for quantifying the
composition of heterogeneous PEG-conjuagte mixtures is presented. The basis of this
method is a microfluidic-based capillary gel electrophoresis (CGE), which was combined
with a precipitation step to conserve the sample composition for structurally unstable
proteins. The method was validated using the example of proteases, which are susceptible
to autocatalysis. This method was found to be highly effective for large data sets as it
provides a low sample consumption of only 2 µL, an analysis time of 40 s per sample,
a high resolution allowing for peak baseline separation between conjugates with varying
conjugation degree and a high sensitivity down to 0.1 mg/mL of PEGylated protein.
In the third publication3, the influence of covalently bound PEG on the phase behav-
ior, the solubility and the protein conformation of lysozyme was investigated. For this
purpose, the automated high-throughput method for the preparation of protein phase
diagrams in microbatch experiments from publication 1 was adapted for the application
to protein conjugates. The PEG molecular weight (2 kDa, 5 kDa and 10 kDa) and the
number of bound PEG molecules (PEGylation degree) were varied as influencing pa-
rameters. Higher PEG molecular weights and PEGylation degrees resulted in increased
shielding of the protein properties. This resulted in an increase in the conformational
protein stability as well as the solubility and a simultaneous decrease in the residual
activities of the conjugates. The methodology used is extremely useful for fine-tuning
PEG molecular weights and PEGylation degree with respect to the conjugate properties
required for specific applications.
While PEG remains useful for the stabilization of therapeutic proteins, some limitations
in its clinical use including antibody formation against PEG (anti-PEG), hypersensitivity
and vacuolation in various tissues upon repeated exposure have begun to emerge driving
the development of alternatives. In addition, the synthesis of activated PEGs with nar-
row dispersity is complex and therefore expensive. The development of protein conjugates
with lower-cost polymers having similar advantages as PEG would increases the avail-
ability of stable biopharmaceuticals to a broader mass of the population. For this reason,
the synthesis of two alternative, biocompatible polymers (poly-(4-acryloylmorpholine) =
PNAM and poly-(oligoethylene glycol methacrylate) = POEGMA) and their effect on
lysozyme stability are described in manuscript 44. An increase in protein solubility was
achieved for all investigated polymers. Compared to PEG, however, higher molecular
2Morgenstern et al., J. Chrom. A, 1462 (2016): 153-164.
3Morgenstern et al., Int. J. Pharm., 519/1-2 (2017): 408-417.
4in preparation: Stability Assessment of Protein-Polymer Conjugates: Alternative Polymers to Polyethy-
lene Glycol.
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weight polymers or conjugation degrees were required to achieve a comparable effect
on solubility, which unfortunately entailed a significant reduction of residual activity.
Nonetheless, a positive result of this study was the uncomplicated transferability of the
methods for analysis, purification and stability assessment developed using PEG enabling
the search for more effective and economically viable alternatives.
Due to the strong differences in the physico-chemical properties of protein conjugates
with a varying degree of conjugation, a separation strategie for the individual species is
expedient. Ion-exchange chromatography (IEX) is among the most important purifica-
tion methods for protein conjugates. The separation principle in IEX is based on different
transport and adsorption properties of the conjugates within the chromatographic col-
umn. Up to now, IEX process design and optimization are mainly performed by empiri-
cal approaches, which are time and material consuming. In publication 55 an alternative
approach for IEX process development is presented which is based on the in silico deter-
mination of mass transfer and adsorption parameters needing solely a few experiments.
In addition to the use as solution additive and for protein conjugation, PEG can also
be functionalized in such a way that a crosslinking to three-dimensional networks is pos-
sible. Due to the hydrophilic character of PEG, these networks swell to a multiple of
their volume in an aqueous environment without dissolving and are therefore referred
to as hydrogels. Due to their high water content and their porous structure, hydrogels
offer a physico-chemical similarity to the natural extracellular matrix and provide an
mechanical support for incorporated proteins. Both protein stability and release from
hydrogels are influenced by various parameters including the mode of crosslinking, the
chemistry and molecular weight of the polymer, pH and ionic strength of the surround-
ing solution, and specific protein properties such as size, three-dimensional structure
and surface characteristics. Since the large number and interaction of these parameters
complicate a mechanistic prediction of protein-hydrogel interactions, a high-throughput
method for their experimental investigation has been established in the last manuscript6.
The hydrogels were cross-linked to high-throughput compatible structures by means of
3D printing and then screened for their protein uptake and release on an automated
pipetting platform. Polyethylene glycol diacrylate (PEG-DA) was used as a polymer and
copolymerized with acrylic acid for further functionalization of the hydrogel. In a case
study with lysozyme, the data generated by the presented approach was comparable to
literature data for the used materials. Compared to conventional methods, however, the
5Morgenstern et al., Biotechnology Journal, accepted (2017), doi: 10.1002/biot.201700255.
6in preparation: Assessment of Hydrogels for Biopharmaceutical Purposes Using a Combination of 3D
Printing and High-Throughput Screening.
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screening process has been significantly accelerated.
In summary, process development for the stabilization of pharmaceutical proteins as well
as their encapsulation into polymeric hydrogels can be significantly accelerated and sim-
plified by the application of the presented methods. For the development and validation of
these methods different model proteins were used in this thesis. However, these strategies
can readily be transferred to other molecules due to their automation and the reduction
of the necessary sample material.
V

German Abstract: Zusammenfassung
Die vorliegende Arbeit ist in das Themengebiet der Verfahrensentwicklung und -optimier-
ung fu¨r die Prozessierung von rekombinanten Proteinen einzuordnen. Rekombinante Pro-
teine sind biologische Makromoleku¨le, welche mit Hilfe von gentechnisch vera¨nderten Or-
ganismen (genetically modified organism - GMO) hergestellt werden. Neben der Anwen-
dung in der Lebensmittelindustrie und fu¨r die Synthese von organischen Verbindungen
werden industriell hergestellte Proteine vor allem im Bereich der Medizin eingesetzt. Dort
leisten sie einen wichtigen Beitrag zur Diagnose, Pra¨vention und Therapie einer Vielzahl
menschlicher Krankheiten. Die Produktion von Proteinwirkstoffen (Biopharmazeutika)
und deren Bereitstellung in einer stabilen und fu¨r den Ko¨rper verfu¨gbaren Darreichungs-
form (Formulierung) stellen aufgrund der Gro¨ße und Komplexita¨t der Moleku¨le eine
Herausforderung dar. Auf dem Weg zum fertigen Arzneimittel durchla¨uft das Zielprotein
von der Kultivierung der GMOs (Upstream) u¨ber diverse Reinigungsschritte (Down-
stream) bis hin zur Formulierung eine lange und komplexe Prozesskette. Das Reaktions-
medium fu¨r den gesamten Herstellungsprozess basiert dabei hauptsa¨chlich auf wa¨ssrigen
Lo¨sungen. Manche der eingesetzten Prozessschritte erfordern extreme Bedingungen, wie
unphysiologische Salzkonzentrationen (z.B. bei der chromatographischen Aufreinigung)
oder saure pH-Werte (z.B. bei der Virus-Inaktivierung), welche potenzielle Stressfak-
toren fu¨r die Proteinintegrita¨t darstellen. Daraus resultierende irreversible Vera¨nderun-
gen der Proteinstruktur und physikalische Instabilita¨ten, wie z.B. Aggregation, ko¨nnen
sowohl die Arzneimittelsicherheit als auch die -wirksamkeit beeintra¨chtigen. Um die
notwendige Produktqualita¨t wa¨hrend des gesamten Herstellungsprozesses zu gewa¨hrleis-
ten, ist die Entwicklung von Strategien zur Stabilisierung von Proteinen in wa¨ssrigen
Lo¨sungen von ho¨chster Wichtigkeit. Aus o¨konomischer Perspektive sind geringe Entwick-
lungszeiten wu¨nschenswert, um die Markteinfu¨hrung eines Arzneimittels zu beschleuni-
gen. Die Etablierung standardisierter Vorgehensweisen in der Prozessentwicklung steht in
engem Zusammenhang mit der Verku¨rzung der Entwicklungszeiten und ist daher Gegen-
stand dieser Dissertation.
Das Ziel dieser Arbeit war die Entwicklung und Optimierung von Methoden zur Be-
wertung und prozesstechnischen Umsetzung von Stabilisierungsstrategien fu¨r Proteine
in wa¨ssrigen Lo¨sungen. Die Arbeit besteht aus einer Einleitung und Motivation, gefolgt
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von sechs Publikationen/Manuskripten, in welchen unterschiedliche Stabilisierungsstrate-
gien fu¨r Proteine adressiert werden. Resultierend aus dem Streben nach schnellen, repro-
duzierbaren und kosteneffizienten Methoden wurden in dieser Arbeit sowohl Hochdurch-
satzverfahren (high-througput screenings - HTS) als auch computerbasierte (in silico)
Verfahren eingesetzt. Im Falle von HTS wurden robotergestu¨tzte Pipettierplattformen
fu¨r die automatisierte und parallelisierte Durchfu¨hrung von Experimenten im Mikroliter-
maßstab eingesetzt. Durch die Erzeugung großer Datenmengen erfordert diese Herange-
hensweise Analytikmethoden, die gleichzeitig einen ausreichend hohen Probendurchsatz
und eine ausreichend hohe Datenqualita¨t liefern. Bei der in silico-Prozessentwicklung
wurden mechanistische Modelle fu¨r physikalische Prozesse verwendet und mit Hilfe von
numerischen Methoden gelo¨st.
In der ersten Publikation1 wurde die Wirkung von Lo¨sungsmitteladditiven auf die Konfor-
mation und das Aggregationsverhalten von Lysozym aus Hu¨hnereiweiß untersucht. Dazu
wurde ein automatisiertes Hochdurchsatzverfahren zur Erstellung terna¨rer Phasendia-
gramme, bestehend aus Protein, Fa¨llungsmittel (Pra¨zipitant) und dem jeweiligen Addi-
tiv etabliert. Fu¨r die Analyse der Proteinkonformation wurde Fourier-Transformations-
Infrarotspektroskopie (FT-IR) angewandt, welche basierend auf den Schwingungen des
Proteinru¨ckgrats Einblick in die Sekunda¨rstruktur der gemessenen Proteinprobe liefert.
Als Additiv wurden exemplarisch Glycerin, Glycin und PEG 1000 (Polyethylenglykol)
mit einem Molekulargeicht von 1 kDa) verwendet. Die Ergebnisse dieser Studie zeigten
einen deutlichen Einfluss der Lo¨sungsmitteladditive auf prozessrelevante Parameter wie
Konformation, Lo¨slichkeit und Aggregationsverhalten von Lysozym. Es wurde ein Zusam-
menhang zwischen der Wirkung der Additive sowie dem pH-Wert und der damit ver-
bundenen konformellen Stabilita¨t von Lysozym hergestellt. Bei pH-Werten mit niedriger
Stabilita¨t der Proteinkonformation im unmodifizierten System versta¨rkte Glycin die Ent-
faltung und Aggregation des Proteins, wohingegen PEG 1000 und Glycerin die Stabilita¨t
der Proteinkonformation erho¨hten und das Aggregationsverhalten vera¨nderten. Es wurde
jedoch keine Vera¨nderung der Proteinlo¨slichkeit beobachtet. Fu¨r pH-Werte, bei denen das
Protein im unmodifizierten System konformell stabil war, hatten die untersuchten Ad-
ditive keinen Einfluss auf die Proteinstruktur, beeinflussten jedoch die Lo¨slichkeit, die
auftretenden Phasenu¨berga¨nge und Kristallgro¨ße sowie -morphologie. Zusammenfassend
ist festzustellen, dass die vorgestellte Methode ein effizientes Werkzeug zur Auswahl
geeigneter Lo¨sungsmitteladditive bietet, um unerwu¨nschte Phasenu¨berga¨nge und Insta-
bilita¨ten zu vermeiden.
Die beobachtete Stabilisierung von Lysozym durch Lo¨sungsmitteladditive initiierte die
1Galm et al., Int. J. Pharm., 494/1 (2015): 370-380.
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Untersuchung, wie die kovalenten Bindung von Nichtprotein-Moleku¨l an das Protein (Pro-
teinkonjugation) das Aggregationsverhalten und die Lo¨slichkeit beeinflusst. Als Nicht-
protein-Moleku¨le wurden in dieser Arbeit synthetische Polymere untersucht. Die ko-
valente Verknu¨pfung von Proteinen und synthetischen Materialien erzeugt neuartige
Hybridmoleku¨le mit einer Kombination der Eigenschaften beider Reaktanten. In der
pharmazeutischen Industrie ist Polyethylenglycol (PEG) Stand der Technik fu¨r die Pro-
teinkonjugation. Die derzeit verwendeten Reaktionsmechanismen nutzen die Seitenketten
natu¨rlich vorkommender Aminosa¨uren auf der Proteinoberfla¨che als Bindungsstellen. Da
die einzelnen Aminosa¨uren wiederholt in einem Protein auftreten, entstehen durch diesen
Ansatz heterogene Reaktionsgemische aus verschiedenen Produkten, die sich in der An-
zahl der gebundenen Polymer-Moleku¨le (Konjugationsgrad) und Position (Isoformen)
unterscheiden. Fu¨r eine schnelle und effiziente Identifizierung der unterschiedlichen Kon-
jugatspezies und fu¨r eine U¨berwachung der Konjugationsreaktion ist eine schnelle und
robuste Analytikmethode unabdingbar.
In der zweiten Publikation2 wird die Entwicklung eines analytischen Verfahrens zur Quan-
tifizierung der Zusammensetzung von heterogenen PEG-Konjugat-Gemischen vorgestellt.
Grundlage dieser Methode ist eine Mikrofluidik-basierte Kapillargelelektrophorese, welche
fu¨r die Analyse von strukturell instabilen Proteinen zusa¨tzlich mit einem Pra¨zipita-
tionsschritt zum Erhalt der Probenzusammensetzung kombiniert wurde. Die Methode
wurde am Fallbeispiel von Proteasen validiert, welche anfa¨llig fu¨r Autokatalyse sind. Die
Methodik zeichnet sich durch einen geringen Probenverbrauch von nur 2 µL, eine Ana-
lysezeit von 40 s pro Probe, eine hohe Auflo¨sung zwischen Konjugaten mit variierendem
Konjugationsgrad und eine hohe Sensitivita¨t von bis zu 0,1 mg/mL PEGyliertem Protein
aus. Durch diese Vorteile erwies sie sich als sehr effektiv fu¨r große Datensa¨tze.
In der dritten Publikation3 wurde der Einfluss von kovalent gebundenem PEG auf das
Phasenverhalten, die Lo¨slichkeit und die Konformation von Lysozym untersucht. Hierfu¨r
wurde das automatisierte Hochdurchsatzverfahren zur Erstellung von Protein-Phasen-
diagrammen in Microbatch-Experimenten aus Publikation 1 fu¨r die Anwendung auf Pro-
teinkonjuagte adaptiert. Als Einflussgro¨ßen wurden das PEG-Molekulargewicht (2 kDa,
5 kDa und 10 kDa) und die Anzahl der gebundenen PEG-Moleku¨len (PEGylierungsgrad)
variiert. Ho¨here PEG-Molekulargewichte und PEGylierungsgrade resultierten in einer
versta¨rkten Abschirmung der Proteineigenschaften. Daraus ergaben sich eine Erho¨hung
der konformellen Proteinstabilita¨t sowie der Lo¨slichkeit und eine gleichzeitige Abnahme
der Restaktivita¨t der Konjugate. Die vorgestellte Methodik eigent sich fu¨r die Feinab-
2Morgenstern et al., J. Chrom. A, 1462 (2016): 153-164.
3Morgenstern et al., Int. J. Pharm., 519/1-2 (2017): 408-417.
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stimmung von PEG-Molekulargewicht und PEGylierungsgrad hinsichtlich der Konjugat-
Eigenschaften fu¨r spezifische Anwendungen.
Neben den vielen Vorteilen der Protein-PEGylierung treten in der klinischen Anwen-
dung einige Nachteile wie allergische Reaktionen und Immunantworten auf, welche die
Entwicklung von alternativen Polymeren vorantreiben. Daru¨ber hinaus ist die Synthese
von aktivierten PEGs mit geringer Dispersita¨t komplex und daher teuer. Die Entwicklung
von Proteinkonjugaten mit kosteneffizienteren Polymeren, welche die positiven Wirkun-
gen von PEG reproduzieren, wu¨rde die Verfu¨gbarkeit von stabilen Biopharmazeutika
fu¨r die Masse der Bevo¨lkerung erho¨hen. Aus diesen Gru¨nden wurde in Manuskript 44
die Synthese zweier alternativer, biokompatibler Polymere (Poly-(4-acryloylmorpholin)
= PNAM und Poly-(oligoethylenglykolmethacrylat) = POEGMA) und deren Wirkung
auf die Lysozymstabilita¨t untersucht. Durch beide Polymere konnte eine Erho¨hung der
Proteinlo¨slichkeit erzielt werden. Im Vergleich zu PEG mussten jedoch Polymere mit
ho¨herem Molekulargewicht oder Konjugationsgrade eingesetzt werden, um eine vergleich-
bare Wirkung auf die Lo¨slichkeit zu erzielen. Dies hatte eine signifikante Reduzierung
der Restaktivita¨t zur Folge. Ein positives Ergebnis dieser Studie war jedoch die ein-
fache U¨bertragbarkeit der mit PEG entwickelten Methoden zur Analyse, Reinigung und
Stabilita¨tsbewertung. Dadurch wird die Suche nach effektiveren und kostengu¨nstigeren
Polymeren fu¨r die Proteinkonjugation vereinfacht.
Aufgrund der starken Unterschiede in den physikalisch-chemischen Eigenschaften von
Proteinkonjugaten mit variierendem Konjugationsgrad ist deren Auftrennung sinnvoll.
Ionenaustausch-Chromatographie (IEX) za¨hlt zu den wichtigsten Aufreinigungsmetho-
den fu¨r Protein-Konjugate. Das Trennprinzip beruht dabei auf unterschiedlichen Trans-
port- und Adsorptionseigenschaften der Konjugate innerhalb der chromatographischen
Sa¨ule. Die Auslegung der Trennprozesse erfolgt noch immer hauptsa¨chlich durch em-
pirische Ansa¨tze, die zeitaufwendig sind und mit einem hohen Verbrauch an Probenma-
terial einhergehen. In Publikation 55 wird ein alternativer Ansatz zur Prozessauslegung
auf Basis der in silico Berechnung von Stoffu¨bergangs- und Adsorptionsparametern an-
hand weniger Experimente vorgestellt.
Neben der Verwendung als Lo¨sungsmitteladditiv und zur Proteinkonjugation kann PEG
auch derartig funktionalisiert werden, dass seine Vernetzung zu dreidimensionalen Netz-
werken mo¨glich ist. In wa¨ssriger Umgebung quellen diese Netzwerke zu einem Vielfachen
ihres Volumens auf und werden daher auch als Hydrogele bezeichnet. Aufgrund ihres
4in preparation: Stability Assessment of Protein-Polymer Conjugates: Alternative Polymers to Polyethy-
lene Glycol.
5Morgenstern et al., Biotechnology Journal, accepted (2017), doi: 10.1002/biot.201700255.
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hohen Wassergehaltes und ihrer poro¨sen Struktur bieten Hydrogele eine physikalisch-
chemische A¨hnlichkeit zur natu¨rlichen extrazellula¨ren Matrix und bieten zusa¨tzlich einen
mechanischen Schutz fu¨r inkorporierte Proteine. Sowohl die Proteinstabilita¨t als auch
die -freisetzung aus Hydrogelen werden durch verschiedene Parameter beeinflusst. Dazu
geho¨ren die Art der Vernetzung, die Chemie und das Molekulargewicht des vernetzten
Polymers, der pH-Wert und die Salzsta¨rke der umgebenden Lo¨sung und spezifische Pro-
teineigenschaften wie Gro¨ße, dreidimensionale Struktur und Oberfla¨chenbeschaffenheiten.
Da die große Anzahl und die Interaktion dieser Parameter eine mechanistische Vorhersage
der Protein-Hydrogel-Interaktionen kompliziert machen, wurde im letzten Manuskript6
ein Hochdurchsatzverfahren zu deren experimenteller Untersuchung etabliert. Die Hy-
drogele wurden mittels 3D-Druck zu hochdurchsatzkompatiblen Strukturen vernetzt und
anschließend auf einer automatisierten Pipettierplattform prozessiert. Als Polymer wurde
dabei Polyethylenglycol-diakrylat (PEG-DA) eingesetzt und zu einer weiterfu¨hrenden
Funktionalisierung des Hydrogels mit Acrylsa¨ure copolymerisiert. In einer Fallstudie mit
Lysozym waren die durch den demonstrierten Ansatz erzeugten Daten vergleichbar mit
Literaturdaten. Im Vergleich zu herko¨mmlichen Methoden konnte der Screening-Prozess
jedoch deutlich beschleunigt werden.
Zusammenfassend ist festzustellen, dass die Prozessentwicklung fu¨r die Stabilisierung
pharmazeutischer Proteine und deren Verkapselung in polymeren Hydrogelen durch die
Anwendung der vorgestellten Methoden deutlich beschleunigt und vereinfacht werden
kann. Fu¨r die Entwicklung und Validierung dieser Methoden wurden in der vorliegen-
den Arbeit Modellproteine verwendet. Durch die Automatisierung der Methoden und die
Reduzierung von beno¨tigtem Probenmaterial ist eine U¨bertragung auf andere Moleku¨le
jedoch ohne weiteres mo¨glich.
6in preparation: Assessment of Hydrogels for Biopharmaceutical Purposes Using a Combination of 3D
Printing and High-Throughput Screening.
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CHAPTER1
Introduction
Proteins are organic macromolecules, which perform numerous functions in the human
body. For example, they are part of the immune system and help defend the body from
foreign molecules (antibodies), they catalyze and regulate biochemical reactions (en-
zymes), and form membrane receptors and channels, thus facilitating the transport of
molecules within a cell or between separate biochemical reaction compartments. Due
to their complex three-dimensional structure, proteins exhibit a high specificity for their
respective target [1]. An insufficient, excessive or defective production of endogenous pro-
teins may cause serious diseases such as diabetes [2], Gaucher’s disease [3], haemophilia
[4], Alzheimer’s disease or Parkinson [5, 6]. The administration of proteins as drug sub-
stance has the potential to cure many human diseases with minimal side effects which
can hardly be achieved by chemically synthesized small molecules [1].
Due to their high significance, it has always been of interest to produce proteins as active
pharmaceutical ingredients (APIs). Initially, proteins were extracted from natural sources
such as the human blood stream or specific cell tissues and organs. There have been seri-
ous issues with this type of production, including the transmission of infectious diseases
and the limited availability of the natural sources. [7] The groundbreaking decipheration
of the DNA molecule by Watson and Crick in 1953 [8] and the creation of the world’s
first recombinant organism by Cohen and Boyer in 1973 [9] marked milestones for the
technical production of protein molecules as APIs. Advances in the process technologies
for cell cultivation and protein purification have enabled the large-scale production of
proteins [10, 11]. In 1982, recombinant human insulin was approved by the U.S. Food
and Drug Administration (FDA) as the world’s first recombinant drug [12]. Nowadays,
protein drugs are an integral part of conventional therapy and it is estimated that in 2020
about 46 % of the sales volume of the 100 highest-selling pharmaceutical products will
be achieved by biopharmaceuticals [13]. According to Strohl and Knight [14], the cur-
rently approved biopharmaceuticals can be categorized into four major groups: (1) protein
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therapeutics with enzymatic or regulatory activity (e.g. insulin, growth hormones, blood
factor replacement therapies), (2) protein therapeutics with special targeting activity
(e.g. monoclonal antibodies, mAbs), (3) protein vaccines, and (4) protein diagnostics.
The production of therapeutic proteins, however, is very demanding due to their size,
complex structure, and biological origin [15]. The development of a manufacturing process
for recombinant proteins usually follows a well-established scheme. At first, the recombi-
nant gene with the necessary transcriptional regulatory elements is transferred into cells
forcing them to synthesize the desired protein in large amounts [16]. Nowadays, about
60-70 % of all recombinant protein drugs are produced in mammalian cells due to their
capacity for proper protein folding, assembly and post-translational glycosylation [16].
Successfully modified cells are cultivated under growth conditions optimized regarding
production needs (upstream processing, USP). From the resulting crude fermentation
broth, the target product is isolated and concentrated in a series of purification steps
(downstream processing, DSP) which can be highly challenging. The highly pure drug
substance resulting from this process is formulated to the final drug product with regard
to storage stability and application in the human body. For reasons of patient safety and
drug efficacy, the development, testing, production, and admission/licensing of biophar-
maceutical products are subject to strict regulations by authorities such as the FDA. In
order to gain regulatory approval, biopharmaceutical process development is nowadays
based on the ‘Quality by Design’ (QbD) approach that aims for an efficient identification
and reduction of errors during the production of biopharmaceuticals [17]. This approach
involves the identification and monitoring of critical quality attributes (CQAs) such as
size, molecular properties, structural and biological integrity and impurity profiles. Even
slight changes in the manufacturing process can influence the CQAs [17, 18]. Therefore,
critical process parameters and a tolerance range in which they can be varied need to
be defined in order to consistently produce a drug product with the desired effect [19].
The investigation of the influencing parameters on protein properties and the associated
analytical techniques are therefore of great importance to the production of biophar-
maceuticals. The enormous expenditure for process development, approval, production,
and quality control of therapeutic proteins leads to extensive costs for biopharmaceutical
products.
2
1.1 Protein Structure and Properties
1.1 Protein Structure and Properties
Proteins are (bio-)polymers composed of monomeric units called amino acids. The in-
dividual amino acids are linked by a peptide bond formed by a condensation reaction
between the α-carboxyl group of one amino acid and the α-amino group of an adjacent
amino acid. The linear amino acid sequence of a protein is also referred to as a primary
sequence. Depending on the number of amino acids, the molecular weights for pharma-
ceutical blockbuster proteins are in the range of approximately 5 kDa (insulin) to 150 kDa
(mAbs). Each amino acid cariies specific properties due to the chemical composition of
its side chain. These side chains are either basic, acidic, non-polar (hydrophobic) or po-
lar. [20, 21]. Therefore, the physicochemical properties of a protein strongly depend on
number, identity, and sequential order of amino acids. Under natural conditions, a pro-
tein is not present in its primary sequence but folds into a three-dimensional structure
which is decisive for the specific interactions and thus the protein’s biological functions
[22]. This natural three-dimensional (3D) structure is unique for every protein and is
referred to as native protein conformation [23, 24]. Non-native protein conformations
cover incorrectly folded protein molecules as well as partially unfolded or completely de-
natured ones [25]. The folding process can be described more specifically by a subdivision
into three further structure hierarchies. The secondary structure defines highly regular
local sub-structures between the polypeptide backbone of nearby amino acids due to
regular hydrogen-bonding. The most common secondary structures are α-helix, β-sheet,
coil regions and random structures [26, 27]. The tertiary protein structure describes the
3D structure of the entire protein and thus also takes into account interactions between
amino acids that are further apart in the primary sequence.
The main driving force for protein folding in aqueous environments is to reduce the
interactions between water and the hydrophobic amino acids [28]. This leads to an accu-
mulation of the hydrophobic amino acids in the interior of the protein molecule, which
is also referred to as hydrophobic core [7, 20]. Additionally, due to the accumulation in
the core and the resulting small distances between these amino acids, attractive van-
der-Waals forces contribute to the stabilization of the protein structure. However, the
hydrophobic amino acids cannot partition independently, since they are covalently linked
to their chain neighbors of the primary sequence [29]. This leads to the existence of sur-
face exposed hydrophobic amino acids as displayed in Fig. 1.1A. In contrast, the basic
and acidic amino acids are ionizable. Their charge is strongly dependent on their logarith-
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Figure 1.1: Representation of the 3D structure of lysozyme from chicken egg white at pH 7
(amino acid sequence from the pdb file 1LYZ of the RCSB protein database,
edited with Yasara software). Left: Surface charges due to the amino acids
lysine, arginine, histidine, aspartic acid and glutamic acid (blue = negative,
red = positive). Right: Hydrophobic surface areas due to the hydrophobic
amino acids alanine, isoleucine, leucine, methionine, phenylalanine, proline,
tryptophan and valine.
mic acid dissociation constant pKa and the pH value of the surrounding solution. The
titratable side group is deprotonated for pH>pKa and protonated for pH<pKa. Charged
amino acids are predominantly oriented towards the surface of the protein molecules (see
Fig. 1.1B) and ensure electrostatic interactions with the water molecules. This results in
a stabilization of the protein in solution by the formation of a solvation or hydrate shell.
The sum of charges of the individual amino acids at a specific pH value results in the net
charge of the entire protein. The pH value where the net charge of the protein equals zero
is defined as isoelectric point (pI) [30]. At this pH, there are still negative and positive
charges, but their number is equal. There are also intrinsic charged amino acids, which
contribute to the protein structure by the formation of salt bridges [31].
The spatial assembly of several tertiary structure monomers to a protein multimer is
referred to as quaternary structure. This is often the case when complex functions in the
human body cannot be fulfilled by a single amino acid chain. For example, a tetrameric
hemoglobin complex is responsible for the transport of oxygen. [32, 33] The described
protein structures are not rigid, but highly dynamic and in constant motion between
different conformational states with similar energy [32, 34]. The fastest motions, vibra-
tions and librations around covalent bonds, result in atoms moving only a fraction of an
A˚ngstro¨m on the picosecond to nanosecond timescale. Ligand binding may involve subtle
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motions like rearrangement of amino-acid residues in the binding site. This molecular
flexibility allows the protein to respond to the presence of other molecules and/or to
variations in the environment.[35]
1.2 Intermolecular Protein Interactions
The previously described protein structure and the formation of charged and hydrophobic
surface regions are decisive for molecular interactions with other molecules in solution.
Interactions between a protein molecule and molecules in its environment determine pro-
tein function, adsorption to surfaces and physicochemical properties such as solubility and
protein stability. For the description of intermolecular interactions between two spheri-
cal particles in a liquid medium Derjaguin, Landau, Verwey, and Overbeek developed
the DLVO theory in the 1940s [36–38]. According to the classical DLVO theory, interac-
tions between dispersed particles in a liquid environment result from a superposition of
van-der-Waals (dispersion) attraction and electrostatic repulsion [39]. Van-der-Waals in-
teractions are short-range, non-covalent interactions between atomic or molecular dipoles
[40]. Those dipoles may be permanent or induced due to rapid intramolecular fluctuations
of the electron clouds of non-polar molecules. In larger molecules the electron clouds are
subject to greater fluctuations so that the van-der-Waals forces are more pronounced
than for small molecules. For the calculation of the van-der-Waals forces FvdW between
two sperical particles, the simple approximation formula
FvdW = −Ha · d
24 · x2 (1.1)
according to the Hamaker theory is often used with Ha being the Hamaker constant, x
the distance between the spheres and d the sphere diameter [41, 42]. In case the spheres
do not have the same diameter, d is further defined by
d =
2 · d1 · d2
d1 + d2
(1.2)
for the two diameters d1 and d2 [41, 42]. According to Israelachvili et al. [43], the Hamaker
constant Ha is primarily a function of particle density. Since most globular proteins have
roughly the same density, it is expected that they have similar values of Ha [44]. For
proteins in water, Ha is approximatley 3-10 kT (1 kT = 4.11 · 10−27 J at 298.15 K) [45].
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Electrostatic interactions occur due to the presence of electric charges and can be de-
scribed quantitatively by Coulomb’s law
FCoulomb = ke · Q1 ·Q2
x2
(1.3)
for two point charges Q1 and Q2 separated by the distance x. ke is the Coulomb’s constant
(ke = 8.99 · 109 Nm2C−2). A charged surface thus creates an electrostatic field which
attracts opposing charges (FCoulomb is negative) and repels equal charges (FCoulomb is
positive) [40]. Electrostatic interactions of proteins in an aqueous environment are influ-
enced by the presence of salts. In the biopharmaceutical industry, salts are ubiquitously
used to control ionic strength and osmolality. Dissociated ions form of a diffuse ionic
layer (electrochemical double layer) shielding the charges on the surface. The concentra-
tion of the counter-ions decreases exponentially from a maximum value at the surface to
the surrounding medium. Therefore, the electrostatic potential and thus the electrostatic
interactions drop with the increase of distance between two molecules and reaches zero
at the boundary of the electrochemical double layer. A measure of the thickness of the
electrochemical double layer is the Debye-Hu¨ckel length, which is also referred to as de-
cay length. Electrostatic forces are very long range in comparison to the forces associated
with other interactions. [39, 46]
In principle, the molecular interactions discussed in this model are relevant for proteins.
However, the classical DLVO theory neglects additional interaction mechanisms such as
solvation, hydrogen bonds, hydrophobic interactions, and steric interactions; all of which
are of major importance for protein solution behavior and function [44, 47, 48]. In addi-
tion, the size and complexity of proteins and the non-uniform distribution of functional
groups on the molecular surface lead to a simultaneous existence of several interaction
forces and thus to a total resulting interaction force (potential of mean force) [49].
Hydrophobic interactions are of particular importance for proteins. Non-polar surface
groups are poorly solvated since they cannot form hydrogen bonds with the surround-
ing water molecules. Instead, hydrophobic structures induce ordered structures of the
water molecules resulting in entropy loss. Surface-exposed hydrophobic amino acids gen-
erate attractive protein-protein interactions in an aqueous environment since the fusion
of these hydrophobic surface areas reduces the overall surface exposed hydrophobic area
and thus minimizes free energy. [28] Israelachvili et al. [50] observed that hydrophobic
interaction forces increase exponentially at separation distances of less than 10 nm and
are therefore more short-range than electrostatic interactions. In consequence, hydropho-
bic interactions become increasingly important at increased ionic strength since repulsive
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electrostatic interaction and thus the distance between molecules are reduced under these
conditions [51].
Experimental decomposition of protein interactions into their individual contribution is
not feasible. Therefore, a solid platform for their theoretical prediction is highly demanded
[52]. Until now, the complexity of protein interactions has hindered the establishment of
a unified theoretical framework to calculate the potential of mean force. However, several
empirical approaches have been developed to characterize protein interactions. These in-
clude thermodynamic equation as free energy minimization [44] and molecular dynamic
(MD) simulations incorporating each atom of the protein explicitly [53]. However, the
number of atoms in a protein molecule renders the computational burden prohibitively
making these methods highly time consuming and expensive. [54, 55].
1.3 Protein Instabilities
According to Remington [56], the stability of a pharmaceutical product may be defined
as the capability to remain within its physical, chemical, microbiological, therapeutic,
and toxicological specifications. To ensure patient safety, the drug stability needs to be
investigated throughout the various processing steps and for the anticipated time period
of storage (shelf life) [57]. Biomolecules are generally very sensitive to their microenvi-
ronment due to their complex and fragile structure [7]. Most recombinant proteins are
prone to instabilities at elevated temperatures (e.g. cell cultivation), extreme pH values
(e.g. virus inactivation), shear stress (e.g. pumping and stirring), and non-physiological
salt concentrations (e.g. binding or elution in chromatography steps). Following the sys-
temic administration, recombinant proteins are susceptible to degradation by endogenous
proteases. [58]. Protein instabilities may result in a loss of function, changes in protein
pharmacokinetics, and immunogenicity [10, 47, 59]. Manning et al. [60] subdivided protein
instabilities further into chemical and physical instabilities. Chemical instabilities com-
prise processes in which covalent bonds are formed or broken resulting in new chemical
entities. Protein-relevant chemical instabilities include proteolysis (peptide bond hydrol-
ysis), deamidation, oxidation, and aspartate isomerization [7]. Physical instabilities are
related to a change in the physical state of the protein without involving an alteration of
the chemical protein composition and thus comprise conformational changes of the pro-
tein structure and colloidal changes (e.g. aggregation). [60] These physical changes are
caused by the perturbation of intramolecular and intermolecular interactions forces. The
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identification and assessment of suitable analytical tools for the detection and characteri-
zation of protein instabilities are of great importance for process control and formulation
development. [61]
1.3.1 Conformational Stability
Thermodynamic Description of Protein Unfolding and Melting Point Determination
According to the thermodynamic hypothesis by Anfinsen [62], the native structure of a
protein is stable under physiological conditions since it is in a global minimum of Gibbs
free energy G [7]. Under non-physiological conditions, the folding is disturbed by changing
molecular interactions favoring a transition from the native and biologically active 3D
structure to an unfolded state. The physicochemical description of this transition is often
based on the simplified two-state model
Folded(F) −−⇀↽− Unfolded(U) (1.4)
which assumes an equilibrium between these two distinct states and neglects any inter-
mediate state of unfolding [63]. The Gibbs free energy G is defined as a function of the
enthalpy H, the entropy S and the temperature T:
G = H − T ·S . (1.5)
The change in in Gibbs free energy ∆G is described by
∆G = ∆H − T ·∆S . (1.6)
For the reaction 1.4 at 25◦C in water, ∆G(H2O) is defined as the conformational stability
of the protein. Colloquially, the conformational stability describes how much more stable
the folded conformation of a protein is relative to its unfolded state. [64]
The overall change in entropy S upon unfolding is due to the combined effect of the
changing protein conformation and the resulting interactions with the surrounding water
molecules. The native, folded state, is characterized by a low entropy, since all protein
atoms are held in a well defined geometry by attractive intramolecular interactions. Upon
unfolding, the conformational entropy of the protein increases since native interactions
are lost and each amino acid residue can assume more degrees of freedom. The large
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increase in entropy of the protein is, however, compensated by a decrease in entropy of
the water in the system due to the hydrophobic effect. This effect causes water molecules
to assume more ordered conformations in order to maximize their hydrogen bonds and
to minimize the contact with non-polar side chains. This results in an entropy reduction
of the solvent relatively to the folded state. [65] ∆H reflects the changes of energy due
to the disruption of internal interactions within the protein molecule (hydrogen bonds,
ionic salt bridges, and van-der-Waals interactions) and the hydration of the groups that
are buried in the native state and become exposed to the solvent upon unfolding [66].
According to Eq. 1.6, ∆G depends on temperature. A temperature increase results in an
increase of the entropy term. If T is sufficiently high, the entropy term becomes greater
than the enthalpy term, resulting in a negative ∆G, and thus to a shift of the equilibrium
to the unfolded state. The melting temperature Tm is described thermodynamically as
the temperature at the equilibrium between the folded and the unfolded state and is
hence the temperature at which ∆G= 0. Tm can therefore be mathematically described
as
Tm =
∆H(Tm)
∆S(Tm)
. (1.7)
Proteins with a higher melting point Tm are evaluated as conformationally more stable,
since unfolding at higher temperatures suggests greater free energies of the native state
[67].
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Figure 1.2: Melting curve of the serine protease Savinase® at pH 5.7.
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Experimental approaches for the determination of Tm are based on the measurement of
changes in different protein properties upon thermal unfolding. In this work, the change
in intrinsic protein fluorescence is measured as observable variable. This analytical tech-
nique is based on the emission of light, occurring at wavelengths between 300 and 360 nm,
when the delocalized electrons of aromatic amino acid residues (e.g. tryptophan) drop
back to their initial state after being stimulated by laser light at 266 nm. Upon protein
unfolding, the fluorescence spectrum shifts to red wavelengths due to a change in the
vicinity of the hydrophobic tryptophan residues from the non-polar protein core to the
polar environment [68, 69]. The plot of fluorescence emission wavelength against temper-
ature results in a sigmoidal curve referred to as melting curve. The melting point Tm of
the protein is defined as the inflection point of the melting curve. In Fig. 1.2, a sample
melting curve is displayed for the serine protease Savinase at pH 5.7.
FT-IR Spectroscopy for Secondary Structure Analysis
In order to further investigate conformational changes at the level of the secondary struc-
ture, Fourier transform infrared (FT-IR) spectroscopy is used in this thesis. In the 1960s
Elliot and Ambrose showed that IR spectroscopy can be used to detect changes in the
conformation of polypeptides and proteins [70, 71]. The absorption of infrared radiation
Figure 1.3: Illustration of the amide I band as superposition from overlapping secondary
structure element bands [72].
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excites vibrational transitions of molecules (primarily stretching and bending motions).
The vibrational frequency and the absorption probability of covalent bonds depend on
the polarity of the binding partners involved. In an FT-IR spectrum of proteins, there
are nine characteristic absorption bands of which the amide I band is the most important
one for secondary structure analysis. [26, 73] The amide I band appears in the wavenum-
ber range of 1600 to 1700 cm−1 and is caused up to 80 % by the stretching vibrations
of the carbonyl group (C=O) of the peptide bond [74, 75]. As already explained in sec-
tion 1.1, the secondary structure of proteins is determined especially by hydrogen bonds
between the functional groups of the peptide backbone. The carbonyl group functions as
an acceptor for hydrogen bonding. The hydrogen bond involved in different secondary
structure elements differ in length and thus in the strength. A change in the strength
of a hydrogen bond leads to a change in the electron density of the C=O double bond.
An increasing electron density of the C=O bond is associated with an increase in the
vibrational frequency. The characteristic electron densities for the different secondary
structural elements lead to characteristic absorption frequencies within the amide I band
as displayed in Fig. 1.3. For this reason, changes in the secondary structure of a protein
result in changes of the FT-IR spectrum. [74]
1.3.2 Colloidal Stability - Protein Solubility and Phase Behavior
Besides the conformational instabilities which indicate changes of native protein struc-
ture, undesired phase transitions may adversely affect the activity of a protein drug.
The term phase refers to matter with a homogeneous chemical composition and spatially
constant physical properties. The phase state of a protein depends on the surrounding
system parameters and may change abruptly in case of variations. [76] Both in industrial
purification and formulation process design, knowledge of the phase behavior of proteins
is indispensable to avoid unwanted phase transitions as well as to exploit the potential
of phase transitions as purification operation [77]. Commonly, protein phase behavior is
determined and visualized by the generation of phase diagrams. Protein phase behavior
is determined as a function of various parameters, e.g. protein concentration, precipitant
(substance capable of inducing a phase transition) type and concentration, additional so-
lutes, pH, and temperature. [78, 79] In Fig. 1.4, a schematic diagram of the phase states
of a protein is displayed as a function of the protein concentration and the concentration
of a precipitant. All other parameters, such as pH, temperature or the presence of addi-
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Figure 1.4: Schematic illustration of a protein phase diagram in dependency of protein
and precipitant concentration according to [78, 80]. The solubility line sep-
arates the undersaturated zone (protein is completely dissolved) from the
supersaturated zone where phase transitions (crystallization, precipitation,
gelation) occur.
tives are kept constant. At low protein and precipitant concentrations, the protein is com-
pletely dissolved in the solvent forming a homogeneous liquid phase. This area is referred
to as the undersaturated zone. The solubility line describes the amount of protein which
can be dissolved at a given precipitant concentration until a thermodynamic equilibrium
is reached [44]. System compositions above the equilibrium solubility result in protein
aggregation. The term protein aggregation describes the assembly of native or non-native
protein monomers to protein multimers, i.e. aggregation describes the formation of pro-
tein crystals, amorphous precipitates and gel-like structures [81, 82]. The driving force
for this phase transition is a thermodynamic imbalance, which is also referred to as su-
persaturation. Depending on the kinetics of phase transition, the supersaturated area can
be further divided into the metastable zone where no crystals are formed but existing
crystals will grow, the nucleation zone which leads to crystal formation and growth and
the precipitation zone [83].
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1.3.2.1 Thermodynamic Description of Supersaturation
The thermodynamic parameter for the description of phase transitions is the chemical
potential µ. The molar chemical potential µ˜ of a component i in a real mixture is defined
by
µ˜i = µ˜
0
i +RT ln ai (1.8)
where µ˜0i is the molar chemical potential of component i in the standard state (T=298.15 K,
p=101.325 kPa), R the universal gas constant, T the temperature and ai is the activity
(or effective concentration [47]) of component i [76, 84]. In contrast to the theory of an
ideal mixture, the activity ai takes into account interactions between the molecules of
the different components in a real mixture. The activity is calculated according to
ai = c˜i · γi (1.9)
as the product of the molar concentration c˜i of the component i and its activity coefficient
γi [76, 85]. In ideal dilute solutions, the activity coefficient γi of the protein is unity and
its effective concentration ai is the actual concentration c˜i [47].
As explained in section 1.3.2, the driving force for the formation of protein aggregates is
the supersaturation. Thermodynamically, this is expressed by the difference between the
chemical potentials of the component i in a supersaturated solution µ˜i and the chemical
potential of the component i in the saturated state µ˜?i [86]:
∆µ˜ = µ˜i − µ˜?i = R · T · ln
(
ai
a?i
)
. (1.10)
The supersaturation Sa is defined as the ratio of the actual activity of the solution divided
by the activity at equilibrium. Using Eq. 1.9 Sa is defined as:
Sa ≡ ai
a?i
=
c˜i · γi
c˜i
? · γ?i
=
ci · γi
c?i · γ?i
. (1.11)
The measurement of activity coefficients for proteins poses a great problem because of
their complex interactions in aqueous solutions [87]. Therefore, activity coefficients are
often assumed to be the same resulting in a concentration-related supersaturation degree
Sc [80]:
Sc =
ci
c?i
. (1.12)
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1.3.2.2 Factors Influencing Protein Aggregation
Protein aggregation mechanisms depend on protein-protein interactions which are influ-
enced by properties of the proteins themselves (e.g. conformation, surface charge distri-
bution, hydrophobicity, and concentration), solution conditions (e.g. pH value, presence
of additional solutes like salt ions, polymers, or additives) and physical processing param-
eters (e.g. temperature and mechanical stress due to shaking, pumping, stirring, freezing,
and thawing). [25, 81, 88] A selection of these influencing parameters will be discussed
in the following section.
Protein Conformation
Due to the presence of different folding states, the initial state of a protein monomer
susceptible to aggregation may differ. Aggregation is either induced by natively folded
protein monomers or by partially or completely unfolded protein monomers referred to as
native and non-native aggregation, respectively [27, 89, 90]. For formulated protein ther-
apeutics, in particular non-native aggregates were found to evoke immunogenic reaction
as the formation of neutralizing antibodies or hypersensitivity responses such as anaphy-
laxis [59]. In aqueous solutions, non-native aggregates are induced mainly by hydrophobic
interactions since hydrophobic amino acids are exposed upon protein unfolding [88].
Protein Concentration
Protein-protein interactions require some spatial proximity between protein molecules.
In dilute protein solutions, intermolecular distances between molecules are compara-
bly large. With increasing concentrations, the separation distance between the protein
molecules decreases and the frequency of molecular collisions increases. [47, 91, 92] Due
to smaller distances between the protein molecules, aggregation propensity increases due
to electrostatic interactions, van-der-Waals interactions, hydrophobic interactions, hydro-
gen bonding [93, 94], and excluded volume effects [95]. The excluded volume originates
from protein molecules occupying space and thereby excluding other molecules from their
proximity. In solutions with increasing concentrations, the volume of solution available
to added molecules is hence restricted. As a result, the effective concentration of macro-
molecules and thus macromolecular thermodynamic activities increase by several orders
of magnitude favoring aggregation. [95, 96]
14
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Solution pH
As illustrated in Fig. 1.5, the solubility of proteins strongly depends on the surrounding
pH as the protein surface charges are altered. As displayed in Fig. 1.5A, the protonatable
amino acids are predominantly charged alike (positively or negatively) for solution pH
values in distance from the pI of the protein and therefore repel each other. Aggregation is
prevented by the repulsion of the molecules and the protein remains in solution. Despite
a net charge of zero, both positive and negative charges are present on the protein surface
at the pI. The spatial orientation of the protein molecules is driven by the approximation
of differently charged areas. Consequently, the level of electrostatic repulsion is minimal,
while electrostatic attractions and hydrophobic interactions are favored enhancing protein
aggregation. As a result, the solubility of a protein is minimal at its pI (Fig. 1.5B).
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Figure 1.5: Surface net charge of a protein in dependence of the pH value (A). At the
isoelectric point (pI) the surface net charge is zero resulting in a solubility
minimum (B).
Salts
The effects of salt ions on the aggregation behavior of proteins can be classified into two
types, that are non-specific and specific effects. The non-specific salt effects are simply due
to their ionic properties leading to charge shielding by the formation of an electrochemical
double layer. At higher salt concentrations (>0.1 M [97, 98]), salts exert specific effects
depending on the type of salt. [25, 99] Salt ions have different sizes, hydration properties,
15
Chapter 1 Introduction
and polarizabilities and thus have different effects on protein-interactions. In 1888, Franz
Hofmeister ordered salts empirically according to their ability to precipitate proteins. The
resulting Hofmeister series can be divided into kosmotropic ions which decrease the pro-
tein solubility (salting-out) and chaotropic ions enhancing protein solubility (salting-in).
[100] Several theories have been developed to understand the Hofmeister series, includ-
ing preferential interaction theory introduced by Arakawa et al. [101, 102]. This theory,
describes intermolecular interactions between proteins, co-solutes and the solvent. In a
ternary system of protein molecules, water molecules and salt ions, water molecules and
salt ions compete for the surface of the protein with the protein being preferably sur-
rounded by one molecular species. Salt ions are classified into ions preferential binding to
proteins and ions preferential excluded form the protein surface[102]. Polar and strongly
hydrated ions tend to interact strongly with water molecules and are preferentially ex-
cluded from the protein surface. As a result, the ‘structuring of water’ is increased and the
protein solvation shell is stabilized. For high salt concentrations, however, the salt com-
petes with the protein for water molecules favoring the exposure of hydrophobic surface
areas and thus aggregation. Non-polar and weakly hydrated ions tend to preferentially
interact with the protein thereby partially replacing the water molecules in the solvation
shell of the protein. These ions exert weak interactions with surrounding water molecules
and reduce the ‘structuring of water’ resulting in a solubility increase [98, 103].
1.3.2.3 Experimental Methods to Determine Protein Solubility and Phase Behavior
There are various approaches described in literature to experimentally determine the
protein phase behavior. In Fig. 1.6, the most frequently used approaches are displayed
schematically. The equilibrium solubility may either be approached from an undersatu-
rated or a supersaturated protein solution [80]. Starting from an undersaturated solution,
the protein concentration is increased by the addition of pure, lyophilized protein until the
solubility limit is reached (see Fig. 1.6 A) . This technique often requires large amounts
of highly pure protein. [80, 104] Instead of dissolving more protein, the protein concen-
tration can also be increased by the reduction of solvent (see Fig. 1.6 B) [105]. In this
case, the solution reaches the equilibrium by forming a second phase, whereas the protein
concentration in the supernatant converges to the solubility value. For this experimental
approach, the protein concentration must reach at least the crystallization range since
no spontaneous phase transition occurs in the metastable region. A popular method for
16
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Figure 1.6: Experimental approaches to determine protein solubility and phase behavior.
concentrating protein solutions for solubility determination is the vapor diffusion tech-
nique using either sitting or hanging drops. The drop is equilibrated against a reservoir
that contains a higher concentration of precipitant than the protein solution. The two
solutions are connected by a gas phase, but sealed from the environment. Due to the re-
sulting vapor pressure gradient, water diffuses from the drop to the reservoir leading to a
volume decrease of the protein drop. As a consequence, protein and precipitant concentra-
tion in the drop increase until the phase transition occurs. In vapor diffusion experiments,
conditions in the protein solution change throughout the equilibration process and pro-
tein as well as precipitant concentration where phase transition occurs cannot exactly
be determined. A better control over the phase transition conditions can be achieved in
batch experiments (see Fig. 1.6 C). An undersaturated protein solution is mixed with a
protein-free precipitant solution and sealed from the environment. If the mixing point is
in the two-phase region, a phase transition occurs and the concentration in the super-
natant approaches the equilibrium concentration. [78, 106, 107] Baumgartner et al. [79]
developed an experimental high-throughput approach to generate protein phase diagrams
and determine protein solubilities on an automated liquid handling station. This method
is characterized by its low sample consumption and high accuracy and is therefore used
in this thesis.
1.4 Stabilization Strategies for Biopharmaceutical Proteins
Due to the previously described protein instabilities, enhancing the robustness of func-
tional biomacromolecules is of major importance in biotechnology [108]. Stabilization of
17
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proteins can be accomplished either by modifying the environmental conditions or by
modifying the protein itself. Influencing the environment is realized by the adjustment of
process and formulation parameters such as pH value, ionic strength and the addition of
formulation additives. Moreover, polymeric drug-delivery vehicles are used to incorporate
the protein in a favorable environment. The chemical modicfication of the product itself
may be carried out prior to expression, cultivation and purification by alteration of the
amino acid sequence (direct evolution/mutagenis) [109] or subsequent to production and
purification by post-translational modifications.
1.4.1 Additives
Solution additives are applied in the biopharmaceutical industry to control protein fold-
ing, stabilize proteins against unfolding and aggregation, increase solubility, reduce sur-
face adsorption or to simply provide physiological osmolality [110, 111]. The stabilizers
encompass a wide variety of molecules, of which osmolytes and the polymer polyethylene
glycol (PEG) are studied in this work. Osmolytes are low molecular weight substances,
which have been found to regulate the osmotic pressure and form part of the milieu for
the biochemical reactions in all cells of bacteria, plants and animals. [107, 112–114] Some
of these substances were found to stabilize the native protein structures in the bacte-
rial cells upon environmental stress [114]. Among them are, for example, polyols such
as glycerol, polysaccharides such as dextrans, sugars such as trehalose and sucrose, or
amino acids such as arginine, glycine and L-gluatmic acid [115–117]. Steric effects and
a reduction of attractive intermolecular protein-protein interactions due to preferential
interaction of the protein by either water or osmolyte are the two most common expla-
nations for the effect of these molecules [111, 117, 118]. Due to their stabilizing effects,
many of these osmolytes are used for the production of biopharmaceuticals [25, 119,
120]. For PEG, the mode of action is strongly influenced by its molecular weight [121]
and concentration [122]. At low PEG molecular weights and concentrations, protein sta-
bilization may be induced by steric shielding of attractive protein-protein interactions. At
high PEG molecular weights and concentrations, however, protein destabilization occurs.
This phenomena is due to the steric exlusion of the protein molecules from the regions of
the solvent occupied by PEG molecules. As a result, the proteins are concentrated and
precipitate as soon as the solubility limit in the non-excluded volume is exceeded. [95,
120, 122, 123]
Despite their diverse use in the biopharmaceutical industry, the underlying mechanisms
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by which solution additives stabilize proteins are not yet fully understood. It is therefore
of great interest to investigate the causes of their effect more closely. Moreover, the devel-
opment of a fast, automated and reproducible strategy for the identification of suitable
additives is indispensable for the formulation development [7]. Along with an estimation
of protein stabilization, a careful consideration is needed regarding local toxicity and
potential immunogenicity of these additives [120].
1.4.2 Protein Conjugation
Besides altering the chemical environment of a protein, the modification of the product it-
self is another approach to protein stabilization. One form of protein modification involves
the covalent attachment of non-protein molecules to the protein. This process is referred
to as protein conjugation. For biopharmaceutical proteins, the covalent attachment of
biocompatible and water-soluble polymers has been found to increase the stability and
extend the in vivo half-life [124, 125]. The aim of protein conjugation is to create hybrid
molecules with a unique combination of properties derived from both biological and syn-
thetic materials [58, 126]. The protein gives the hybrid molecule the biological activity
with a high specificity for a reaction at low temperatures and concentrations. Synthetic
polymers exhibit higher stabilities against thermal and chemical influences. Furthermore,
polymer chemistry allows the incorporation of desired functional groups and thus enables
the hybrid molecule to react to biological and non-biological stimuli. [126, 127]
The creation of such hybrid materials requires efficient chemical pathways to specifi-
cally couple proteins to polymers. The functional side groups of the amino acids cysteine
(Cys), lysine (Lys), tyrosine (Tyr) and glutamine (Gln) as well as the N-terminus of the
peptide backbone offer naturally occurring reaction partners for the chemical modifica-
tions [127, 128]. For the covalent binding to these amino acids, various reactive groups
may be introduced into the polymer. The most frequent conjugation strategies are shown
schematically in Fig. 1.7.
In this thesis, the very efficient reaction of polymer-aldehydes and N-hydroxysuccinimide
(NHS) activated polymers to the ε-amine group of lysine (Lys) is exploited. Both of
these amine-modifying methods result in multi-conjugation as many proteins have several
surface-available lysine residues. For conjugated proteins, a distinction is made between
the degree of conjugation (indicating the number of bound polymer molecules) and diffe-
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Figure 1.7: Natural occurring attachment sites for protein conjugation. Illustration
adapted from [129].
rent isoforms (specifying the binding site). Both conjugation degree and isoform distri-
bution influence the physicochemical and biological properties of the resulting mixture.
For this reason, separation of the differently conjugated species is necessary after the
reaction. [130] The desire to circumvent this additional process step raised considerable
research efforts on side-specific conjugation reactions in order to install a single polymer
chain at a defined protein site [131, 132].
1.4.2.1 PEGylation
First attempts to protein conjugation were undertaken in the 1970s by Davis and Abu-
chowski [133, 134] using the polymer polyethylene glycol (PEG). PEG consists of co-
valently linked ethylene oxide (EO) monomers having a molecular weight of 44 Da per
monomer [58]. In their studies, Davis and Abuchowski observed a prolonged half-life in
the circulatory system and a reduced immunogenicity of PEG-modified proteins com-
pared to the native form. Since then, coupling of PEG chains to a therapeutic molecule
(PEGylation) has emerged to a well-established technology with significant therapeutic
value [126, 135]. In 1990, a PEGylated form of adenosine deaminase, Adagen® (Enzon
Pharmaceuticals, USA), was the first conjugated protein to be approved by the FDA
[136]. By now, a total of 12 PEGylated products are in clinical practice [137], includ-
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ing the blockbuster drugs PegIntron® (Schering-Plough, USA), Pegasys® (Hoffman-La
Roche, USA), Neulasta® (Amgen,USA), and Mircera® (Hoffman-La Roche, USA) [136,
138].
The overwhelming gain from PEGylated biopharmaceuticals arises from their altered
physicochemical properties [58]. Due to the high hydration of PEG, PEGylated proteins
have a significantly greater hydrodynamic radius than unmodified proteins with a com-
parable molecular weight [139, 140] resulting in a reduced systemic clearance [129]. An
enhanced in vivo half-life leads to less frequent administrations thus increasing patient’s
convenience. Furthermore, the polymer modification provides steric shiedling of protein
surface properties and thus changes molecule interactions. As a result, recognition by the
patient’s immune system, digestion by endogenous enzymes [141], and toxicity of the drug
are reduced. Another positive aspect of PEGylation may comprise a reduced aggregation
propensity which is explained with masked hydrophobic patches on the protein surface by
attached hydrophilic PEG. In contrast to these improvements, the conjugation may evoke
changes in the drug activity by changing the native conformation, sterically interfering or
altering binding properties [142]. Parameters influencing the properties of the conjugate
include the type of polymer (chemistry, linear vs. branched [140]), the molecular weight
of the polymer and the conjugation degree as well as the isoform distribution. A careful
consideration and combination of these parameters allows for fine-tuning the properties
of the conjugated drug product.
From the perspective of process development, despite almost 40 years of research and
application of PEGylated proteins, there are still issues concerning purification, pro-
cess control and characterization of protein conjugates. The attachment of the PEG
molecules increases the heterogeneity of the resulting drug product increasing the need
for sophisticated analytical techniques [125]. The analytical tasks to be fulfilled include,
identification and quantification of conjugated species with different number of bound
polymer molecules and their characterization with regard to their physical stabilities un-
der process-relevant conditions. In order to reduce material consumption and shorten
development times, those methods require automated processing of low sample volumes.
In addition, computer-based (in silico) methods are a helpful tool for the cost-effective
development of purification processes as well as for understanding of the underlying phys-
ical principles [143]. The parameters estimated by experimental and in silico approaches
can be used for process up-scaling, process optimization, and process control.
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1.4.2.2 Alternative Polymers for Protein Conjugation
While PEG remains useful for the modification of therapeutic proteins, some limita-
tions in its clinical use have begun to emerge driving the development of alternatives.
Discussions about these potential drawbacks include antibody formation against PEG
(anti-PEG), hypersensitivity to PEG and vacuolation in various tissues upon repeated
exposure [126, 144]. From a processing point of view, standard linear PEG is commonly
prepared by anionic polymerization of EO, a sensitive and expensive process [145]. Novel
monomers and new controlled polymerization techniques permit to extend the therapeu-
tic use of protein-polymer conjugates. Controlled radical polymerization techniques such
as reversible addition-fragmentation chain transfer (RAFT) polymerization [146] are the
means of choice as they allow for the introduction of various functional endgroups, the
strict control over polymer molecular weight and a narrow molecular weight distribution
[126]. Since PEG is up to now the only FDA-approved polymer for bio-conjugation, these
alternative polymers must be thoroughly investigated from a process-based, clinical, and
regulatory perspective before being approved for use in humans.[147] Moving beyond
therapeutical applications, the coupling of novel polymers to proteins opens up new ap-
plication fields for technical hybrid systems including biosensing and diagnostics as well
as biocatalysis [148].
1.5 Mechanistic Chromatography Modeling
In case of random conjugation, the existence of multiple binding-sites and the result-
ing heterogeneous product mixture necessitates a post-modificational purification of the
resulting conjugate species. Ion-exchange chromatography (IEX) is one of the most fre-
quently used purification methods for conjugated proteins [129, 130]. In case of IEX, the
surface of the adsorber particles is functionalized with charged ligands facilitating the
separation of protein molecules according to differences in charge. For protein conjugates,
Seely and Richey [149] proposed the ‘charge-shielding effect’ which explains a decrease
in binding strength and thus retention time [150] with increasing conjugation degree due
to weakened electrostatic interactions.
The development and optimization of chromatographic separation processes is nowadays
either based on experimental or model-based approaches. Mechanistic modeling and nu-
merical simulations permit to reduce the number of experiments and thus costs during
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Figure 1.8: Mass transfer and adsorption/mechanisms determining chromatographic sep-
aration of proteins. Illustration adapted from [151].
process optimization by in silico predictions [143, 151]. Based on the mathematical de-
scription of the underlying physical processes, mechanistic modeling additionally allows
to estimate experimentally inaccessible parameters. In order to quantitatively describe
the behavior of protein species during the separation process by mathematical equations,
an understanding of the underlying physical processes in the column is necessary [152].
Those physical effects are schematically displayed in Fig. 1.8. During chromatographic
separation, a solution containing a mixture of proteins that are to be separated (mobilen
phase) is pumped through a packed bed of porous adsorber particles (stationary phase).
The relevant mass transfer processes on the macroscopic column level are convection due
to the forced fluid flow and dispersion. The environment surrounding a single particle
in the packed bed is thought to be a film in which the mobile phase is stagnant. The
mass transfer from the bulk phase through the film layer to the outermost edge of the
particle is purely diffusive and is denoted as film diffusion. The actual separation takes
place on the surface of the adsorber particles where the protein molecules interact with
the ligands. To improve the performance of adsorbers, the particles have a high porosity
increasing the total available surface area. Inside the pores, the proteins are transported
via pore diffusion. This process is frequently the rate-determining process of a chromato-
graphic separation.
In literature, several models to describe fluid dynamics, mass transfer and adsorption/des-
orption phenomena have been suggested, of which a comprehensive summary is provided
in the text books by Schmidt-Traub et al. [151] and Guiochon et al. [153]. In this thesis,
the general rate model (GRM) is used to describe fluid dynamics and mass transfer phe-
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nomena as it includes axial dispersion as well as resistance to external and internal mass
transport [152]. The GRM includes two mass balance equations for a component i, one
for the inter-particle phase (Eq. 1.13) and one for the inner-pore phase (Eq. 1.14):
∂ci(x, t)
∂t︸ ︷︷ ︸
change of
bulk concentration
= −u(t)∂ci(x, t)
∂x︸ ︷︷ ︸
convective
transport
term
+Dax
∂2c(x, t)
∂x2︸ ︷︷ ︸
axial
dispersion
term
− 1− εb
εb
kfilm,i
3
rp
(ci(x, t)− cp,i(x, t))︸ ︷︷ ︸
mass transfer term
(1.13)
∂cp,i(x, t)
∂t
=

1
r2
∂
∂r (r
2Dp,i
∂cp,i(x,t)
∂r )− 1−εpεp
∂qi(x,t)
∂t for r ∈ (0, rp),
kfilm,i
εpDp,i
(ci(x, t)− cp,i(x, t)) for r = rp,
0 for r = 0.
(1.14)
Eq. 1.13 describes the change of the bulk concentration ci(x, t) of a component i in the
inter-particle phase at a position x in a column of length L dependent on the time t.
Term 1 in Eq. 1.13 describes the convective transport influenced by the flow velocity of
the mobile phase u in the inter-particle phase. The middle term describes hydrodynamic
dispersion in axial direction by the axial dispersion coefficient Dax. Hydrodynamic dis-
persion is mainly influenced by the quality of column packing. The last term describes
the transition of molecules from the bulk phase having the concentration ci to the pore
phase having the concentration cp,i. In Eq. 1.13, εb is the bed porosity, kfilm,i the film
diffusion coefficient referring to the mass transfer over the film layer and rp the particle
radius. Eq. 1.14 describes the exchange between the pore volume concentration cp,i(x, t)
and the stationary phase qi depending on the particle porosity εp and the component-
specific pore diffusion coefficient Dp along the radial pore position r within the particle.
[154]
A thermodynamic adsorption model is used to describe the mass transition from the
pore phase to the surface of the adsorber. In this thesis, the semi-mechanistic steric mass
action (SMA) isotherm introduced by Brooks and Cramer [155] is used. The underlying
assumption is that in IEX the proteins and the salt ions compete for the available lig-
ands on the stationary phase. The adsorber is characterized by the total ionic capacity
Λ which is the total ligand concentration on the adsorber surface. Proteins are charac-
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terized by a specific number of characteristic binding charges νi which are involved in
binding. According to the reaction
cp,i(x,t) + νi · qsalt(x,t) kads−−−⇀↽ −
kdes
qi(x,t) + νi · cp,salt(x,t) , (1.15)
a protein displaces an equal amount of counter ions form the adsorber surface upon
adsorbing to the ion exchange resin. In Eq. 1.15, qsalt and cp,salt are the concentration of
the salt ions adsorbed and in solution inside the pore, respectively and kads and kdes the
rate coefficients of adsorption and desorption, respectively. In addition, proteins cover
binding sites without direct electrostatic interactions by steric shielding due to their
molecular size. Therefore, the SMA model includes the steric shielding factor σi. For
protein conjugates, this phenomenon is important because of the dynamic polymer layer
and the resulting increased hydrodynamic radius [130, 139] reducing the apparent binding
capacity in the non-linear range of the isotherm (overloaded state). According to Nilsson
et al. [156], the kinetic formulation of the SMA isotherm for k protein species is:
kkin,i
∂qi(x,t)
∂t = keq,i (Λ−
k∑
j=1
(νi + σi)qj(x, t))
νicp,i(x, t)︸ ︷︷ ︸
adsorption-
promoting
− cp,salt(x, t)νiqi(x, t)︸ ︷︷ ︸
desorption-
promoting
(1.16)
Eq. 1.16 reproduces the influence of the counter-ion concentration cp,salt on the adsorp-
tion/desorption kinetics of the proteins. The equilibrium of adsorption/desorption is de-
scribed by the adsorption equilibrium coefficient keq,i = kads,i/kdes,i and the velocity of
the reaction by the coefficient kkin,i = 1/kdes,i. The salt concentration in the stationary
phase is described by
qsalt(x, t) = Λ−
k∑
j=1
νjqj(x, t) (1.17)
as a function of proteins bound to the adsorber surface. qsalt(x, t) equals the number of
salt ions still attached to the adsorbent surface.
In this thesis, the resulting system of differential equations is solved numerically using
the simulation software ChromX (GoSilico, Germany). The system parameters required
for a numerical solution are accessible experimentally. This involves the determination of
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the bed porosity εb and the axial dispersion coefficient Dax by the injections of non-pore-
penetrating tracer solutions, the particle porosity εp by the injection of pore-penetrating
tracer solutions as well as the total ionic capacity Λ by acid-base titration [157]. For
proteins, the individual parameters are estimated in calibration runs by minimizing the
discrepancy between measurement and the simulation. This approach is called inverse
modeling. Finally, the parameters are verified by an external set of validation runs. [158]
1.6 Hydrogels as Drug Delivery Systems
According to Webster et al. [159], a drug delivery system (DDS) is defined as device to
introduce an API into the body. The main goal in the development of DDSs is to deliver
the intact drug at the intended site of action in cells and tissues at a controlled rate.
It is desirable to develop controlled release formulations and devices that can maintain
a desired blood plasma level of the drug over an extended period of time avoiding fre-
quent administration [1]. In this context, polymeric carrier materials have developed as
a basis for the accommodation and delivery of a variety of drugs [160–163]. Particularly
three-dimensional crosslinked networks of hydrophilic polymers are suitable for the use
in DDSs since they swell without dissolving to a multiple of their volume in an aque-
ous environment forming a so called hydrogel [164]. Due to their high water content and
porous structure, hydrogels provide a physiochemical similarity to the native extracellular
matrix and thus a favorable and mechanically supportive environment for proteins [161,
165]. Hydrogels can be synthesized from a single species of monomers (homopolymers)
or from a mixture of two or more different monomer species (copolymers) [166]. The
applied polymeric materials need to be biocompatible and cannot cause any immuno-
logical reaction [163, 167]. Synthetic polymers often used for the synthesis of hydrogels
for protein delivery include polyethylene glycol-diacrylate (PEG-DA), poly(vinyl alcohol)
(PVA), polylactic acid (PLA), polyacrylamide, (meth)acrylic acid, and polyvinylpyrroli-
done (PVP) [168, 169]. In addition to the choice of polymer, the hydrogel will be defined
by the mode of crosslinking, the molecular weight of the polymer, the initial monomeric
content and the presence of crosslinkers. The chemical composition of the hydrogel de-
fines the physiochemical properties such as porosity, swelling behavior, mass transport
profiles, and mechanical stability. [161, 170] DDSs can be classified according to the
mechanism that controls the release of the therapeutic ingredient. The release is either
diffusion controlled (reservoir systems and matrices, e.g. transdermal patches or drug-
loaded stents [171]), chemically controlled (bioerosion or biodegradation) or responsive/-
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solvent controlled (swelling, osmosis, change of intermolecular interactions) [1, 164, 172].
The multiplicity of factors affecting the drug delivery result renders the engineering of
hydrogel-based drug delivery system with specified responses to particular stimuli chal-
lenging.
1.7 3D Printing to Synthesize Photopolymerized Hydrogels
Three-dimensional (3D) printing is an additive manufacturing technique in which three-
dimensional objects are created by applying material in thin layers. For this purpose,
3D models are first designed with a computer-aided design (CAD) software and then
converted into a vector-based machine code (G-code). This technique enables precise
manufacturing of highly complex components with an arbitrary design and sophisticated
internal features that are impossible to fabricate by conventional manufacturing pro-
cesses. Moreover, it is an automated approach that offers a pathway for scalable and
reproducible production. [83, 173, 174] Bioprinting is a subset of 3D printing in which
3D objects are built up from biological or biocompatible materials [175]. For biopharma-
ceutical applications, 3D printing represents an elegant tool to fabricate custom-tailored
protein delivery systems with individualized dosage and accurate control of the desired
release profile [176, 177]. In the field of medicine, 3D printing enables the production of
personalized applications ranging from medical devices to implants and prostheses [178].
Previous printing successes for various types of human tissue nourish the vision of arti-
ficial human organs [175].
There are different 3D bioprinting techniques, which can be grouped into extrusion-based
printing, inkjet-based printing and laser-based printing [173, 179]. In this thesis, a 3D
printing technology called digital light processing (DLP) is used. This process is related
to the laser-based sterolithography (SLA) patented by Charles W. Hull in 1986. The
basis of both techniques is photopolymerization in which a light-sensitive photoinitiator
is cleaved into free radicals by irradiation with light of a certain wavelength leading to
the crosslinking of the monomer precursor [180]. In the case of SLA, only the area which
forms the cross-sectional area of the 3D object in this specific layer is selectively exposed
by a focused laser beam leading to a spatially defined curing of the monomer precursor.
After one layer is finished, the printing object is coated with a fresh layer of uncured
precursor and the process is repeated until the 3D object is built [181]. DLP uses a con-
ventional light source to project an entire layer of the model to be printed, which makes
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it faster than the laser-based SLA [182].
In this work, DLP is used to crosslink PEG-DA-based hydrogels to 3D objects. The
reaction mechanism of the radical polymerization is displayed in Fig. 1.9. At first, the
reaction is initiated by the formation of a free methyl radical due to the irradiation of
the photoinitiator. The resulting radical attacks the carbon-carbon double bond of PEG-
DA thus creating a PEG-DA radical. During the propagation step, the chain length and
crosslinking density increases by reactions of a radical with a carbon-carbon double bond
of the forming network. The chain propagation is terminated by the reaction of two rad-
icals.
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Figure 1.9: Reaction mechanism of photopolymerization of PEG-DA for the formation of
a crosslinked hydrogel network. Illustration adapted from [167, 183].
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Research Proposal
Protein drugs (biopharmaceuticals) offer unique opportunities and give hope for treat-
ing and healing severe diseases. The functionality and high selectivity of proteins for
molecular targets in the human body is due to their complex three-dimensional struc-
ture. As previously described, the structure of proteins depends on various intra- and
inter-molecular interactions. Both technical production of proteins and their integration
into polymeric drug delivery systems may require conditions which influence molecular
interactions and thus promote protein instabilities and functional loss. In addition to
structural instabilities [184], the low solubility and the unwanted formation of protein
aggregates are identified as a key challenge [185, 186]. Methods to stabilize the native
protein structure as well as to selectively manipulate protein aggregation behavior are
crucial to the development and manufacturing of safe and efficient drug products. Ac-
cordingly, the question arises of suitable stabilization strategies and their implementation
in development and production of therapeutic proteins.
In recent years, various strategies have been studied to overcome the protein stability
issue. Manipulation of protein-protein interactions through the addition of additives is
reported as effective [110]. Especially, some uncharged sugars, polyols, and free amino
acids as well as biocompatible polymers have shown to stabilize the proteins’ native state
and to reduce aggregation propensity [113, 116]. The addition of solution additives offers
the advantage of simplicity since the components solely need to be dissolved and no ad-
ditional process step is required. In addition, different additives can be combined in any
ratio. However, the mechanisms underlying stabilization are not yet fully understood.
Therefore, suitable solution additives are often identified in trial and error experiments,
which are time and material consuming. Against this background, the first subsection
of this work is devoted to the development and implementation of an automated, repro-
ducible and efficient methodology for assessing the effect of solution additives on protein
29
Chapter 2 Research Proposal
stability. In order to gain a deeper understanding of how the investigated additives sta-
bilize proteins, this study focuses on an integrated examination of protein conformation
and aggregation.
The success of solution additives as protein stabilizers have led to the idea of cova-
lently binding those stabilizers to the protein. The resulting stabilization strategy is
entitled protein conjugation. Protein conjugation has the benefit that the stabilization
is not solely based on interactions and can thus be maintained under changing process
conditions. Moreover, the covalently bound molecule can be functionalized imparting
additional properties to the protein molecule. In the pharmaceutical industry, the most
prominent example is the covalent attachment of polyethylene glycol (PEGylation) [187].
In order to avoid additional and complex modifications of the target protein, polyethylene
glycol (PEG) is most commonly attached to the naturally occurring surface amino acids
in random conjugation reactions. Since the individual amino acids occur repeatedly in a
protein, this approach results in a heterogeneous product mixture of molecules with dif-
ferent number (conjugation degree) and position of bound polymers. For the regulatory
approval of conjugated protein drugs, the authorities require an extensive characteriza-
tion concerning the distribution of different conjugate species. The second part of this
work hence deals with the development of a fast analytical method to investigate the
conjugate distribution in PEG-protein mixtures with low sample consumption. The dis-
tribution of different conjugate species is mainly influenced by reaction conditions. The
developed analytical method is used to optimize the latter.
The different conjugate species have shown to differ significantly in their physicochemical
properties [133, 139]. The third part of this study aims to investigate the potential of
PEGylation for the stabilization of the protein conformation and for enhancing solubil-
ity. Increasing protein solubility is of great interest to the biopharmaceutical industry as
it allows the development of highly concentrated protein formulations. In a systematic
study, the influence of PEG molecular weight and conjugation degree is examined. In
the fourth part, the method developed for PEGylated proteins are applied to alternative
polymers. The desire for alternative polymers for protein conjugation is driven by several
ideas. On the one hand, clinical limitation of PEGylated proteins emerged including an-
tibody formation against PEG (anti-PEG), hypersensitivity and vacuolation in various
tissues upon repeated exposure. On the other hand, the synthesis of activated PEGs with
narrow dispersity is complex and therefore expensive. The development of protein con-
jugates with lower-cost polymers having similar advantages as PEG would increases the
availability of stable biopharmaceuticals to a broader mass of the population. Finally, the
use of different monomers allows for a variation in protein functionalization with regard
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Due to the different properties of the conjugates, methods for the separation of the indi-
vidual molecules on a production scale are required. Ion-exchange chromatography (IEX)
is among the most frequently used purification methods for conjugated proteins. Purifica-
tion processes are typically developed and optimized in small-scale experiments. However,
transfer of laboratory methods to the production level (scale-up) is not straightforward
and remains largely empirical [188]. To address this issue, the purification process must
be characterized by key parameters which are independent of the equipment used. For
a chromatographic separation, this can be realized by determining mass transfer and
adsorption parameters. In this context, mechanistic chromatography modeling provides
an excellent tool to obtain these parameters with a low number of experiments and is
hence applied in the fifth part of this thesis to describe PEGylated proteins in IEX.
In addition to the use as solution additive and for protein conjugation, PEG can also
be functionalized to form three-dimensional, highly crosslinked and biocompatible net-
works. Due to their high water content and the porous support structure, these networks
(hydrogels) provide a protective environment for proteins. Protein-hydrogel interactions
are influenced by the highly complex physical and chemical properties of the hydrogel,
the surrounding solution conditions and the protein itself. In the last section of this
thesis, an automated, reproducible and efficient methods for the evaluation of hydrogels
for biopharmaceutical purposes is presented. This method involves crosslinking the hy-
drogel precursor with a 3D printer. The results of this study are intended to provide
an insight into whether hydrogels are applicable in the context of the emerging field of
3D bioprinting. The long-term goal is to produce three-dimensional objects with arbi-
trary geometries from functional and technically relevant hybrid materials having both
biological and polymer properties.
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1. Manipulation of Lysozyme Phase Behavior by Additives as Function of
Conformational Stability
Lara Galm, Josefine Morgenstern and Ju¨rgen Hubbuch
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The potential of selected
solution additives, namely
glycerol, PEG 1000 and
glycine for the stabiliza-
tion of lysozyme from
chicken egg white was in-
vestigated in this study.
For this purpose, a combi-
nation of automated gen-
eration of protein phase di-
agrams on a liquid han-
dling station and sec-
ondary structure analysis using Fourier transform infrared spectroscopy (FT-IR) was
used. The effect of the additives on solubility as well as crystal size and morphology
was investigated by the protein phase diagrams. It was shown that the influence of the
additives on the lysozyme phase behavior and the equilibrium solubility depends on the
solution pH. The pH dependent impact was explained by differences in the conformational
stability of lysozyme. Of the investigated additives, glycerol and PEG 1000 stabilized the
native protein conformation while glycine destabilized it.
International Journal of Pharmaceutics 494/1 (2015): 370-380.
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2. Quantification of PEGylated Proteases with Varying Degree of Conjuga-
tion in Mixtures: An Analytical Protocol Combining Protein Precipitation
and Capillary Gel Electrophoresis
Josefine Morgenstern, Markus Busch, Pascal Baumann and Ju¨rgen Hubbuch
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In this article, the develop-
ment of a fast and repro-
ducible analysis for the quan-
tification of protein-PEG con-
jugates with varying degree of
conjugation (PEGamers) is pre-
sented for both stable and unsta-
ble proteins. As an example for
structurally unstable proteins,
proteases were examined being
prone to autocatalysis. An in-
crease in sample throughput was
achieved by using a microchip-
based capillary gel electrophore-
sis (HT-CGE) enabling an im-
plementation in high-throughput
screenings. An increase in appar-
ent molecular weight of the conjuagtes as well as band broading effects were considered
by calibrating the HT-CGE system with purified PEGamer samples. For structurally
unstable proteins, a conservation of the sample composition was established by protein
precipitation and redissolution prior to analysis. The potential of the presented method
is demonstrated by a case study on the optimization of the reaction conditions for protein
conjugation with respect to the distribution of PEGamers.
Journal of Chromatography A 1462 (2016): 153-164.
3. Effect of PEG Molecular Weight and PEGylation Degree on the Physical
Stability of PEGylated Lysozyme
Josefine Morgenstern, Pascal Baumann, Carina Brunner and Ju¨rgen Hubbuch
This article presents a systematic, high-throughput study investigating the influence of
PEG molecular weight and PEGylation degree on the phase behavior, equilibrium solu-
bility, melting point and residual activity of lysozyme conjugates. The physico-chemical
34
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properties of the conjugates have
shown to result form a superposition
of protein and polymer characteristics.
Higher PEG molecular weights and
PEGylation degrees resulted in an am-
plified shielding of the protein proper-
ties yielding an increase in conforma-
tional and colloidal stability. However,
the residual activities of the conjugates decreased simultaneously. The origin of the result-
ing conjugate activities is discussed as a combination of steric hindrance and molecular
flexibility. The methodology employed is extremely useful for the selection of suitable
polymers and the fine tuning of the conjugate properties for particular applications.
International Journal of Pharmaceutics 519/1-2 (2017): 408-417.
4. Stability Assessment of Protein-Polymer Conjugates: Alternative Polymers
to Polyethylene Glycol
Josefine Morgenstern*, Gabriela Gil Alvaradejo*, Nicolai Bluthardt, Guillaume Delaittre
and Ju¨rgen Hubbuch
* These authors contributed equally to this work
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In this manuscript, alternatives to
the current gold standard (PEG) are
investigated for their potential use
in protein-polymer conjugation. The
alternative, biocompatible polymers
PNAM and POEGMA are synthesized
by reversible addition-fragmentation
chain transfer (RAFT) polymerization
and randomly coupled to lysozyme
from chicken egg. After chromato-
graphic purification, the conjugate species are screened for phase behavior and residual
activity. Compared to the unmodified protein an increase in equilibrium solubility was
achieved for all investigated conjugate species. Compared to PEG conjugates, however,
a higher polymer molecular weight was necessary for a comparable increase in the solu-
bility. The decrease in residual enzyme activity due to steric hindrance was comparable
to that observed in case of PEGylation.
Manuscript in preparation.
35
Chapter 3 Comprehensive Overview of Publications & Manuscripts
5. Model-based Investigation on the Mass Transfer and Adsorption Mecha-
nisms of Mono-PEGylated Lysozyme in Ion-Exchange Chromatography
Josefine Morgenstern*, Gang Wang*, Pascal Baumann and Ju¨rgen Hubbuch
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In this study, mechanistic chromatog-
raphy modeling was used for the in
silico determination of mass trans-
fer and sorption parameters for PEG-
ylated lysozyme conjugates in IEX.
For parameter estimation, a system
of differential equations describing
fluid dynamics, mass transfer and ad-
sorption/desorption phenomena in the
chromatography column was solved
numerically and validated experimentally. Since both molecular weight and surface prop-
erties influence the separation result in IEX, the PEG molecular weight has been varied.
Changes in mass transfer and sorption processes are discussed with regard to chromato-
graphically relevant parameters such as retention time, peak shape and binding capac-
ity.
Accepted manuscript: to appear in Biotechnology Journal, doi: 10.1002/biot.201700255.
6. Assessment of Hydrogels for Biopharmaceutical Purposes Using a Combi-
nation of 3D Printing and High-Throughput Screening
Josefine Morgenstern*, Carsten Philipp Radtke*, Cathrin Du¨rr and Ju¨rgen Hubbuch
* These authors contributed equally to this work.
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Both protein stabilization and
release by hydrogels are influ-
enced by various parameters, in-
cluding the type and molecu-
lar weight of the crosslinked
polymer, pH and salt strength
of the surrounding solution and
protein-specific properties. This
study presents the development
of a rapid and cost-effective screening-tool for the investigation of protein-hydrogel inter-
actions. The hydrogels are crosslinked to high-throughput compatible structures using
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3D printing and subsequently processed on a liquid handling station. By comparing the
obtained results with literature data generated by conventional methods, a high data
consistency is demonstrated.
Manuscript in preparation.
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Manipulation of Lysozyme Phase Behavior by Additives as
Function of Conformational Stability
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Abstract
Undesired protein aggregation in general and non-native protein aggregation in particular
need to be inhibited during bio-pharmaceutical processing to ensure patient safety and
to maintain product activity. In this work the potency of different additives, namely glyc-
erol, PEG 1000, and glycine, to prevent lysozyme aggregation and selectively manipulate
lysozyme phase behavior was investigated. The results revealed a strong pH dependency
of the additive impact on lysozyme phase behavior, lysozyme solubility, crystal size and
morphology. This work aims to link this pH dependent impact to a protein-specific pa-
rameter, the conformational stability of lysozyme. At pH 3 the addition of 10 %(w/v)
glycerol, 10 %(w/v) PEG 1000, and 1 M glycine stabilized or destabilized lysozymes’
native conformation resulting in a modified size of the crystallization area without in-
fluencing lysozyme solubility, crystal size and morphology. Addition of 1 M glycine even
promoted non-native aggregation at pH 3 whereas addition of PEG 1000 completely in-
hibited non-native aggregation. At pH 5 the addition of 10 %(w/v) glycerol, 10 %(w/v)
PEG 1000, and 1 M glycine did not influence lysozymes’ native conformation, but strongly
influenced the position of the crystallization area, lysozyme solubility, crystal size and
morphology. The observed pH dependent impact of the additives could be linked to a
differing lysozyme conformational stability in the binary systems without additives at
pH 3 and pH 5. However, in any case lysozyme phase behavior could selectively be ma-
nipulated by addition of glycerol, PEG 1000 and glycine. Furthermore, at pH 5 crystal
size and morphology could selectively be manipulated.
Keywords: Osmolytes; solubility line; crystallization area; non-native aggregation; FT-
IR
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4.1 Introduction
The term protein aggregation describes the assembly of native or non-native protein
monomers to protein multimers, i.e. aggregation characterizes both the formation of pro-
tein crystals and amorphous precipitates and includes native and non-native aggregation
forms. Protein aggregation can occur through different mechanisms [82] and during dif-
ferent steps of a production process [88]. However, crystallization and precipitation are
also acknowledged process steps in biopharmaceutical industries either for formulation or
purification purposes [189]. Crystalline drug formulations for example have shown signif-
icant benefits in the delivery of protein therapeutics to achieve high-concentration, high-
stability, low-viscosity and controlled-release formulations [190, 191]. Crystalline insulin
formulations are market approved [190, 192, 193] and crystalline antibody formulations
are studied, too [194]. For formulated protein therapeutics, the presence of precipitates is
typically considered to be undesirable because of the concern that especially non-native
precipitates may lead to immunogenic reactions [88]. The widespread opinion exists that
aggregation processes are usually associated with a conformational change, i.e. partial
unfolding of the proteins [25, 89] and aggregation processes that resulted in non-native
protein conformations have been observed [26, 195–198]. Moreover, aggregation processes
might influence biological activity of protein therapeutics. Thus, in either case it is es-
sential to ensure that the target protein remains in its native conformation and that
biological activity is preserved despite aggregation. Thus, in cases where non-native ag-
gregation is likely to occur aggregation needs to be prevented completely unless there are
possibilities to stabilize the native conformational state. In cases where native aggregation
occurs, the selective control of phase states is considered to be beneficial as sometimes
either crystalline or precipitated forms are preferred e.g. due to a better bioavailability
in the respective aggregate state [193]. Particular additives are thought to stabilize the
proteins’ native state, for example stabilize the protein against thermal denaturation,
and thus might be used to prevent non-native aggregation processes. According to Harris
and Ro¨sgen [199] particular additives influence protein solubility as well, resulting in a
manipulation of the protein phase behavior, i.e. protein aggregation might be completely
inhibited or protein phase states (e.g. crystallization, precipitation) might be selectively
changed. Frequently used additives are polymers (polyethylene glycol, PEG) and os-
molytes. Osmolytes are low molecular weight additives, that can be grouped into the
major categories of free amino acids and derivates (e.g. glycine), polyols and uncharged
sugars (e.g. glycerol), methylamines, and urea [113]. The impact of these additives on
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protein stability is described to be due to a preferential binding or a preferential exclusion
of the additives from the proteins’ local domain. In cases where they are preferentially
excluded from the proteins’ local domain they are known to stabilize the proteins’ native
state [115, 116, 200–204]. The impact of additives on protein solubility is according to
Harris and Ro¨sgen [199] not as easy as predicting protein stability and no general models
exist. Though, the mode of action of osmolytes and PEG on protein stability is as well
not as easy as it might sound since for some additives stabilizing as well as destabilizing
effects have been observed. Parameters that strongly influence the stabilizing or destabi-
lizing character of additives are the additive concentration, the molecular weight of the
additive, and the solvent pH. PEG, dimethylglycine, and betaine for example have been
found to stabilize proteins up to a certain concentration and destabilize them for higher
concentrations [201, 205]. High molecular weights of PEG have been found to be destabi-
lizing as well [202], whereas high molecular weight polyols stabilize proteins better than
their low molecular weight counterparts [206]. Additive impact as function of solvent pH
is even harder to generalize. According to Singh et al. [207], polyols have a higher potency
to stabilize the proteins’ native state at low pH, whereas methylamines are described to
act most stabilizing at neutral pH and destabilizing at low pH and amino acids were
found to stabilize the native state of proteins almost independent of the pH [208]. This
pH dependent osmolyte action has been related to the chemical nature of the osmolytes,
e.g. the pKa values [209–211], but could not explain all pH dependent observations [212].
In contrast, there are indications that the pH dependent mode of action of additives
might have its origin in the nature of the proteins instead [208, 212]. It is for example
known that proteins at extreme pH values are conformationally unstable, i.e. prone to
at least partial unfolding [27]. Thus, our work aims to find a link between the pH de-
pendent mode of action of additives and the conformational stability of a model protein
in its initial state without additive. To the best of our knowledge up to now there are
no investigations on the pH dependent mode of action as a function of conformational
stability of proteins in their initial state without additive. Furthermore, this publica-
tion examines if the additives impact protein solubility and thus protein phase behavior.
Lysozyme from chicken egg white was studied as a model protein, but the presented
approaches can easily be transferred to other biopharmaceutical proteins. Lysozyme was
investigated at pH 3 and pH 5. Sodium chloride was added as precipitant to induce
phase transitions of lysozyme (e.g. crystallization and precipitation) in order to study
the phase behavior of lysozyme. In the following the term binary describes lysozyme in
aqueous sodium chloride solutions ranging from 0 M to 2.5 M sodium chloride. This was
also referred to as the initial state of lysozyme above. The term ternary in the follow-
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ing describes lysozyme in aqueous sodium chloride solutions ranging from 0 M to 2.5 M
sodium chloride and with a constant additive concentration. Lysozyme conformational
stability, solubility, and phase behavior in these ternary systems (with additive) will be
compared to lysozyme conformational stability, solubility, and phase behavior in the bi-
nary systems (without additive), i.e. to lysozymes’ initial state. Glycerol and glycine as
additives were chosen as representatives of two osmolyte classes and PEG 1000 as addi-
tive beyond the osmolyte class. Fourier-Transformed-Infrared (FT-IR) spectroscopy was
applied to monitor lysozyme conformation and to account for non-native conformational
changes. This allows to evaluate the impact of the additives on conformational stability
and their potency to stabilize or destabilize the proteins’ native state. Ternary phase
diagrams, consisting of lysozyme, sodium chloride and the respective additive as solution
components, were generated and compared to binary ones, consisting of lysozyme and
sodium chloride. The comparison of the phase diagrams reveals information about how
strong the additives manipulate lysozyme phase behavior, i.e. if they completely prevent
aggregation, delay it or if they can be used to selectively control phase states, e.g. transfer
former precipitated to crystalline phase states. The phase diagrams additionally allow to
experimentally determine lysozyme solubility in cases where crystallization occurs as the
supernatant of a crystalline solution is saturated and the lysozyme concentration in the
supernatant thus reflects lysozyme solubility [78, 213, 214]. Experimentally determined
solubility data points are fitted to an empirically found equation, resulting in continuous
solubility lines. Comparison between the binary and ternary systems gives the additive
impact on lysozyme solubility lines.
Altogether this publication aims to elucidate the potential origin of pH dependent ad-
ditive action and tries to expand the basic knowledge on additive impact on protein
solubility and phase behavior.
4.2 Materials and Methods
4.2.1 Materials
The used buffer substances were citric acid (Merck, Darmstadt, Germany) and sodium
citrate (Sigma-Aldrich, St. Louis, MO, USA) for pH 3 and sodium acetate (Sigma-Aldrich,
St. Louis, MO, USA) and acetic acid (Merck, Darmstadt, Germany) for pH 5. PEG 300
and PEG 1000 were obtained from Sigma-Aldrich (St. Louis, MO, USA). Sodium chlo-
ride as well as glycine were purchased from Merck (Darmstadt, Germany), glycerol was
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from Alfa Aesar (Ward Hill, MA, USA) and lactose from Carl Roth GmbH & Co. KG
(Karlsruhe, Germany). Hydrochloric acid and sodium hydroxide for pH adjustment were
obtained from Merck (Darmstadt, Germany). pH adjustment was performed using a
five-point calibrated pH-meter (HI-3220, Hanna Instruments, Woonsocket, RI, USA). All
buffers were filtered through 0.2 µm cellulose acetate filters (Sartorius, Goettingen, Ger-
many).
Lysozyme from chicken egg white was purchased from Hampton Research (Aliso Viejo,
CA, USA). The lysozyme solutions were filtered through 0.2 µm syringe filters with cel-
lulose acetate membranes (VWR, Radnor, PA, USA) previous to further desalting via
size exclusion chromatography. Size exclusion chromatography was conducted using a
HiTrap Desalting Column (GE Healthcare, Uppsala, Sweden) on an AEKTAprime plus
system (GE Healthcare, Uppsala, Sweden). A subsequent protein concentration step was
performed using Vivaspin® centrifugal concentrators (Sartorius, Goettingen, Germany)
with PES membranes and molecular weight cutoffs of 3 kDa.
Binary and ternary protein phase diagrams, consisting of lysozyme and sodium chloride
or lysozyme, sodium chloride and additive as solution components, were prepared on
MRC Under Oil 96 Well Crystallization Plates (Swissci, Neuheim, Switzerland) in 24 µL
scale microbatch experiments with a Freedom EVO® 100 (Tecan, Maennedorf, Switzer-
land) automated liquid handling station. The MRC Under Oil 96 Crystallization Plates
were covered with HDclear sealing tape (ShurTech Brands, Avon, OH, USA) to prevent
evaporation. The sealed plates were stored at 20◦C and for 40 days in a Rock Imager
182/54 (Formulatrix, Waltham, MA, USA) automated imaging system.
Lysozyme concentration in the supernatant of crystalline phase states was determined us-
ing a NanoDrop 2000c UV-Vis spectroscopic device (Thermo Fisher Scientific, Waltham,
MA, USA). An extinction coefficient of 1%280 nm,Savinase = 22.00 was used.
Fourier-Transformed-Infrared (FT-IR) spectra of selected binary and ternary lysozyme
systems were measured with a Bruker Tensor 27 (Bruker Corporation, Billerica, MA,
USA) Fourier-Transformed-Infrared (FT-IR) spectrophotometer with CONFOCHECK
configuration at 20◦C. Infrared analysis was conducted using the attenuated total reflec-
tion technique in a Bio-ATR II cell (Bruker Corporation, Billerica, MA, USA).
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4.2.2 Methods
4.2.2.1 Preparation of Stock Solutions
To set up the buffers all substances were weighed in and dissolved in ultrapure water of
approximately 90 % of the final buffer volume. Buffer capacity was 100 mM for all buffers.
pH was adjusted with the appropriate titrant with an accuracy of ± 0.05 pH units. After
pH adjustment the buffers were brought to their final volume using ultrapure water. All
buffers were filtered through 0.2 µm cellulose acetate filters. Buffers were used at the
earliest one day after preparation and after repeated pH verification.
To set up the protein stock solutions, protein was weighed in and dissolved in the ap-
propriate buffer. The protein solution then was filtered through a 0.2 µm syringe filter,
and further desalted using size exclusion chromatography. Protein concentration was ad-
justed to 65.25±1 mg/mL via centrifugal concentrators. A volume of 1 mL of protein
stock solution was required for generation of one ternary phase diagram.
4.2.2.2 Generation of Phase Diagrams
Binary protein phase diagrams for lysozyme from chicken egg white were generated earlier
[79]. Binary phase diagrams of lysozyme from chicken egg white at pH 3 and pH 5 using
sodium chloride as precipitant showed multiple phase transitions. Therefore, lysozyme in
aqueous sodium chloride solutions at pH 3 and pH 5 was selected for further investiga-
tion in ternary phase diagrams using 1 M glycine, 10 %(m/v) glycerol and 10 %(m/v)
PEG 1000 as additives. In total six ternary phase diagrams were generated. Additive
concentration was constant in any of the 96 wells on the crystallization plates for the
respective pH and additive type. Only lysozyme and sodium chloride concentrations were
varied in exactly the same way as in the binary phase diagrams. The resulting protein
and sodium chloride concentrations on the crystallization plates thus ranged between 2.5
and 21.75 mg/mL lysozyme and between 0 and 2.5 M sodium chloride. For generation
of 96 different ternary system points on the crystallization plates 8 µL of solutions with
varying sodium chloride concentration and a fixed concentration of additive were mixed
with 16 µL of solutions with varying lysozyme concentrations in the respective buffer
without sodium chloride and additive. After mixing crystallization plates were treated as
described by Baumgartner et al. [79]. The images after 40 days were visually examined
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to distinguish between the following phase states: soluble, crystalline, precipitated, skin
formation, gelation, liquid-liquid phase separation.
4.2.2.3 Determination of Solubility Lines
After 40 days and after scoring of the phase states the plates were removed from the
Rock Imager. In cases where crystalline phase states occurred, lysozyme concentration
in the supernatant of these crystalline solutions was determined. The supernatant of
a crystalline solution is saturated and the lysozyme concentration in the supernatant
thus reflects lysozyme solubility [78, 213, 214]. Therefore, experimental data points for
lysozyme concentration in the supernatant of crystalline solutions will be referred to as
solubility hereafter and were used to fit solubility lines. For determination of lysozyme
solubility 3 µL of the supernatant of crystalline solutions were transferred to a Nan-
odrop 2000c UV-Vis spectroscopic device to determine the lysozyme concentration in
the supernatant. This was conducted two- or threefold depending on the available su-
pernatant volume. Values were averaged and solubility lines were fitted using Eq. 4.1
resulting from a Box Lucas 1 model with S being the protein solubility, S0 the theo-
retical protein solubility for a sodium chloride concentration of 0 M. A and R0 < 0 are
adaptable parameters and cNaCl the sodium chloride concentration.
S = S0 +A · e(R0·cNaCl) (4.1)
4.2.2.4 FT-IR Analysis
Lysozyme solutions were scanned 24 h after preparation in absorbance mode with 700 scans
at a spectral resolution of 2 cm−1. Spectra were recorded from 4000 to 1000 cm−1. Back-
ground spectra were recorded for the respective solution the protein was dissolved in also
with 700 scans at a spectral resolution of 2 cm−1. Sample volume was 20 µL. All measure-
ments were conducted in duplicate. The OPUS 6.5 spectroscopy software was used for
recording and data processing of the recorded FT-IR spectra. Data pre-processing was
performed as follows: atmospheric compensation and vector normalization (Euclidean
norm) were carried out to delete the influence of water vapor bands on the spectra and to
delete protein concentration dependent effects. After data pre-processing second deriva-
tive spectra were calculated. Calculation of second derivative spectra was conducted in
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a wavenumber region from 1700 to 1600 µL and with 25 smoothing points. Changes in
the second derivate spectra correlate to conformational changes of lysozyme.
4.3 Results
4.3.1 FT-IR Spectra of Binary Lysozyme Systems at pH 3 and pH 5
The upper left section of Fig. 4.1 shows results from FT-IR spectroscopic measurements
of lysozyme at pH 3 in different binary systems (without additive). FT-IR second deriva-
tive spectra of soluble, crystalline, crystalline and coexisting precipitated phase states of
lysozyme and for phase states where skin formation occurred are shown. The different
Figure 4.1: Second derivative spectra from FT-IR measurements of lysozyme at pH 3
with different sodium chloride concentrations and without additive (upper
left), with 10 %(m/v) glycerol (upper right), with 1 M glycine (lower left),
with 10 %(m/v) PEG 1000 (lower right).
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phase states were induced by addition of different concentrations of sodium chloride
following the conditions from the phase diagrams. For the binary systems at pH 3 the
spectrum of crystalline lysozyme was very similar to the native soluble one. The sample
with lysozyme in coexisting crystalline and precipitated states deviated slightly from the
native soluble spectrum but the most evident deviation occurred for the sample with skin
formation. Here, a significant deviation occurred in a wavenumber region between 1640
and 1620 cm−1, which corresponds to the β-sheet region.
The upper left section of Fig. 4.2 shows results from FT-IR spectroscopic measurements of
lysozyme at pH 5 in different binary systems (without additive). FT-IR second derivative
spectra of soluble, crystalline, precipitated phase states of lysozyme are shown. At pH 5
the second derivative spectra of the investigated phase states in the binary systems were
very similar, even the precipitated state showed only small deviations from the native
soluble state.
Figure 4.2: Second derivative spectra from FT-IR measurements of lysozyme at pH 5
with different sodium chloride concentrations and without additive (upper
left), with 10 %(m/v) glycerol (upper right), with 1 M glycine (lower left),
with 10 %(m/v) PEG 1000 (lower right).
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4.3.2 Impact of Investigated Additives on Lysozyme Conformation as
Function of pH
4.3.2.1 Impact on Lysozyme Conformation at pH 3
The upper right and the lower sections of Fig. 4.1 show the second derivative spectra of
the FT-IR spectroscopic measurements of lysozyme at pH 3 in different ternary systems
(with additives). Addition of 10 %(m/v) glycerol (Fig. 4.1, upper right) smoothed the
deviation between the second derivative spectra of different phase states in comparison
to the spectra of different phase states in binary systems (Fig. 4.1, upper left). The
spectrum for coexisting crystallization and precipitation was much more similar to the
native soluble one than in the binary case. Even the spectrum for the sample with skin
formation was more similar to the soluble, native spectrum than in the binary case. The
same accounted for the addition of 10 %(m/v) PEG 1000 (Fig. 4.1, lower right). Deviation
between the second derivative spectra of different phase states was smoothed by addition
of PEG 1000. In contrast, addition of 1 M glycine (Fig. 4.1, lower left) increased deviation
between the second derivative spectra of the different phase states. The spectrum of
the sample with coexisting crystalline and precipitated lysozyme deviated stronger from
soluble, native spectrum than in the binary case, especially in a wavenumber region
between 1660 and 1640 cm−1. A decrease of the peak depth in this region corresponds
to a dissipation of α-helix structures. The spectrum of the sample with skin formation
again deviated strongest in the wavenumber region between 1640 and 1620 cm−1.
The FT-IR analysis results for pH 3 showed that addition of glycerol and PEG 1000
reduced deviations between the second derivative FT-IR spectra of different phase states.
Glycine in contrast increased deviations between the second derivative FT-IR spectra
compared to the samples without additive.
4.3.2.2 Impact on Lysozyme Conformation at pH 5
The upper right and the lower sections of Fig. 4.2 show the second derivative spectra of
the FT-IR spectroscopic measurements of lysozyme at pH 5 in different ternary systems
(with additives). The addition of 10 %(m/v) glycerol, 10 %(m/v) PEG 1000 and 1 M
glycine hardly influenced the second derivative FT-IR spectra of lysozyme in different
phase states. Even for addition of glycine the spectra hardly deviated.
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4.3.3 Impact of Investigated Additives on Lysozyme Phase Behavior as
Function of pH
For examination of the impact of selected additives on lysozyme phase behavior ternary
phase diagrams with lysozyme, sodium chloride and additive as solution components were
compared to binary phase diagrams, consisting of lysozyme and sodium chloride, at pH 3
and pH 5. In particular, the sodium chloride concentration for initiation of crystallization,
the size of the crystallization area and the crystal size and morphology were compared.
4.3.3.1 Impact on Lysozyme Phase Behavior at pH 3
Fig. 4.3 shows the binary (upper left) and ternary (upper right, lower right, and lower
left) phase diagrams of lysozyme at pH 3. The sodium chloride concentration for initiation
Figure 4.3: Phase diagrams of lysozyme at pH 3 depending on sodium chloride concen-
tration without additive (upper left), with 10 %(m/v) glycerol (upper right),
with 1 M glycine (lower left), and with 10 %(m/v) PEG 1000 (lower right).
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of lysozyme crystallization did not change by addition of glycerol, PEG 1000 or glycine.
In any case lysozyme crystallization started at 0.45 M sodium chloride. This said, the
lysozyme concentration for crystallization was influenced and was higher than in the bi-
nary case for addition of 10 %(m/v) glycerol (upper right) and lower than in the binary
case for addition of 10 %(m/v) PEG 1000 and 1 M glycine (lower right and left). Adding
10 %(m/v) glycerol to the solutions resulted in a wider crystallization area, a smaller pre-
cipitation area and reduced skin formation. Glycerol reduced the number of conditions
where skin formation occurred to 4 in contrast to 20 in the binary phase diagram. Ad-
dition of 10 %(m/v) PEG 1000 enlarged the size of the crystallization area and delayed
precipitation even further than glycerol. The most remarkable difference was that the
addition of PEG 1000 completely inhibited skin formation. The addition of 1 M glycine
decreased the size of the crystallization area dramatically and enlarged the precipitation
area as well as the area where skin formation occurred. The number of conditions where
skin formation occurred was increased to 28.
In summary, at pH 3 the additives did not strongly affect the sodium chloride concentra-
tion needed for initiation of aggregation (crystallization) but they did influence the size
of the crystallization and precipitation area, and the size of the area where skin forma-
tion occurred. Thus, the phase states or rather the aggregate states could be successfully
selectively manipulated, for example from former precipitated states to crystalline ones.
Figure 4.4: Phase states of 21.75 mg/mL lysozyme after 40 days at pH 3 with 0.68 M
sodium chloride (upper row) and pH 5 with 1.36 M sodium chloride (lower
row). Additive concentrations: without additive (a), 10 %(m/v) glycerol (b),
10 %(m/v) PEG 1000 (c), 1 M glycine (d), without additive (e), 10 %(m/v)
glycerol (f), 10 %(m/v) PEG 1000 (g), 1 M glycine (h).
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No significant influence on crystal size and morphology was observed for addition of
glycerol, PEG 1000 or glycine as can be seen in Fig. 4.4(a-d).
4.3.3.2 Impact on Lysozyme Phase Behavior at pH 5
Fig. 4.5 shows the binary (upper left) and ternary (upper right, lower right, and lower
left) phase diagrams of lysozyme at pH 5. In contrast to pH 3 the sodium chloride
concentration for initiation of lysozyme crystallization was influenced by addition of
glycerol and glycine. The addition of 10 %(m/v) glycerol at pH 5 caused a shift of the
crystallization area to higher sodium chloride concentrations. The addition of 1 M glycine
shifted the crystallization area slightly towards lower sodium chloride concentrations.
PEG 1000 did not shift the sodium chloride concentration for initiation of lysozyme
crystallization but shifted the crystallization area to higher lysozyme concentrations.
Moreover, addition of PEG 1000 caused a crystallization area that was interspersed with
Figure 4.5: Phase diagrams of lysozyme at pH 5 depending on sodium chloride concen-
tration without additive (upper left), with 10 %(m/v) glycerol (upper right),
with 1 M glycine (lower left), and with 10 %(m/v) PEG 1000 (lower right).
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soluble conditions. These shifts of the crystallization areas caused a decrease of the size of
the crystallization areas by addition of 10 %(m/v) glycerol and 10 %(m/v) PEG 1000 and
an increase by addition of 1 M glycine. Addition of 10 %(m/v) glycerol and 10 %(m/v)
PEG 1000 turned some former crystalline phase states to soluble phase states, i.e. inhib-
ited aggregation. Compared to the binary phase diagram with 51 crystalline phase states
and one precipitated phase state, addition of 10 %(m/v) glycerol reduced the number
of crystalline phase states to 27 and one phase state with coexisting crystallization and
precipitation. Addition of 10 %(m/v) PEG 1000 reduced the number of crystalline phase
states to 31 and completely inhibited precipitation. Addition of 1 M glycine increased the
number of crystalline phase states to 61 but also completely inhibited precipitation. The
influence of the investigated additives on crystal size and morphology was strong as can
be seen in Fig. 4.4(e-h). In the binary systems three-dimensional crystals with a size of
averagely 400 µm occurred up to sodium chloride concentrations of 2.05 M (exemplarily
shown in Fig. 4.4e). For higher sodium chloride concentrations small, sea-urchin shaped
two-dimensional crystals evolved instead. Addition of 10 %(m/v) glycerol and PEG 1000
(Fig. 4.4f and g) caused the formation of single, three-dimensional crystals with averagely
twice the size of the crystals in the binary case over the whole sodium chloride concen-
tration range. Glycine in contrast inhibited the formation of three-dimensional crystals
from 1.36 M sodium chloride (Fig. 4.4h) and small, sea-urchin shaped two-dimensional
crystals evolved instead.
In summary, at pH 5 the additives strongly affected either the sodium chloride concentra-
tion and/or the lysozyme concentration for initiation of aggregation (crystallization), i.e.
caused a shift of the crystallization area. This as well influenced the size of the crystalliza-
tion area. Thus, aggregation could be successfully inhibited or accelerated. Furthermore,
a striking influence on lysozyme crystal size and morphology was observed.
4.3.4 Effect of Investigated Additives on Lysozyme Solubility
4.3.4.1 Determination of Lysozyme Solubility and Fit of Solubility Lines
Lysozyme concentration in the supernatant of crystalline solutions at pH 3 could be de-
termined with a maximum relative deviation of 6.4 % for the binary system and 13 %
for the ternary systems. Lysozyme concentration in the supernatant of crystalline so-
lutions at pH 5 could be determined with a maximum relative deviation of 16.9 % for
the binary system and 24.9 % for the ternary systems. Inaccuracies could have been due
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to development of incomplete equilibria in the ternary systems as described by Asherie
[78]. There, the presented approach to determine protein solubility starting with a super-
saturated solution is described to be more difficult and less accurate than to dissolve a
protein crystal in an undersaturated protein solution. This is however not possible with
the experimental approach described in this study. Nevertheless, solubility lines could
be fitted to these experimental solubility data points with a high accuracy using Eq. 4.1
which arised from a Box Lucas 1 fit model. This fit model was found to give the best
approximation to the solubility data points, but exponential correlations between protein
solubility and salt concentration as described in Eq. 4.1 were empirically found earlier,
too, employed for example in the Cohn equation [215]. Eq. 4.1 though could even fit
the ternary systems with a high accuracy as can be seen in Table 4.1 , i.e. the addition
of additives did not influence the validity of the used exponential correlation. The only
exception from this was the solubility line for the ternary system consisting of lysozyme,
sodium chloride and 10 %(m/v) glycerol at pH 5. In this case no correlation between the
experimental solubility data points and Eq. 4.1 could be found. In the other cases the
coefficient of correlation was above 0.98. The fit parameters as well as the coefficients
of correlation for the individual binary and ternary systems are listed in Table 4.1. The
calculated lysozyme solubility lines as well as the experimental data points are shown in
Fig. 4.6.
Table 4.1: Fit parameters and coefficients of correlation for fit of the experimental data
to Eq. 4.1
pH S0 A R0 R
2
without additive 3 0.95617 115.70692 -4.77088 0.98775
+ 10 %(m/v) glycerol 3 1.27213 48.94989 -2.94109 0.9909
+ 1 M glycine 3 0.83462 61.11589 -3.98231 0.99325
+ 10 %(m/v) PEG 1000 3 1.42829 199.84551 -5.64349 0.99394
without additive 5 3.29623 42.61535 -3.40082 0.98851
+ 10 %(m/v) glycerol 5 - - - -
+ 1 M glycine 5 2.07977 125.1018 -4.41318 0.99529
+ 10 %(m/v) PEG 1000 5 5.89109 88.6513 -3.71137 0.98821
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4.3.4.2 Impact on Lysozyme Solubility at pH 3
At pH 3 (Fig. 4.6, left) the addition of glycerol, PEG 1000 and glycine did not signifi-
cantly influence lysozyme solubility in comparison to the binary system. The addition of
10 %(m/v) glycerol slightly enhanced lysozyme solubility in a sodium chloride concentra-
tion range between 0.68 and 1.82 M. The addition of 1 M glycine slightly decreased the
lysozyme solubility below 0.68 M sodium chloride. The experimental data points as well
as the fitted solubility line for the ternary system with PEG 1000 are almost identical to
the binary system.
4.3.4.3 Impact on Lysozyme Solubility at pH 5
At pH 5 (Fig. 4.6, right) the addition of glycerol, PEG 1000 and glycine significantly influ-
enced the lysozyme solubility. The addition of 10 %(m/v) glycerol caused an enhancement
of the lysozyme solubility for sodium chloride concentrations from 1.14 M to 2.5 M. The
addition of 10 %(m/v) PEG 1000 enhanced lysozyme solubility in the whole investigated
sodium chloride concentration range: The addition of glycine increased lysozyme solubil-
ity up to 0.68 M sodium chloride and decreased lysozyme solubility for sodium chloride
concentrations from 0.91 M to 2.5 M. Thus, the effect of glycine on lysozyme solubility
at pH 5 depended on the sodium chloride concentration.
Figure 4.6: Solubility lines of lysozyme at pH 3 (left) and pH 5 (right) depending on
sodium chloride concentration without additive and with 10 % (m/v) glycerol,
1 M glycine and 10 % (m/v) PEG 1000. The solid lines depict the solubility
lines fitted using Eq. 4.1 with fit parameters as provided in Table 4.1.
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4.4 Discussion
4.4.1 Impact of Investigated Additives on Lysozyme Phase Behavior,
Conformation and Solubility at pH 3
Deviation between the FT-IR spectra of different phase states of lysozyme in the binary
systems at pH 3 is high, i.e. conformational instability of lysozyme at pH 3 in different
phase states is high. Even non-native changes in lysozyme conformation during aggre-
gation could be observed in the binary system as the spectrum of the sample with skin
formation showed a significant deviation and according to Zeelen [216] this skin is a
layer of denatured protein. Addition of glycerol and PEG 1000 reduced the deviation
between the FT-IR spectra of different phase states of lysozyme in the ternary systems,
i.e. glycerol and PEG 1000 increase conformational stability of lysozyme. In contrast,
addition of glycine increased the deviation between the FT-IR spectra, i.e. glycine fur-
ther increased conformational instability. The differing impact of glycerol, PEG 1000 and
glycine on conformational stability was also reflected in a differing impact on lysozyme
phase behavior in the ternary phase diagrams compared to the binary ones. Addition
of glycerol and PEG 1000 enlarged the size of the crystallization area, whereas addition
of glycine reduced the size of the crystallization area. Under the assumption that crys-
tallization is a oligomerization of native protein molecules [82, 217] the above further
supports the results from the FT-IR experiments and indicates that glycerol as well as
PEG 1000 stabilized the native state of lysozyme whereas glycine destabilized the native
state of lysozyme. Additionally, skin formation could be reduced or completely inhibited
by addition of glycerol and PEG 1000 at pH 3 and was enhanced by addition of glycine.
As this skin represents a non-native phase state [216], reduction or inhibition of skin
formation shows the potency of glycerol and PEG 1000 to delay or completely inhibit
non-native aggregation. In contrast, addition of glycine promoted non-native aggrega-
tion. This again further supports the results from the FT-IR experiments. The impact of
glycerol, PEG 1000 and glycine on conformational stability was not reflected in a signifi-
cant influence on lysozyme solubility lines at pH 3. Lysozyme solubility lines were hardly
influenced by the addition of glycerol, PEG 1000 and glycine. As protein solubility in
many cases is described as directly related to protein-protein interactions [218–221], no
influence on the solubility lines implies no influence on protein-protein interactions by
addition of glycerol, PEG 1000 and glycine. Fig. 4.4(a-d) shows that glycerol, PEG 1000
and glycine did not significantly influence lysozyme crystal size and morphology. This
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indicates that they as well did not influence aggregation kinetics [222–224]. This is fur-
ther supported by the fact that both, lysozyme solubility lines and the initiation of
crystallization, were not significantly influenced by addition of glycerol, PEG 1000 and
glycine. However, lysozyme phase states could be selectively controlled by addition of
glycerol, PEG 1000 and glycine. For example, precipitation and skin formation could be
transformed to crystallization or the other way around.
Altogether, additive action at pH 3 was identified to be simply driven by structure stabi-
lizing or destabilizing tasks. This is in agreement with the preferential interaction theory.
Addition of glycerol and PEG 1000 stabilized the native lysozyme conformation and thus
seem to cause a preferential hydration of lysozyme, i.e. glycerol and PEG 1000 are pref-
erentially excluded from lysozymes’ local domain. Addition of glycine destabilized the
native state, i.e. it is preferentially bound to or enriched at the lysozyme surface. The
destabilizing properties of glycine were surprising, though. Glycine was earlier described
as stabilizing osmolyte even for concentrations up to 5 M [205, 225]. However, it has
to be mentioned that according to Singh et al. [207] osmolyte action is extremely pH
dependent and the above named investigations with lysozyme and glycine whose results
are in opposition to ours were conducted at pH 5.8-6.5.
In summary, at pH 3, glycerol and glycine exhibited typical osmolyte character that
could be explained by the preferential interaction theory. PEG 1000 action could also be
explained using the preferential interaction theory, but its stabilizing impact was stronger
compared to glycerol as it could even completely inhibit non-native aggregation. Protein-
protein interactions and aggregation kinetics were not only or only weakly influenced by
addition of glycerol, glycine, and PEG 1000 as far as could be evaluated here.
4.4.2 Impact of Investigated Additives on Lysozyme Phase Behavior,
Conformation and Solubility at pH 5
Deviation between the FT-IR spectra of different phase states of lysozyme in the binary
systems at pH 5 is low. Thus, conformational stability of lysozyme at pH 5 is high,
even during precipitation. The additives investigated did have no apparent influence on
the FT-IR spectra, i.e. conformational stability of lysozyme seems to be untouched by
addition of glycerol, PEG 1000 and glycine. In contrast to the impact of the additives
on lysozyme phase behavior at pH 3, where only the size of the crystallization area was
changed, at pH 5 the investigated additives caused a shift of the crystallization area to
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Figure 4.7: Phase states of 21.75 mg/mL lysozyme after 40 days at pH 5 with varying
sodium chloride concentrations. The upper row shows the phase states for
binary systems without additive, the lower row the phase states for ternary
systems with 1 M glycine. Sodium chloride concentrations are 0.45 M (a and
h), 0.68 M (b and i), 0.91 M (c and j), 1.14 M (d and k),1.36 M (e and l),
1.59 M (f and m), and 1.82 M (g and n).
higher or lower sodium chloride and/or lysozyme concentrations. The addition of 10 %(m/v)
glycerol significantly shifted the crystallization area to higher sodium chloride and lysozyme
concentrations. The addition of PEG 1000 caused a shift of the crystallization area to
higher lysozyme concentrations and the ternary crystallization area is interspersed with
soluble conditions. Therefore, glycerol and PEG 1000 successfully completely inhibited
aggregation in some cases compared to the binary system. Glycine shifted the crystal-
lization area to lower sodium chloride concentrations and thus promoted aggregation in
comparison to the binary system. This shift of the crystallization area caused by the
additives at pH 5 is not due to an impact of glycerol, PEG 1000 and glycine on lysozyme
conformational stability. Furthermore, in contrast to pH 3 glycine at pH 5 did not induce
or promote non-native aggregation. However, at pH 5 lysozyme solubility lines were sig-
nificantly changed by addition of glycerol, PEG 1000 and glycine. Addition of glycerol
and PEG 1000 enhanced lysozyme solubility at pH 5, whereas glycine enhanced lysozyme
solubility up to 0.68 M sodium chloride and decreased solubility for higher sodium chlo-
ride concentrations. Thus, instead of affecting lysozyme conformational stability glycerol,
PEG 1000 and glycine seem to strongly influence protein-protein interactions. Addition
of glycerol and PEG 1000 probably reduced attractive protein-protein interactions in
comparison to the binary system over the whole sodium chloride concentration range.
Attractive protein-protein interactions were either reduced or enhanced by addition of
glycine dependent on sodium chloride concentration, yielding in increased or decreased
solubility. The impact of the additives on lysozyme solubility and intermolecular interac-
tions was also reflected in crystal size and morphology, i.e. in aggregation or crystallization
kinetics. Much bigger lysozyme crystals than in the binary system at pH 5 evolved in
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presence of 10 %(m/v) glycerol and PEG 1000, i.e. glycerol and PEG 1000 slowed ag-
gregation or crystallization kinetics. The diverse impact of glycine on lysozyme solubility
and intermolecular interactions is also reflected in the crystal size and morphology for
the ternary systems as can be seen in Fig. 4.7. Up to 1.14 M sodium chloride crystal size
was increased, i.e. aggregation or crystallization kinetics slowed in comparison to the bi-
nary system, whereas for higher sodium chloride concentrations small, two-dimensional,
sea-urchin shaped crystals occurred, i.e. aggregation or crystallization kinetics were ac-
celerated.
In summary, the presented results for pH 5 indicate that additives that do not influence
lysozyme conformational stability mainly act on lysozyme solubility, i.e. protein-protein
interactions, and on crystal size and morphology, i.e. aggregation or crystallization ki-
netics. The mode of action of the additives at pH 5 could not be correlated to the pref-
erential interaction theory as no influence on lysozyme conformation could be detected
and lysozymes’ native conformational state was very stable.
4.4.3 Impact of Investigated Additives as Function of pH
Generally a pH dependency of osmolyte action was described earlier [207, 208]. So far,
pH dependent osmolyte action was connected to the chemical nature of the osmolyte,
e.g. the pKa value [209–211]. This could be excluded in our case as no pKa is exceeded
between pH 3 and pH 5 for the investigated additives. More likely the differences be-
tween pH 3 and pH 5 are associated with the conformational stability of lysozyme in
the binary systems. At pH 3 FT-IR investigations of the binary system showed that
lysozyme is conformationally unstable. Here, glycerol, PEG 1000 and glycine exhibited
no impact on lysozyme solubility lines, crystal size and crystal morphology. At pH 3 the
additives however stabilized (glycerol and PEG 1000) or destabilized (glycine) the native
conformation of lysozyme and reduced (glycerol), completely inhibited (PEG 1000) or
promoted (glycine) non-native aggregation. Stabilization or destabilization of lysozymes’
native conformation resulted in modified sizes of the crystallization area, the precipitation
area and the area where skin formation occurred. Thus, a selective control of lysozyme
phase states is possible.
At pH 5 FT-IR investigations of the binary system showed that lysozyme is conforma-
tionally stable. Here, glycerol, PEG 1000 and glycine exhibited a significant impact on
lysozyme solubility lines, the initiation of crystallization, crystal size and morphology, but
no impact on lysozyme conformation could be identified. Aggregation or crystallization
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in particular could be selectively inhibited or promoted and crystal size and morphology
could be selectively manipulated.
This in summary indicates that in cases where protein conformational stability is threat-
ened additives adopt stabilization tasks. Their mode of action in these cases can be
described following the preferential interaction theory [115, 116, 200–204]. In cases where
protein conformational stability is not threatened the ability of the additives to stabilize
proteins is not needed, but their ability to increase the solubility of native proteins is es-
sential. This was described earlier by Auton et al. [226] and is further supported by Bolen
and Baskakov [227] who stated that stabilizing osmolytes act mainly on the denatured
state leaving the native state largely unperturbed.
4.5 Conclusion
The impact of the additives on lysozyme phase behavior and solubility lines was observed
to be pH dependent. The pH dependent impact could be explained by differences in the
conformational stability of lysozyme at pH 3 and pH 5 in presence of sodium chloride.
pH dependent additive impact was described earlier but the presented work allowed to
reduce this to lysozyme conformational stability. This publication additionally expanded
the basic knowledge about additive impact on protein solubility and could present a math-
ematical description for a solubility line that could capture lysozyme solubility in binary
and ternary systems. For conditions where the native conformational state of lysozyme
was unstable in the binary system the impact caused by the investigated additives could
be explained by the preferential interaction theory. Native conformation was stabilized by
glycerol and PEG 1000 and destabilized by addition of glycine. PEG 1000 in particular
even completely inhibited non-native aggregation, whereas glycine even promoted non-
native aggregation. Stabilization or destabilization of the native conformational state
resulted in a modified lysozyme phase behavior without affecting solubility lines and
crystal size and morphology. Phase states could be successfully selectively controlled. For
conditions where the native conformational state of lysozyme was stable in the binary
system no impact of the additives on lysozymes’ native conformation could be observed.
Though, the additives exhibited a significant impact on lysozyme solubility lines, the ini-
tiation of crystallization, crystal size and morphology. Glycerol and PEG 1000 increased
lysozyme solubility and crystal size. Glycine increased or decreased lysozyme solubility
and crystal size depending on sodium chloride concentration in the ternary systems. All
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of the three additives showed characteristics that could be of interest for biopharmaceu-
tical industries: aggregation processes could be successfully manipulated with or without
effects on solution characteristics like solubility or aggregate characteristics like crystal
size and morphology.
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Abstract
PEGylation, i.e. the covalent attachment of chemically activated polyethylene glycol
(PEG) to proteins, is a technique commonly used in biopharmaceutical industry to
improve protein stability, pharmacokinetics and resistance to proteolytic degradation.
Therefore, PEGylation represents a valuable strategy to reduce autocatalysis of bio-
pharmaceutical relevant proteases during production, purification and storage. In case of
non-specific random conjugation the existence of more than one accessible binding site
results in conjugates which vary in position and number of attached PEG molecules.
These conjugates may differ considerably in their physicochemical properties. Optimiz-
ing the reaction conditions with respect to the degree of PEGylation (number of linked
PEG molecules) using high-throughput screening (HTS) technologies requires a fast and
reliable analytical method which allows stopping the reaction at defined times.
In this study an analytical protocol for PEGylated proteases is proposed combining
preservation of sample composition by trichloroacetic acid (TCA) precipitation with
high-throughput capillary gel electrophoresis (HT-CGE). The well-studied protein hen
egg-white lysozyme served as a model system for validating the newly developed analyt-
ical protocol for 10 kDa mPEG-aldehyde conjugates. PEGamer species were purified by
chromatographic separation for calibrating the HT-CGE system. In a case study, the ser-
ine protease Savinase® which is highly sensitive to autocatalysis was randomly modified
with 5 kDa and 10 kDa mPEG-aldehyde and analyzed. Using the presented TCA proto-
col baseline separation between PEGamer species was achieved allowing for the analysis
of heterogeneous PEGamer mixtures while preventing protease autocatalysis.
Keywords: Autocatalysis; Protease PEGylation; TCA precipitation; PEGamer quantifi-
cation; High-throughput capillary gel electrophoresis
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5.1 Introduction
Proteases already are widely applied as industrial catalysts in food processing (e.g. man-
ufacturing of cheese in dairy industry), in the leather industry and as laundry detergents
[228]. The rapid technological progress in the field of biotechnology enables the pro-
duction of proteases with novel properties and substrates causing an increased interest
in proteases for diagnostic and therapeutic applications in the pharmaceutical industry
[228]. The global pharmaceutical market benefits from proteases as a growing class of
drugs. In 2011 twelve protease therapies had been approved by the Food and Drug Ad-
ministration (FDA) [229]. For instance, the recombinant extracellular serine proteases
plasmin and tissue plasminogen activator (tPA) are applied in thrombolytic therapy as
a treatment of heart attacks and ischemic stroke [230]. Both cardiovascular diseases rep-
resent the major causes of death in the western world [231]. They are both caused by
circulatory blockages of blood vessels consisting mainly of insoluble fibrin. Plasmin di-
rectly degrades fibrin initiating clot breakdown whereas tPA catalyzes the reaction of the
precursor plasminogen to the active plasmin by cleavage of a single bond [232, 233]. In
the case of tPA the therapeutic application is aggravated due to a fast clearance from
the blood stream resulting in an extremely short half-life of only two to six minutes [234,
235].
Moreover, proteases such as enterokinase, thrombin and factor Xa are used during the
production of recombinant proteins for the removal of fusion tags [236–238]. Those tags
are often attached to different peptides and proteins in order to simplify their expression,
purification and analytics as well as to improve their solubility [238–240]. Fusion tags
often need to be cleaved from protein drugs for meeting the regulatory standards since
the tag may potentially modify the biological activity of the target protein or induce an
immune response in the patient [241].
Modern biotechnology is capable of producing recombinant proteases to an industrial
scale with high production efficiencies. However, a high loss of protease activity due
to autoproteolytic degradation during production, purification and storage represent a
major challenge [239, 242]. Different approaches to solve both short serum half-life of
therapeutic proteins and autoproteolytic degradation include mutagenic variations of
the amino-acid sequence [242], incorporating proteins into drug-delivery vehicles such
as liposomes [235, 243] or microspheres of biodegradable polymers [244] and protein
conjugation [142].
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Protein conjugation denotes the linkage of synthetic polymers to a native protein in order
to alter its physicochemical properties [245]. The attached molecules shield the protein
surface which results in an enhanced stability towards proteases and a reduced recogni-
tion of the protein by the immune system [142], [246], [187]. The covalent attachment
of chemically activated polyethylene glycol (PEG) to proteins is by this means one of
the most commonly used technique in biopharmaceutical industry. PEG is especially in-
teresting as a modifier for biopharmaceuticals since it is approved by the FDA for use
in pharmaceuticals. It proved to show little toxicity and immunogenicity and it is elim-
inated from the body by the kidneys or in the feces [142]. The use of the hydrophilic
polymer PEG as modifier results in an increased hydrodynamic radius of the protein in
solution [247]. This effect engenders both an increased protein solubility and a decreased
clearance from the blood stream. Several proteins, reaction mechanisms and conditions
have been studied following first pioneering studies on PEGylated albumin and bovine
liver catalase in the 1970s by the group of Abuchowski [133, 134]. Most commonly amino
coupling PEG reagents binding to the N-terminus or to surface lysines, such as PEG-
aldehyde are used [187]. The existence of more than one accessible binding site results in
conjugates varying in position and number of attached PEG molecules. Those conjugates
can significantly differ in their physicochemical properties [248]. The PEGylation reac-
tion and thereby the conjugate mixture can be controlled through reaction conditions
like the PEG to protein ratio, reaction time, temperature and solution pH. The inter-
actions between these factors, however, make it difficult to reproduce protein batches in
terms of Quality by Design (QbD) [19]. One of the key tools within the QbD-framework
to gain a deeper process understanding are high-throughput screenings (HTS) coupled
with Design of Experiments (DoE). Since speed and throughput of experimental facilities
are constantly increasing appropriate high-throughput compatible analysis techniques of
high resolution are crucial to determine the experimental outcome. The quantification of
PEGylation processes remains a challenge due to poor spectrophotometric properties of
PEG [249]. The increased molecular mass of protein conjugates promotes size exclusion
chromatography (SEC) for quantitative separation of protein PEGamers. However, most
SEC-based assays are limited by a maximum throughput of a few samples per hour. Ap-
proaches to increase the throughput of SEC include interlaced injection of samples, the
parallel operation of two columns and multivariate evaluation of chromatographic data
with poor resolution [250]. Especially protein conjugation with low molecular weight
PEG molecules lead to poor separation of individual PEGamers by SEC. Capillary gel
electrophoresis (CGE) represents an alternative to SEC with a reduced processing time
of approximately 60 s per sample [125]. Due to the microfluidic measurement principle,
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CGE provides a high peak resolution. As SEC, CGE separates proteins by molecular
weight and therefore the conjugates by the number of attached PEG molecules [251].
This work demonstrates the potential of high-throughput capillary gel electrophoresis
(HT-CGE) for the quantification of PEGylated proteins with varying degrees of conjuga-
tion. In the first part of this study the applicability of the standard HT-CGE protocol is
shown for structural stable proteins using the model protein lysozyme from hen egg-white.
For proteins that are subject to structural degradation an improved analytical protocol is
presented which combines TCA (trichloroacetic acid) precipitation and high-throughput
capillary gel electrophoresis. As an example the model serine protease Savinase® was
chosen which could not be analyzed with the standard protocol due to high autocataly-
sis rates triggered by high temperatures used for denaturation during HT-CGE sample
preparation. The benefit of integrating TCA precipitation into the analytical protocol is
the immediate inactivation of the proteases and the resulting preservation of the sample
composition. Moreover, TCA is assumed to precipitate all proteins in solution whereas
salts and other buffer components remain in solution. TCA precipitation hence reduces
the concentration of critical components from the sample [252] which otherwise may alter
electrophoretic mobility of proteins in HT-CGE. The validated analytical method was
subsequently used to determine the PEGamer composition for PEGylated Savinase®
mixtures.
5.2 Materials and Methods
5.2.1 Overview of Workflow
The methods applied in this work are summarized schematically in Fig. 5.1. After pro-
ducing PEGylated proteins via batch reactions a chromatographic purification was per-
formed to isolate pure PEGamer (molecules with a varying number of attached PEG
molecules) fractions. The purification of PEGylated lysozyme was performed by a two-
step chromatography process of SEC followed by CEX. Savinase® was purified by a
single CEX step (Fig. 5.1A). In this study a distinction is made between native proteins
(non-PEGylated), proteins with one attached PEG molecule (mono-PEGylated) and pro-
teins with two attached PEG molecules (di-PEGylated). Proteins with more than two
attached PEG molecules (poly-PEGylated) are taken into consideration using a mass
balance only. Each purified PEGamer fraction was subsequently used to determine a
linear calibration curve for HT-CGE by linking the fluorescence signal to the PEGamer
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concentration (Fig. 5.1B). For the standard protocol the PEGamer fractions were thereby
used without further treatment. For the TCA protocol samples were precipitated with
trichloroacetic acid before HT-CGE analysis. The described HT analytic was then applied
to PEGylated protein samples with an unknown mixture composition(Fig. 5.1C).
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Figure 5.1: Schematic overview of the workflow for the development of a new analytical
protocol for PEGylated proteins.
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5.2.2 Preparation of Buffer and Protein Solutions
All solutions were prepared with ultrapure water provided by a PURELAB Ultra wa-
ter purification system (ELGA Labwater, Germany). The used buffer substances were
sodium acetate trihydrate (Sigma–Aldrich, St. Louis, MO, USA) and acetic acid (Merck,
Germany) for pH 5 and sodium phosphate monobasic dihydrate (Sigma-Aldrich, USA)
as well as di-sodium hydrogen phosphate dihydrate (Merck, Germany) for pH 6.2, pH 7.2
and pH 8.2. The buffer capacity was set to 25 mM for all buffers. Sodium chloride (NaCl)
included in the SEC running buffer and the CEX elution buffer was purchased from
Merck (Germany). pH adjustment within a range of ± 0.05 units was performed using a
five-point calibrated pH-meter HI-3220 (Hanna Instruments, USA) with a SenTix® 62
pH electrode (Xylem Inc., USA). For pH correction hydrochloric acid and sodium hy-
droxide were obtained from Merck (Germany). Buffers were used at the earliest one day
after preparation and repeated pH verification. All buffers were filtered using a 2 µm
cellulose-acetate filter (Sartorius, Germany) and degassed for chromatographic purposes.
Protein solutions were prepared using Savinase® (Protease from Bacillus sp. liquid, ≥16
U/g) from Sigma-Aldrich (USA) and hen egg-white lysozyme (subsequently referred to
as lysozyme) from Hampton Research (USA). Methoxy-PEG-propionaldehyde (mPEG-
aldehyde) with an average molecular weight of 5 kDa (Sunbright ME-050 AL) and
10 kDa (Sunbright ME-100 AL) was obtained from NOF Corporation (Japan). Sodium
cyanoborohydride (NaCNBH3) as reducing agent for PEGylation and L-lysine for termi-
nating the reaction were purchased from Sigma-Aldrich (USA). The Trichloroacetic acid
(TCA) stock solution consisted of 50% (w/w) TCA (AppliChem, Germany) in ultrapure
water.
5.2.3 Batch PEGylation
For the PEGamer isolation, PEGylation experiments were performed batch-wise in 15 mL
Falcon Tubes (BD Biosciences, USA). 25 mM sodium phosphate buffer (pH 7.2) contain-
ing 20 mM NaCNBH3 for lysozyme and 60 mM for Savinase
® was used to dissolve
mPEG-aldehyde. Protein was then added based on the desired molar PEG to protein
ratio (r =NPEG/Nprotein with N being the concentration of moles per volume). In case
of lysozyme PEGamer isolation was performed with r=6.67 and r=15 for Savinase®, re-
spectively. The set protein concentration was 5 mg/mL for lysozyme and 10 mg/mL for
Savinase®. For the PEGylation reaction the tube was continuously shaken in an overhead
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shaker (Labinco LD79, Labinco BV, Brade, Netherlands) for 3.5 h in case of lysozyme
and 24 h for Savinase®. The PEGylation reaction was stopped by adding 200 mM of
L-lysine according to Ottow et al. [253].
5.2.4 Preparative Purification of PEGamers
Preparative separation of PEGamers was performed on an A¨KTA purifier system equip-
ped with an Autosampler A-905 and a Fraction Collector Frac-950 (GE Healthcare,
Sweden). The purification of PEGylated lysozyme was performed by a two-step process
involving a size exclusion (SEC) step followed by a cation exchange (CEX) step. A single
CEX step was used to separate the different PEGylation degrees in case of Savinase®.
5.2.4.1 Purification of Lysozyme PEGamers
The separation of lysozyme PEGamers was performed on a Superdex 200 Increase 10/300
GL (ID x L = 10 x 30 mm) (GE Healthcare, Uppsala, Sweden) SEC column using a
25 mM sodium phosphate buffer with 150 mM sodium chloride at pH 7.2. The column
was loaded with 250 µl of sample and the system was run at a flow rate of 0.8 mL/min.
Fractions of 250 µl were collected into a 96-well deep well plate (VWR, Radnor, PA,
USA). The PEGamer containing fractions of multiple runs were pooled for each PEGamer
species separately. As a desalting step for the subsequent cation exchange chromatogra-
phy a buffer exchange to 25 mM sodium phosphate buffer (pH 7.2) was performed using
Vivaspin® centrifugal concentrators (Sartorius, Germany) with PES membranes and a
molecular weight cutoff of 5 kDa. The protein concentration was equally adjusted to
approximately 3 mg/mL. Lysozyme concentrations were determined using a NanoDrop
2000c UV-Vis spectroscopic device (Thermo Fisher Scientific, USA) using an extinction
coefficient of 1%280 nm,lysozyme = 22.00 [254]. For PEGylated species the extinction coeffi-
cient of native lysozyme was assumed (Supplementary Figure A.1). Appropriate blanks
were subtracted.
Polishing of lysozyme PEGamers was performed using cation exchange chromatography.
Toyopearl GigaCap S-650M (mean particle diameter = 75 µm) provided by Tosoh Bio-
science (Germany) was used as stationary phase. The adsorber material was packed into
an Omnifit® column (0.34 cm2∗10.5 cm = 3.6 mL). For column loading, 25 mM sodium
phosphate buffer at pH 7.2 was used and the injection volumes were set to 300 µl. Elution
was performed by applying an NaCl step gradient with an elution buffer containing 1 M
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sodium chloride in 25 mM sodium phosphate buffer at pH 7.2. The elution steps were set
to 0.045 M for di-PEGylated lysozyme and 0.1 M NaCl for mono-PEGylated lysozyme.
The final elution step at 1 M NaCl for native lysozyme was followed by a 3.5 column vol-
umes (CV) wash step at 1 M NaCl and a 2.5 CV reequilibration step with 25 mM sodium
phosphate buffer (pH 7.2). The flowrate for binding, elution and equilibration was set to
1 mL/min. To obtain sufficient sample for HT-CGE calibration multiple chromatogra-
phy runs were pooled. The pools were transferred into 25 mM sodium phosphate buffer
(pH 7.2) and the protein concentrations were adjusted to 1 mg/mL using Vivaspin® cen-
trifugal concentrators (Sartorius, Germany) with PES membranes and molecular weight
cutoffs of 3 kDa for non-PEGylated species and 5 kDa for PEGylated species.
5.2.4.2 Purification of Savinase® PEGamers
Purification of Savinase® PEGamers was performed using a self-packed Omnifit® col-
umn with Toyopearl GigaCap S-650M as described in section 2.4.1. For column loading,
25 mM sodium acetate buffer at pH 5 was used. In order to reduce the influence of
unreacted PEG on the binding behavior of the PEGamers to the cation exchange resin
the PEGylation batch was diluted 1:50 in 25 mM sodium acetate buffer at pH 5. In-
jection of the diluted batch was performed using a 50 mL super loop purchased from
GE Healthcare (Sweden). The flowrate for binding was set to 0.7 mL/min. Elution was
performed by applying an NaCl step gradient with an elution buffer containing 1 M
sodium chloride in 25 mM sodium acetate buffer at pH 5. The elution steps were 0.03 M
for di-PEGylated Savinase® and 0.1 M NaCl for mono-PEGylated Savinase®. The final
elution step at 1 M NaCl for native Savinase® was followed by a 2 CV wash step at 1 M
NaCl and a 2 CV reequilibration step with 25 mM sodium acetate buffer (pH 5). The
flowrate for elution, wash and equilibration was set to 1 mL/min. Again consecutive runs
were pooled and transferred into 25 mM sodium acetate buffer (pH 5) using Slide-A-
Lyzer Dialysis Cassettes (Thermo Fisher Scientific, USA) with a molecular weight cut
off of 10 kDa and a volume of 3-12 mL. Protein concentrations of the native Savinase®
and the mono-PEGylated Savinase® pool were above 1 mg/mL. For HT-CGE analyt-
ics those pools were diluted to 1 mg/mL using 25 mM sodium acetate buffer (pH 5) in
order to ensure a measurement in the linear range of the HT-CGE instrument. Di-PEG
Savinase® needed to be concentrated to 1 mg/mL. Since di-PEGylated molecule species
adsorbed to the PES membranes of the Vivaspin® centrifugal concentrators, concen-
trating was performed using a vacuum concentration unit RVC 2-33 CDplus (Martin
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Christ Gefriertrocknungsanlagen GmbH, Germany). Savinase® concentrations were de-
termined by a NanoDrop 2000c UV-Vis spectroscopic device using an extinction coeffi-
cient of 1%280 nm,Savinase = 10.09. The extinction coefficient was calculated with ExPASy
ProtParam tool [255] using the UniProtKB-P29600 amino acid sequence. For PEGy-
lated species the same extinction coefficient was assumed (Supplementary Figure A.1).
Appropriate blanks were subtracted.
5.2.5 TCA Precipitation Protocol
In the TCA protocol, the samples first were precipitated with Trichloroacetic acid (TCA).
800 µL protein sample and 200 µL ice-cold TCA stock solution (50% (w/w)) were mixed
in 2 mL Eppendorf tubes (Eppendorf, Germany). The mixtures were incubated for 30
minutes on ice. Subsequently, the precipitate was centrifuged for 15 minutes at 13300 rpm
in a table-top Heraeus Pico 17 centrifuge (Thermo Fisher Scientific, USA). Then the
pellet was washed twice with an equal volume of cold ultrapure water. After removing
the water, 1000 µL of −20◦C cold pure acetone (Merck, Germany) were added to the
protein pellet and 800 µL of the acetone were directly removed. The sample was vortexed
gently and centrifuged for 10 minutes at 13300 rpm on a table-top centrifuge. Remaining
acetone evaporated overnight under a hood. The obtained protein pellets were redissolved
in 800 µL ultrapure water for at least 1 h at 80◦C in a Thermomixer Comfort (Eppendorf,
Germany) for further analysis.
5.2.6 Protein Analysis Using HT-CGE
5.2.6.1 Analytical Procedure
For protein quantification an automated capillary gel electrophoresis device Caliper
LabChip® GX II with an HT Protein Express LabChip® and an HT Protein Express
Reagent Kit (Perkin Elmer, USA) were used. Experiments were carried out using the HT
Protein Express 200 assay in the LabChip® GX 3.1 software. The LabChip® installa-
tion, sample preparation and analysis were performed according to the manufacturer’s
standard protocol. Sample preparation was performed in skirted 96-well polypropylene
twin.tec® PCR plates from Eppendorf (Germany). Molecular weight determination was
performed according to protein standards from the HT Protein Express Reagent Kit. Peak
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area determination was conducted with MATLAB’s (MathWorks, USA) trapezoidal nu-
merical integration algorithm. To compensate for variations between different batches of
the HT Protein Express Reagent Kit a scaling of the peak area to an external lysozyme
protein standard of 1 mg/mL was performed for all protein measurements performed.
5.2.6.2 HT-CGE Calibration
For quantitative analysis of PEGamer concentrations in the Caliper LabChip® GX II
HT-CGE system a calibration was required since PEG attached to the protein altered the
retention behavior as well as the peak area of proteins. A ten point calibration between
0.1 mg/mL and 1 mg/mL was performed in 0.1 mg/mL steps as triplicates. Therefore, a
serial dilution either of the concentrated PEGamer samples for the standard protocol or
the redissoluted TCA pellets for the TCA protocol were prepared.
5.2.7 HT-CGE Validation: Automated Batch PEGylation Screenings for
Lysozyme
To validate the adapted TCA protocol, 29 samples with an unknown PEGamer compo-
sition were analyzed by the HT-CGE manufacturer’s standard protocol and the TCA
protocol for the model protein lysozyme. The 29 samples were prepared by PEGylation
under varying reaction conditions in 300 µL scale in 96-well UV-Star full-area plates
(Greiner Bio-One, Austria) on a fully automated robotic liquid handling station (Free-
dom EVO® 200 from Tecan, Germany). The liquid handling station was operated using
Evoware 2.5. Accurate liquid handling for a reproducible generation of PEGylated pro-
tein samples was assured by using custom liquid classes for buffers, PEG and protein
solutions, respectively. The method to determine liquid classes, including important vari-
ables such as plunger volume, aspiration and dispense speed, was described earlier by
Oelmeier et al. [256].
The 29 PEGylation experiments were selected according to an experimental design plan
by MODDE 10.1 (Umetrics, Sweden). The design space was based on a D-optimal design
with a quadratic model. pH values were varied in three steps covering 6.2, 7.2 and 8.2. In
addition, the three different protein to PEG ratios r=2.86, r=4 and r=6.67 were screened
resulting in nine different buffer conditions in total. To obtain kinetic PEGylation data,
samples of the same buffer conditions were mixed with L-lysine for reaction termination
according to Ottow et al. [23] after reaction times between 1.5 h and 12 h in 1.5 h intervals.
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For t=0 it was assumed that the reaction mixture consisted of 100% native protein and
no chemical reaction product was formed. This assumption was included as a boundary
condition in the model although experiments for t=0 were not carried out. The lysozyme
concentration was set to 4 mg/mL in all samples. During incubation, the plates were
covered to avoid evaporation and mixed at 700 rpm on a Te-Shake orbital mixer (Tecan,
Germany). The mixture composition of all samples was analyzed with HT-CGE using
both the standard protocol and the adapted TCA protocol.
5.2.8 Application of the TCA Protocol to PEGamer Mixtures of Savinase®
The validated TCA protocol was consecutively applied to the serine protease Savinase®.
First, four mixtures with a predetermined composition of the individual PEGamers (pu-
rified and quantified as described in section 2.4.2) were mixed in the concentration ratios
displayed in Table 5.1. The prepared mixtures were precipitated according to the TCA
protocol and analyzed using HT-CGE. Subsequently, the adapted TCA protocol was
applied to a PEGylation sample with unknown composition. A PEGylation batch with
r=15 at pH 7.2 (in 25 mM sodium phosphate) and a reaction time of 24 h was diluted
to a total protein concentration of 1 mg/mL. 800 µl of the diluted batch sample were
precipitated by TCA and the resulting protein pellet was redissoluted in 2000 µl of ul-
tra pure water. The resulting protein solution was analyzed with HT-CGE. The same
procedure was applied for a modification of Savinase® with 5 kDa mPEG-aldehyde for
comparing the applicability of the analytical procedure for other PEG molecules.
Table 5.1: Predefined composition of Savinase® PEGamers
Mixture 1 Mixture 2 Mixture 3 Mixture 4
c(Native) [mg/mL] 0.34 0.11 0.26 0.81
c(mono-PEGylated) [mg/mL] 0.34 0.81 0.26 0.11
c(di-PEGylated) [mg/ml] 0.34 0.11 0.51 0.11
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5.3 Results and Discussion
5.3.1 Preparative Purification of PEGamers
5.3.1.1 Purification of Lysozyme PEGamers
Since the PEGylation was performed using a PEG to protein excess, unreacted PEG
remained in the mixture after the conjugation reaction. This weakened the interaction of
native and PEGylated lysozyme with the cation-exchange media (results not shown). For
lysozyme it was decided to use a SEC step to remove the excess PEG. SEC was performed
using a Superdex 200 Increase 10/300 GL column with a bed volume of 23.6 mL. In
Fig. 5.2 the SEC chromatogram of a PEGylation batch at pH 7.2 with r=6.67 after
3.5 h reaction time is displayed. The absorption signal at 280 nm is plotted against the
retention volume. The chromatogram shows four peaks with maxima at retention volumes
of 10.6 mL, 11.6 mL, 14.5 mL and 19.2 mL, respectively. Peak allocation for the PEG-
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Figure 5.2: SEC chromatograms of a heterogeneous PEGamer mixture after batch PEGy-
lation of lysozyme (pH 7.2, r=6.67 and t=3.5 h). The black triangles indicate
the respective pooling limits for each PEGamer species.
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amer species was performed on basis of the elution order in accordance with the results
of Maiser et al. [257]. The peak eluting at 19.2 mL was assigned to native lysozyme by a
reference sample. Baseline separation between the single species was not achieved apply-
ing SEC separation alone. From the chromatogram it is evident that under the selected
reaction conditions only traces of tri-PEGylated lysozyme and no higher PEGylated
species were formed. For this reason, PEGamer species with more than two attached
PEG molecules were combined as poly-PEGylated in the further course of this study.
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Figure 5.3: CEX chromatograms for pooled hen egg-white lysozyme fractions after SEC:
A) native, B) mono-PEGylated, C) di-PEGylated, D) poly-PEGylated. The
black triangles indicate the respective pooling limits for each PEGamer
species.
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After SEC separation of PEGamer species a cation exchange chromatography step was
performed. In Fig. 5.3 the resulting CEX chromatograms with an NaCl gradient for
the pooled PEGamer fractions after SEC are illustrated. The pooled fractions con-
tained mainly the targeted PEGamer species. Impurities of the other species can be
attributed to the wide pooling limits during SEC (illustrated by the black triangles in
Fig. 5.2 for each PEGamer species). The comparison of Fig. 5.3A-D indicates that non-
PEGalyated lysozyme has the highest binding affinity to the adsorbent material of all
PEGamers. The attachment of one PEG molecule already results in a significant decrease
in binding strength, since mono-PEGylated lysozyme elutes at a conductivity of approxi-
mately 9 mS/cm (see Fig. 5.3B) whereas native lysozyme starts eluting at approximately
50 mS/cm (see Fig. 5.3A). All four sub-images show a flow-through which is especially
pronounced for the di- and the poly-PEGylated SEC fractions. HT-CGE analysis of flow-
through fractions showed a considerable amount of di- and poly-PEGylated species (data
not shown) indicating a low binding affinity of di-PEGylated lysozyme to the GigaCapS
650M resin. These observations are described in literature inter alia by Yoshimoto et al.
[258] and can be explained by PEG shielding the protein surface and respective surfaces
charges necessary for protein-adsorbent-interactions. Fractions of 250 µl were taken and
pooled for the individual peaks in order to isolate pure protein samples for TCA pre-
cipitation and HT-CGE calibration (illustrated by the black triangles in Fig. 5.3A-C for
native, mono-PEGylated and di-PEGylated lysozyme). PEGylated species that appeared
as an impurity in one CEX run were added to the respective pure PEGamer sample pools
and were not discarded. The purities of the individual PEGamer species were determined
by HT-CGE and were above 98% for all PEGamers and pure lysozyme.
5.3.1.2 Purification of Savinase® PEGamers
SEC is a time consuming process step. In case of proteases long process times promote
the formation of autocatalysis products. Therefore, the reduction of the purification pro-
cess to a single cation exchange step was crucial for Savinase®. Initial experiments re-
vealed that PEGylation of Savinase® requires a higher PEG to protein ratio compared
to lysozyme (data not shown). With the aim to use a cation exchanger for PEGamer
purification, the need for dilution of residual PEG increased analogously. The reduction
of the negative influence of PEG during binding of proteins to the cation exchange resin
was achieved by a 1:50 dilution of the reaction batch with cation exchange loading buffer
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Figure 5.4: CEX chromatogram of a 1:50 diluted Savinase® PEGylation batch (r=15,
pH 7.2, 24 h) loaded with a 50 mL loop. The black triangles indicate the
respective pooling limits for each PEGamer species.
before binding. In Fig. 5.4 the resulting CEX chromatogram with an NaCl gradient is
displayed. The first 48 mL of the chromatography run correspond to sample loading with
a 50 mL loop. Through three salt steps 0.03 M, 0.1 M and 1.0 M NaCl baseline separated
PEGamer peaks were generated. The allocation of the peaks for the PEGamer species was
done by comparing the elution order to runs of PEGylated lysozyme (see Fig. 5.3). The
electropherograms of PEGylated Savinase® species indicated similar molecular weights
as those of the corresponding lysozyme species. The purities of the pooled PEGamer
fractions (pooling limits are indicated in Fig. 5.4 by the black triangles) were determined
by HT-CGE and were above 97% for all species.
5.3.2 Calibration of HT-CGE
Throughout HT-CGE analysis PEGylated species showed molecular masses which were
higher than the expected total nominal weights of protein and polymer. For example, the
mono-PEGylated Savinase® peak was correlated to a molecular weight of 69 kDa instead
of the expected 37 kDa. Moreover, PEGylated species showed a distinct increase in peak
area compared to the native protein. Both phenomena, the change in migration properties
and the increase in peak area have been described in literature for sodium dodecyl sulfate
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polyacrylamide gel electrophoresis (SDS-PAGE) [259, 260] as well as for CGE [125]. Both
effects indicate that PEG attached to proteins hinders the electrophoretic mobility in the
gel matrix of the microfluidic separation channel. The change in mobility is attributed to
sample preparation and operating principle of HT-CGE. As the protein sample denatures,
its tertiary structure resolves and the molecule is linearized. Linearized molecules follow
the laminar flow profile in the microfluidic channel resulting in a narrow residence time
distribution. Attached PEG molecules act as non-linearized side chains with an uncertain
conformation. The nonlinearity deviates migration of PEGylated proteins from the ideal
flow path and thereby slows down permeation through the gel matrix. Furthermore, a
statistical distribution in residence time of single molecules within one PEGamer species
is created which in turn results in peak broadening in the electropherogram of HT-CGE.
This effect may be increased by the presence of different positional isoforms within on
PEGamer species. Since in LabChip® GXII the internal molecular mass standard is
used to allocate runtimes to molecular masses, a slowing effect not solely based on the
molecular mass but also on the non-linearity of the molecule causes PEGylated species
to appear heavier than they truly are [125].
A further effect is involved in the increase in peak area which is also described extensively
in literature [261, 262]. Sodium dodecyl sulfate (SDS) binds at concentrations above the
critical micelle concentration (CMC) to PEG molecules having a molecular weight above
4 kDa [261]. Since during HT-CGE analysis the CMC of SDS is exceeded, the attached
PEG molecules act as an additional protein surface to which SDS adheres. Thus, the
concentration of bound fluorescent marker increases and enhances the fluorescent peak
area for PEGylated species. A higher fluorescence signal per PEGylated protein molecule
in combination with the decelerated electrophoretic mobility explains higher peak areas.
Since LabChip® GXII determines concentrations based on the peak area, the observed
increase in peak area results in disproportional concentration results. A calibration of
peak area with known protein concentrations was indispensable for PEGamers to com-
pensate for such phenomena.
The calibration was performed by means of a serial dilution of each purified PEGamer
species (see section 2.6.2) on the LabChip® GXII device. In Fig. 5.5 the resulting cali-
bration curves are depicted for lysozyme analyzed by the standard protocol (A) and by
the TCA protocol (B). In Fig. 5.5C the resulting electropherograms of a dilution series of
mono-PEGylated Savinase® analyzed by the TCA protocol are exemplary shown for the
calibrated concentration range between 0.1 mg/mL and 1 mg/mL. Through peak integra-
tion of the measured fluorescence signals for each PEGamer concentration and PEGamer
species the calibration curves shown in Fig. 5.5D were calculated. As expected, for both
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Figure 5.5: PEGamer concentration to peak area calibration for hen egg-white lysozyme
analyzed by the standard HT-CGE protocol (A) and the TCA protocol (B),
fluorescence signals of a linear dilution series of mono-PEGylated Savinase®
gained using the TCA protocol (C) and the resulting calibration curves for
all Savinase® species (D).
proteins the peak area increases with increasing PEGamer concentration for all species.
A linear relationship (peak area = slope * concentration) between applied concentration
and peak area was determined for all examined proteins and PEGamer species with ade-
quate coefficients of determination. It becomes apparent that the slopes of the calibration
curves increase with the number of bound PEG molecules. For lysozyme (Fig. 5.5A and
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B) the two analytical protocols show similar progressions of calibration for the different
PEGamer species within the measurement uncertainty. This indicates that in the case
of lysozyme the TCA protocol and the standard protocol deliver equivalent analytical
results. The TCA protocol could thus be used for Savinase®. For lysozyme, a linear
increase of the slope of the calibration curve with an increasing number of bound PEG
molecules was observed. For Savinase® a similar behavior of native and mono-PEGylated
protein was observed as for lysozyme. However, the calibrations of mono-PEGylated and
di-PEGylated Savinase® result in a comparable slope. The different behavior between
lysozyme and Savinase® during the measurement of PEGylated species in HT-CGE
might be explained by different interactions between the protein backbone and the bound
PEG molecules in the denatured state. Attached PEG molecules with an uncertain con-
formation may result in a different electrophoretic mobility and SDS accessibility during
the analysis. However, when performing adequate calibrations with purified PEGamers,
such a behavior can be compensated for.
5.3.3 Validation of TCA Protocol
The establishment of a new analytical protocol requires the verification of obtained results
in terms of accuracy and reproducibility. In this study the validation of the presented TCA
protocol was performed using random batch PEGylation of the model protein lysozyme
for which many reference values can be found in literature. By batch PEGylations at dif-
ferent reaction conditions PEGamer mixtures with unknown composition were produced.
Those mixtures were analyzed by HT-CGE using both the standard protocol specified
by the manufacturer and the adapted TCA protocol for determining non-PEGylated,
mono-PEGylated and di-PEGylated lysozyme concentrations. The results were used to
fit a response surface model investigating the influence of the parameters pH, reaction
time and PEG to protein ratio r on the PEGylation behavior using MODDE. The model
yielded an average value of 0.95 for R2 and 0.91 for Q2 for both analytical protocols and
the three PEGamer species. These values indicate that the model formed by MODDE is
valid and can therefore be used to predict the PEGamer fractions within the calibrated
range for reaction conditions which were not investigated experimentally. In Fig. 5.6A
the influence of the parameters pH value, reaction time and PEG to protein ratio r on
the mixture composition is illustrated as analyzed by the standard protocol. The repro-
ducibility of the automated PEGylation reactions was above 94% for all PEGamer species
and the mass balances showed a recovery of total protein above 89% for all samples.
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Figure 5.6: Design of experiments for investigating the PEGylation behavior of lysozyme
for different reaction conditions: Comparison of the standard HT-CGE (A)
and the TCA protocol (B) for the model protein hen egg-white lysozyme.
These results indicate precise liquid handling. It is obvious that a high PEG excess results
in a decrease of native lysozyme for all pH values and reaction times. A simultaneous
accumulation of PEG-protein conjugates can be observed as shown by [263] and [264].
Maximal concentrations of mono-PEGylated lysozyme were identified for PEG to protein
ratios in a range of 3 to 4 and reaction times above 6 h. For higher PEG to protein
ratios and reactions times a decrease of mono-PEGylated lysozyme is recorded which is
accompanied by an increase in di-PEGylated lysozyme. In accordance with Maiser et. al
[264] a lower buffer pH yields a faster PEGylation reaction as the maximal amount of
di-PEGylated lysozyme was generated at pH 6.2. Comparing the results of the standard
protocol to the adapted TCA protocol, differences in the fractions of each PEGamer are
negligible. Thus, a comparable reaction behavior as a function of the investigated reaction
parameters is detectable. The reproducibility and the consistency of the mass balance
are in accordance with the standard protocol. As for the calibration of HT-CGE, this
experimental set-up shows that the new TCA protocol provides results as the standard
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protocol. The TCA protocol is therefore suitable for the analysis of proteins which cannot
be analyzed by the standard protocol such as proteases of autocatalytic activity.
5.3.4 Analyzing Mixtures of PEGylated Savinase® Species Using the TCA
Protocol
The described analytical method was tested within the calibrated concentration range
with regard to linearity, reproducibility and accuracy for the used model protease Savinase®
using four predefined samples of known composition. In Fig. 5.7 the PEGamer concen-
trations measured by the TCA protocol are plotted against the nominal concentration
values for the four predefined mixtures. For all samples an evaluation of PEGamer con-
centrations in mixtures was achieved, which represents a major improvement compared
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Figure 5.7: Comparison between predefined concentrations of Savinase® and the ones
analyzed by the adapted TCA protocol for the model protease Savinase® in
the PEGamers mixtures 1 (•), 2 (), 3 (N) and 4 (H).
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to the HT-CGE measurements without the TCA precipitation step where the protease
was entirely eliminated by autocatalysis (see Fig. 5.8A, black line). The linearity of gained
results was shown both for the native protein as well as the PEGylated species with re-
gression coefficients above 0.98. The multiple determinations of the individual PEGamer
concentrations in the mixtures show a high reproducibility with the exception of na-
tive Savinase® at 0.8 mg/mL (mixture 4). All measured PEGamer concentrations are
slightly undervalued compared to the nominal concentration value applied. The reduced
measured values can be explained by protein losses during precipitation and redissolu-
tion of the denatured protein pellet. The largest deviations of up to 64% relative error
between nominal and measured PEGamer concentration were observed for small pro-
tein concentrations of 0.1 mg/mL which corresponds to an absolute error of no more
than 0.064 mg/mL. At this point the quantification limit was reached. With increasing
protein concentration in the sample the relative error in the measurement decreases. For
native and mono-PEGylated Savinase® the relative error was reduced to a range of 4.9%
and 12.8% for protein concentrations above 0,1 mg/mL. Through an undervaluation of
all absolute concentrations to a similar degree, however, the percentage composition of
the different PEGamer species in mixtures are well displayed. Therefore, the introduced
analytical protocol represents a valuable method to perform a high-throughput-based
optimization of reaction conditions for the PEGylation of pharmaceutically relevant pro-
teases.
After validating the adapted HT-CGE protocol for mixtures of known composition a
PEGylated Savinase® batch with unknown PEGamer fractions was analyzed by HT-
CGE. In Fig. 5.8A the resulting electropherogram is shown (red line). The peaks of the
different PEGamer species are baseline-resolved so that integration and thus the quan-
tification of the individual species in an unknown mixture is possible. The peak between
10 kDa and 25 kDa can be attributed to autocatalysis products formed during the 24
hours of PEGylation reaction. The peaks at 27 kDa, 70 kDa and 150 kDa correspond
to native Savinase®, mono-PEGylated Savinase® and di-PEGylated Savinase®, respec-
tively. Identical PEGylation conditions were used for the purification of PEGamer species
(Fig. 5.4). In the chromatogram of the preparative purification and the electropherogram
(Fig. 5.8, red line) similar fractions of the different protein species can be recognized but
in a reverse order of runtimes. By integration of the peak area from the electropherogram
and application of the calibration function PEGamer concentrations were calculated. The
PEGylation of Savinase® with an initial protein concentration of 10 mg/mL at pH 7.2
with a PEG to protein ratio of r=15 yielded 3.77 mg/mL native Savinase®, 4.22 mg/mL
mono-PEGylated Savinase® and 0.56 mg/mL di-PEGylated Savinase® after 24 hours.
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Figure 5.8: Comparison of 5 kDa and 10 kDa PEGylated Savinase® mixtures (r=15,
pH 7.2 and t=24 h) analyzed by the TCA protocol and a native Savinase
sample analyzed by the standard protocol (A) as well as comparison of 5 kDa
and 10 kDa PEGylated lysozyme mixtures (r=6,67, pH 7.2 and t=14.5 h)
analyzed by the standard protocol (B).
For comparison, the electropherogram of a native Savinase® sample (c=1.5 mg/mL)
analyzed by the standard protocol is displayed in Fig. 5.8A (black line). An identification
of individual protein species is not possible. Rather small protein fragments are detectable
which may be aggregated partially. The decomposition of the sample is likely to be caused
by high autocatalysis rates due to the elevated temperature used for denaturation during
HT-CGE sample preparation.
The question which arises for a practical application of the presented PEGylation an-
alytics is whether the method is applicable to other PEG molecular weights without a
reduction of resolution. As an example, Savinase® was modified with a smaller molecu-
lar weight mPEG-aldehyde of 5 kDa as shown in Fig. 5.8A (green line). The individual
PEGamer species remain baseline separated, but show lower molecular weights than the
PEGamer species modified with 10 kDa mPEG-aldehyde (red line). As can be seen, the
molecular weights of 5 kDa di-PEG and 10 kDa mono-PEG conjugates equal each other.
They consequently have the same hydrodynamic radius. The increase in size upon PEGy-
lation is therefore only dependent on the molecular weight of the bonded PEG molecules
and regardless of their number. This observation has already been demonstrated by
Fee and Van Alstine [139] for size exclusion chromatography. The same observation was
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made for lysozyme as displayed in Fig. 5.8B. These results demonstrate that HT-CGE
is a valuable tool to analyze both stable (with the standard protocol) and instable pro-
tein conjugates (with the TCA protocol) with respect to their degree of conjugation for
variable polymer molecular weights within the studied parameter range.
5.4 Conclusion
In the presented work, purified samples of protein PEGamers were used for the cal-
ibration of high-throughput capillary gel electrophoresis (HT-CGE). A distinction was
made between the standard protocol specified by the manufacturer and the newly applied
TCA protocol. As shown for lysozyme, the standard protocol is applicable to monitor
PEGylation reactions for structurally stable proteins. In this case, HT-CGE provides an
analytical method with a low sample consumption of only 2 µL, an analysis time of 40 s
per sample, a high resolution allowing for peak baseline separation and a high sensitivity
down to 0.1 mg/mL of PEGylated species. In contrast, the TCA protocol includes a de-
naturing precipitation step by trichloroacetic acid. The main advantage of this approach
is the preservation of the sample composition, which allows time-resolved measurements
of proteins which are subject to degradation. In this study, the model protease Savinase®
was examined as an example of a critical protein, since proteases are highly affected by
autocatalysis. However, the method can be applied to all kinds of kinetic studies of pro-
tein reactions. The validation of the new protocol has successfully been carried out for
mixtures of PEGylated lysozyme. The two protocols resulted in comparable PEGamer
concentration ratios for a DoE of PEGylation experiments under distinct reaction con-
ditions. The validated TCA protocol was successfully applied for the model protease
Savinase®. The problem of autocatalysis resulting in irreproducible results during the
analysis of PEGylated proteases can be overcome by applying a protein precipitation
step. The presented combination of TCA precipitation and HT-CGE analytics was found
to be a fast and reproducible tool for the tracking of PEGylated species for both stable
and instable proteins.
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Abstract
During production, purification, formulation, and storage proteins for pharmaceutical
or biotechnological applications face solution conditions that are unfavorable for their
stability. Such harmful conditions include extreme pH changes, high ionic strengths or
elevated temperatures. The characterization of the main influencing factors promoting
undesired changes of protein conformation and aggregation, as well as the manipulation
and selective control of protein stabilities are crucially important to biopharmaceutical
research and process development. In this context PEGylation, i.e. the covalent attach-
ment of polyethylene glycol (PEG) to proteins, represents a valuable strategy to improve
the physico-chemical properties of proteins.
In this work, the influence of PEG molecular weight and PEGylation degree on the
physical stability of PEGylated lysozyme is investigated. Specifically, conformational
and colloidal properties were studied by means of high-throughput melting point deter-
mination and automated generation of protein phase diagrams, respectively. Lysozyme
from chicken egg-white as a model protein was randomly conjugated to 2 kDa, 5 kDa
and 10 kDa mPEG-aldehyde and resulting PEGamer species were purified by chromato-
graphic separation. Besides protein stability assessment, residual enzyme activities were
evaluated employing a Micrococcus lysodeikticus-based activity assay. PEG molecules
with lower molecular weights and lower PEGylation degrees resulted in higher resiudal
activities. Changes in enzyme activities upon PEGylation have shown to result from a
combination of steric hindrance and molecular flexibility. In contrast, higher PEG molec-
ular weights and PEGylation degrees enhanced conformational and colloidal stability.
By PEGylating lysozyme an increase of the protein solubility by more than 11 fold was
achievd.
Keywords: PEGylation; Protein phase diagram; Melting point determination; Molecular
flexibility; Enzyme activity
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6.1 Introduction
The outstanding potential of proteins for industrially relevant applications is based on
their highly specific interactions with a target molecule due to their individual amino
acid sequence and three-dimensional structure. The high activity of proteins at moder-
ate concentrations and temperatures renders them an extremely beneficial alternative to
small molecule compounds [77]. The current state of knowledge of biotechnology enables
the production of recombinant proteins for pharmaceutical or biotechnological applica-
tions with high production efficiencies. However, many recombinant proteins are prone to
instabilities during cell cultivation, purification, formulation and storage, which manifest
mostly in a loss of functionality. In terms of pharmaceutical proteins, instabilities may
equally result in immune responses and serious side effects when applied to the patient
[6].
Protein instabilities can be divided into two classes being of chemical and physical nature
[60]. Chemical instabilities include processes in which covalent bonds are formed or broken
[60]. On the other hand, physical instabilities are related to a change in the physical state
of the protein without involving an alteration of the chemical protein composition [60].
Therefore, physical instabilities comprise conformational changes of the protein structure
and colloidal changes (e.g. aggregation). Za´vodszky et al. [265] further divide the term
conformational stability into macrostability and microstability. Macroscopically stable
proteins maintain the integrity of their native state and are not subject to either partial
or complete unfolding. Microstability is described as the flexibility of the protein molecule
due to fluctuations of the internal energy. Furthermore, it is stated that the enzyme
activity and conformational flexibility are closely correlated for a macroscopically stable
protein. The term colloidal stability in the sense of protein aggregation describes the
assembly of protein monomers to multimers and characterizes the formation of protein
crystals, amorphous precipitates and also incorporates cross-linked structures such as
protein gels.
The occurrence of protein instabilities is often caused by a complex and hardly pre-
dictable interplay of environmental conditions such as extreme pH values, presence of
organic solvents, non-physiological salt concentrations, high protein concentrations and
high temperatures influencing molecule interactions [81, 82]. Characterization and control
of protein stabilities as critical quality attributes are essential to process development.
In order to take a step towards predictability of protein stabilities, several analytical
techniques have to be employed and interlinked [266].
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Also, a thorough characterization of protein stabilization strategies for an enhanced ro-
bustness of functional biomolecules presents one of the critical challenges in biotechnology.
Stabilization strategies are based either on modulation of properties of the surrounding
aqueous solution or on modifications of the protein itself. For some therapeutic proteins
such as the granulocyte colony stimulating factor (G-CSF) [25, 267] or the recombinant
human tissue factor pathway inhibitor (rhTFPI) [268] moderate salt concentrations can
already induce instabilities. In a review by Hansen et al. effects of buffer substances, pH
levels, precipitating agents, surfactants are summarized for the enzyme Xylanase [269].
Besides adjusting the pH value and the salt concentration, a stabilization of proteins can
be achieved by the addition of various excipients. Most commonly low molecular weight
osmolytes such as polymers and polyols [254] are employed. Additional stabilizing can-
didates were determined to be cyclodextrins and surfactants [270], as well as sugars (e.g.
sucrose), enzymatic co-factors, amino acids [271], and ampholytes such as Tween®20
[272].
Besides altering the chemical surroundings of the protein, protein modification is another
approach for stabilization. The portfolio of modification includes site-directed mutagen-
esis, the addition of protein fusion tags and polymer conjugation. In case of site-directed
mutagenesis specific and rational changes of the primary amino acid sequence are per-
formed via recombinant DNA technologies [60]. When using fusion tags for engineer-
ing protein stability, additional amino acids are fused to the product which are mostly
composed of an amino acid sequence from a highly stable or soluble peptide or pro-
tein. Such tags include the maltose-binding protein (MBP) [273], Thioredoxin (Trx),
the phage T7 protein kinase (T7PK) [274], the Cherry-Tag [238, 275, 276], as well as
synthetic solubility-enhancing tags (SETs) used by Zhang et al. [277]. Polymer conjuga-
tion denotes the linkage of synthetic polymers to a native protein in order to alter its
physico-chemical properties. In contrast to protein and peptide fusion tags where the ad-
ditional amino acids are already added to the genetic code of the host strain, the chemical
modification of the protein is performed after product isolation and purification.
In this study, the potential of PEGylation, i.e. the covalent attachment of chemically
activated polyethylene glycol (PEG), as an example of polymer conjugation for the sta-
bilization of proteins is demonstrated. In order to understand stabilization mechanisms,
several analytical methods are applied and their results compared. PEG is especially in-
teresting as a modifier for biopharmaceuticals since it is approved by the FDA for the
use in pharmaceuticals. It proved to show little toxicity and immunogenicity and it is
eliminated from the body by the kidneys or in the feces [142]. Da Silva Freitas et al. [278]
illustrated that PEGylation of lysozyme with a 5 kDa polymer entails a stable protein
100
6.2 Materials and Methods
conformation, an improved thermal stability, as well as resistance to enzymatic degra-
dation. Further examples can be found in a study by Nie et al. for recombinant human
endostatin modified with 5 kDa PEG [279] and by Basu et al. for interferon-beta using
40 kDa PEG [280].
Whereas the beneficial effect of PEG is widely proven in industry and academia, there
is a lack of detailed and systematic studies on the influence of PEG molecular weight,
as well as PEGylation degree on different types of protein stability. In particular, knowl-
edge of the functional, conformational and colloidal stability of PEGylated proteins is
missing. Therefore the aim of this study is to investigate systematically physical stability
attributes using different PEG molecular weights and PEGylation degrees. To assess the
influence of PEG molecular weight on the physico-chemical properties upon PEGylation,
2 kDa, 5 kDa and 10 kDa mPEG-aldehyde is conjugated to the model protein lysozyme
(from chicken egg white). In order to evaluate the differences in stability in dependency of
the PEGylation degree, protein species with different numbers of attached PEG molecules
(PEGamers) are purified by chromatographic separation after random batch PEGylation.
A distinction is made between native proteins (non-PEGylated), proteins with one at-
tached PEG molecule (mono-PEGylated) and proteins with two attached PEG molecules
(di-PEGylated).
Since PEGylation is known to evoke changes of the in vitro activity (resp. functional
stability) of proteins [142], the residual enzyme activity after PEGylation is assessed
and compared to the native protein using the lysozyme-specific activity assay based on
the substrate Micrococcus lysodeikticus. Furthermore, the influence of PEGylation on the
physical stability is investigated by evaluation of the macroscopic conformational stability
by means of melting point determination using intrinsic protein fluorescence under an
increased salt concentration. Additionally, the colloidal stability of PEGylated lysozyme
is evaluated using an automated screening technique described by Baumgartner et al. [79].
Thereby, the combined influence of an extreme pH value (pH 3) and non-physiological
salt concentrations are investigated.
6.2 Materials and Methods
6.2.1 Materials
All solutions were prepared with ultrapure water provided by a PURELAB Ultra wa-
ter purification system (ELGA Labwater, Germany). The used buffer substances were
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citric acid monohydrate (Merck, Germany) as well as sodium citrate tribasic dihydrate
(Sigma-Aldrich, USA) for pH 3, sodium acetate trihydrate (Sigma-Aldrich, USA) for pH 5
and sodium phosphate monobasic dihydrate (Sigma-Aldrich, USA) as well as di-sodium
hydrogen phosphate dihydrate (Merck, Germany) for pH 7.2. Sodium chloride (NaCl)
included in the cation exchange chromatography (CEX) elution buffer and the precipita-
tion buffers for phase diagrams were purchased from Merck (Germany). Sodium sulfate
(Na2SO4) for the study of colloidal stability was purchased from Merck (Germany). pH
adjustment of all buffers within a range of ± 0.05 units was performed using a five-point
calibrated pH-meter HI-3220 (Hanna Instruments, USA) with a SenTix® 62 pH electrode
(Xylem Inc., USA). For pH correction hydrochloric acid and sodium hydroxide were ob-
tained from Merck (Germany). All buffers were filtered using a 0.2 µm cellulose-acetate
filter (Sartorius, Germany) and degassed for chromatographic purposes.
Protein solutions were prepared using chicken egg-white lysozyme (subsequently re-
ferred to as lysozyme) from Hampton Research (USA). Methoxy-PEG-propionaldehyde
(mPEG-aldehyde) with an average molecular weight of 2 kDa (Sunbright®ME-020 AL),
5 kDa (Sunbright®ME-050 AL) and 10 kDa (Sunbright®ME-100 AL) was obtained from
NOF Corporation (Japan). Sodium cyanoborohydride (NaCNBH3) as reducing agent for
PEGylation and L-lysine for terminating the reaction were purchased from Sigma-Aldrich
(USA). Caliper LabChip®GX II system, HT ProteinExpress LabChip® and HT Protein
Express Reagent Kit for HT-CGE analysis were obtained from PerkinElmer (USA).
6.2.2 Methods
6.2.2.1 Batch PEGylation and Purification of PEGamers
PEGylation experiments were performed batch-wise in 50 mL Falcon Tubes (BD Bio-
sciences, USA). 25 mM sodium phosphate buffer (pH 7.2) containing 20 mM NaCNBH3 as
reducing agent was used to dissolve lysozyme and mPEG-aldehyde. The lysozyme concen-
tration was kept constant at 5 mg/mL for all PEGylation experiments. mPEG-aldehyde
addition was based on the desired molar PEG to protein ratio (r =NPEG/Nprotein with
N being the concentration of moles per volume) of 6.67 [264, 281]. To investigate the
influence of the PEG molecular weight on the different stability attributes of PEGylated
proteins, 2 kDa, 5 kDa and 10 kDa mPEG-aldehyde was conjugated to lysozyme. For the
PEGylation reaction, the tube was continuously shaken in an overhead shaker (Labin-
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coLD79, Labinco BV, Netherlands) for 3.5 h at room temperature. The PEGylation
reaction was stopped by adding 200 mM of L-lysine according to [253].
6.2.2.2 Isolation of PEGamers by Cation Exchange Chromatography
In order to reduce the influence of unreacted PEG on the binding behavior of the native
protein and the PEGamers to the cation exchange resin the PEGylation batch was diluted
1:12 in 10 mM sodium acetate buffer (pH 5) [281]. Preparative separation of PEGamers
was performed on an A¨KTA purifier system equipped with a Fraction Collector Frac-950
(GE Healthcare, Sweden). As stationary phase a 5 mL prepacked MiniChrom column with
Toyopearl GigaCap S-650M resin (Tosoh Bioscience, Deutschland) was used. For column
loading, the system was equilibrated in 10 mM sodium acetate buffer (pH 5). Sample
application was performed using a 50 mL super loop (GE Healthcare, Sweden). Elution
was performed by applying an NaCl step gradient with an elution buffer containing 1 M
sodium chloride in 10 mM sodium acetate buffer at pH 5. The NaCl molarities used
for the step elution of the different PEGamers are displayed in Table 6.1 in dependence
of the molecular weight of the attached PEG molecules. The flow rate for binding and
elution was set to 1 mL/min. Fractions of 2 mL were collected into a 96-well deep well
plate (VWR, USA). To obtain sufficient sample volume for stability assessment of the
different PEGamer species the corresponding fractions of multiple chromatography runs
were pooled. Peak allocation to the different PEGamer species and purity determination
were performed by high-throughput capillary gel electrophoresis (HT-CGE) using the
Caliper LabChip®GX II device (PerkinElmer, USA) as described in [281].
Table 6.1: NaCl steps in mol/L used for the elution of different PEGamer species from
Toyopearl GigaCap S-650M at pH 5 in dependency of the PEG molecular
weight
Native lysozyme mono-PEGylated
lysozyme
di-PEGylated
lysozyme
Mw=2 kDa 1 0.46 0.29
Mw=5 kDa 1 0.35 0.16
Mw=10 kDa 1 0.25 0.075
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6.2.2.3 Sample Conditioning and Concentration Determination
The characterization of the isolated PEGamer species with regard to the different stability
attributes required a sample conditioning consisting of buffer exchange (resp. pH-change)
and concentration increase. Buffer exchange was carried out using Slide-A-Lyzer Dialysis
Cassettes (Thermo Fisher Scientific, USA) with a molecular weight cut-off of 2 kDa.
The dialysis buffer was thereby determined by the pH value required for the succeeding
stability test. Concentrating of protein samples was performed by evaporation using a
vacuum concentration unit RVC 2-33CDplus (Martin Christ Gefriertrocknungsanlagen
GmbH, Germany) operated at 24 mbar. Lysozyme concentrations were determined using
a NanoDrop 2000c UV-Vis spectroscopic device (Thermo Fisher Scientific, USA) using
an extinction coefficient of 1%280 nm,lysozyme = 22.00 [254]. For PEGylated species the
same extinction coefficient was assumed [281]. Since the bound PEG molecules do not
absorb at 280 nm [281], the absorption measurement yields the mass concentration of
lysozyme molecules in the sample without considering the mass of the bound PEG.
To avoid confusion, the mass concentrations of native lysozyme and protein conjugates
of different PEG molecular weights were converted into molar concentrations. For this
purpose, a molecular weight of lysozyme of 14.3 kDa was used [282]. This approach allows
the comparison of stability properties for a constant number of total molecules.
6.2.2.4 Determination of Stability Attributes for PEGylated Lysozyme
Purified lysozyme PEGamers with varying PEGylation degree (non-PEGylated = native,
mono-PEGylated and di-PEGylated) and molecular weight of attached PEG (2 kDa,
5 kDa and 10 kDa) were tested for their functional, conformational and colloidal stabil-
ity.
6.2.2.5 Functional Stability - Activity Assay using Micrococcus Lysodeikticus
Quantification of enzyme activity was performed using Micrococcus lysodeikticus cells
(Sigma Aldrich, USA) as substrate. The kinetic assay is based on the lysis of the bacte-
rial cells by lysozyme resulting in a decrease of turbidity over time. The turbidity was
monitored by measuring the absorption at 450 nm (resp. light scattering) with an UV-vis
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Infinite M200 plate reader from Tecan (Germany) which was controlled by the software i-
control 1.9. Absorption measurements were carried out in 96-well flat-bottom UV-Star®
full-area micro-plates (Greiner Bio-One, Germany).
The Micrococcus lysodeikticus cells were suspended in 25 mM sodium phosphate buffer at
pH 7.2. The starting OD value of the Micrococcus lysodeikticus suspension was adjusted
to 1.7 AU. Samples of native lysozyme and mono-PEGylated as well as di-PEGylated
lysozyme with 2 kDa, 5 kDa and 10 kDa PEG molecules attached were adjusted to
a concentration of 6, 99 · 10−2 mmol/L (corresponds to 1 mg/mL unmodified protein)
in 10 mM sodium acetate buffer (pH 5) as described in section 2.2.3. From this stock
solution a serial dilution from 6, 99 ·10−3 mmol/L to 6, 99 ·10−2 mmol/L (corresponds to
0.1 to 1 mg/mL unmodified protein) in 6, 99 · 10−3 mmol/L steps was prepared. Of each
diluted sample 7.5 µL were pipetted to a 96 well micro-plate and 200 µL Micrococcus
lysodeikticus suspension were added. Absorption measurements at 450 nm was performed
for 10 minutes in 75 s intervals with orbital shaking in between the measurements. A
blank consisting of 7.5 µL 10 mM sodium acetate buffer (pH 5) and 200 µL Micrococcus
lysodeikticus suspension was measured likewise. The absorbance values of the protein
samples were subtracted from the absorbance values of the Micrococcus lysodeikticus
blank resulting in a positive slope of the measured values over time. Every sample was
measured as triplicate and for calculation of reaction rate the average was used.
6.2.2.6 Conformational Stability - Melting Point Determination
Elevated temperatures and non-physiological concentrations are among the main influ-
encing factors favoring protein unfolding. The exposure of the hydrophobic amino acid
residues (e.g. tryptophan) to an aqueous environment upon unfolding results in a shift
of the fluorescence emission from blue to red wavelengths [69]. A plot of fluorescence
emission wavelength (barycentric mean fluorescence = BCM) against the applied tem-
perature is sigmoidal, with the inflection point being denoted as protein melting point
temperature (Tm). An increasing Tm reflects an increase in macroscopic conformational
stability [60, 283].
In this study, the combined influence of increased temperature and elevated NaCl con-
centrations on the conformational stability of native and PEGylated lysozyme species
was evaluated by melting point determination. Protein stock solutions were prepared in
100 mM citric buffer (pH 3) and concentrations of native and PEGylated lysozyme solu-
tions were set to 1,89 mmol/L. According to Baumgartner et al. [79] twelve salt solutions
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with an uniform increase in NaCl concentration between 0 M and 5 M were prepared
by mixing of 100 mM citric buffer (pH 3) and 100 mM citric buffer (pH 3) containing
2.5 M NaCl or 100 mM citric buffer (pH 3) containing 2.5 M NaCl and 100 mM citric
buffer (pH 3) containing 5 M NaCl. The samples for melting point determination were
generated by mixing equal amounts of protein stock solution and salt solution. Final
samples contained 0,94 mmol/L protein and salt concentrations between 0 M and 2.5 M
NaCl.
For the prepared samples, Tm was determined non-invasively in multi-cuvette arrays
with the Optim® II device (Avacta Analytical, England) by measuring the intrinsic
fluorescence evoked by the intrinsic tryptophan residues. The system was operated with
the Optim 2.1 software. A temperature ramp with 0.25◦C/min steps from 20◦C to 95◦C
was performed. The filters UV 266 and Blue 473 were each set to a constant value of
0.25 before each measurement. For export of raw data Igor Pro 6.37 software was used.
Obtained raw data was fitted using MATLAB (MathWorks, USA) fits of sigmoidal shape
and the inflection point of the fit was assigned as melting point.
6.2.2.7 Colloidal Stability - Generation of Phase Diagrams
Phase diagrams of non-PEGylated lysozyme from chicken egg white were generated ear-
lier [79]. At pH 3 using sodium chloride as precipitant, lysozyme from chicken egg white
showed multiple phase transitions including crystallization, precipitation and skin for-
mation. Therefore, pH 3 (100 mM Citric buffer) and sodium chloride as precipitant
were selected for investigating the effect of PEGylation on the colloidal stability of pro-
teins. Using the methodology presented by [79] in total four protein phase diagrams for
mono-PEGylated lysozyme with 2 kDa, 5 kDa and 10 kDa PEG molecules as well as for
di-PEGylated lysozyme with 2 kDa attached PEG molecules were generated on an auto-
mated liquid handling station (Freedom EVO®200 from Tecan, Germany). Evaluation
of phase states was conducted based on photographs taken by the Rock Imager 182/54
automated imaging system (Formulatrix, USA). In order to determine solubility lines
the protein concentration in the supernatant of batch systems where a phase transition
occurred was determined after 40 days using a NanoDrop 2000c UV-Vis spectroscopic
device (Thermo Fisher Scientific, USA) [254].
In order to compare the colloidal stability of native and PEGylated lysozyme samples
for additional protein and salt concentration extremes not included in the preliminary
screening, two outlying system compositions with NaCl as precipitant were examined.
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These systems consisted firstly of 1.52 mmol/L protein and 3.75 M NaCl and secondly
of 3.04 mmol/L protein and 2.5 M NaCl. The mixtures were equally prepared in a 24 µL
scale on crystallization plates (MRC Under Oil 96 Well Crystallization Plates purchased
from Swissci, Switzerland). In Table 6.2 the required stock solutions and the mixed vol-
umes are displayed. Furthermore, Baumann et al. [284] have shown that native lysozyme
precipitates under the influence of 1.25 mol/L sodium sulfate (Na2SO4) at pH 3 instantly.
No stable solution conditions for lysozyme were detected even for protein concentrations
below 2 mg/ml. For this reason, the colloidal stability of native and PEGylated species
(2 kDa mono- and di-PEGylated, 5 kDa mono-PEGylated and 10 kDa mono-PEGylated)
was additionally investigated using Na2SO4 as precipitant. The chosen system composi-
tion, required stock solutions and the mixed volumes are displayed in Table 6.2.
Table 6.2: Concentrations of stock solutions for the preparation of the isolated systems
for the evaluation of colloidal stability
1.52 mmol/L
protein
+ 3.75 M NaCl
3.04 mmol/L
protein
+ 2.5 M NaCl
1.52 mmol/L
protein
+ 1.25 M Na2SO4
c(Protein) [mg/mL] 87 87 65.25
V(Protein) [µL] 6 12 8
c(salt) [M] 5 5 1.875
V(Salt) [ L] 18 12 16
6.3 Results and Discussion
6.3.1 Preparative Purification of Lysozyme PEGamers
Preparative purification of lysozyme PEGamers was performed by a single cation ex-
change step. In Fig. 6.1 the resulting CEX chromatograms with an NaCl step gradient
for 1:12 diluted PEGylation batches with 2 kDa (A), 5 kDa (B) and 10 kDa (C) are
displayed. Native lysozyme had the highest binding affinity to the adsorbent given that
a higher salt concentration is required to elute it than for PEGylated species. For PE-
Gylated species, a decrease in binding strength with increasing PEGylation degree was
observed for all PEG molecular weights. The comparison of the salt concentration nec-
essary for the elution of PEGylated species in Figure 1A-C indicates that for a constant
PEGylation degree the binding strength decreases with increasing PEG molecular weight.
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Figure 6.1: CEX chromatograms of 1:12 diluted PEGylation batches (r=6.67, pH 7.2,
3.5 h) loaded with a 50 mL loop for 2 kDa PEG (A), 5 kDa PEG (B) and
10 kDa PEG (C). The triangles indicate the respective pooling limits for each
PEGamer species.
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Modified binding affinities can be explained by weakened electrostatic interactions be-
tween protein binding site and adsorber surface due to the attached polymer [149, 258].
Whereas for 5 kDa and 10 kDa the differences in binding strength of the individual
PEGamer species were high enough to achieve baseline separation between the individ-
ual protein species, the differences in the binding strength for the 2 kDa conjugates were
significantly lower. For 2 kDa PEGylation, a very exact adjustment of the salt steps was
necessary for a separation which did not allow for a complete baseline separation. De-
spite the careful selection of salt steps, an isocratic elution of mono-PEGylated lysozyme
is apparent in the chromatogram for 2 kDa PEG. By appropriate choice of the pooling
limits (indicated in Figure 1 by the triangles) purities above 98.2% were achieved for
all PEGamer species (determined by HT-CGE). These findings indicate that the mod-
ification of the apparent surface charge of proteins upon PEGylation depends on the
PEGylation degree as well as on the PEG molecular weight.
In addition to altering the binding strength, PEGylation also increases the hydrodynamic
radius of PEGylated proteins. Previous studies had shown that the increase in size upon
PEGylation was solely dependent on the total nominal weight of attached PEG molecules
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Figure 6.2: Increase in the hydrodynamic radius of PEGylated proteins in dependence
of number and molecular weight of attached PEG molecules measured by
HT-CGE. The error bars correlate to the 95 % confidence interval (1.96 σ).
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and regardless of their number [139, 257, 281]. This finding was verified with a linear
relationship between the nominal weight of total bound PEG (e.g. 2 kDa di-PEGylated
lysozyme has in total 4 kDa PEG attached) and the apparent molecular weight of PEGy-
lated proteins for 2 kDa, 5 kDa and 10 kDa PEG upon HT-CGE analysis (see Fig. 6.2).
6.3.2 Functional Stability - Residual Activity of PEGamers
The effect of PEG molecular weight and PEGylation degree on the catalytic activity
of PEGylated lysozyme was investigated. The activity of an enzyme corresponds to the
rate of the catalyzed reaction, i.e. the substrate depletion ∆csubstrate per time interval
∆t [285]. The reaction rate for lysozyme rlys is therefore described by Eq. 6.1 for a given
initial substrate to protein ratio.
rlys =
∆csubstrate
∆t
∝ ∆Abs450nm
∆t
(6.1)
In this study, the reaction rate was derived from the slope of a linear fit of the measured
absorbance values since the absorption at 450 nm is proportional to the concentration
of substrate when the substrate is not limiting. For reaction rate calculations, only the
linear part of the progression curve (absorption at 450 nm over time) was taken into
account (=initial rate period). The Michaelis-Menten equation describes how this reaction
rate differs with a changing initial substrate to protein ratio [285]. In order to consider
varying substrate to protein ratios into the activity assay, protein concentrations between
6, 99 · 10−3 mmol/L and 6, 99 · 10−2 mmol/L were examined for a constant substrate
concentration. The measured reaction rates of these ten protein concentrations were
plotted against the nominal protein concentration and again the slope of a linear fit was
determined. The respective slope was used as enzyme activity. To allow a comparison
for different PEGylated species, calculated activities were normalized to the activity of
native lysozyme.
The resulting catalytic activities of native and PEGylated lysozyme species are displayed
in Fig. 6.3. With the exception of 2 kDa mono-PEGylated lysozyme, all PEGylated
lysozyme species had a lower in vitro activity than the native protein. Increasing the
molecular weight of mPEG for a constant PEGylation degree as well as increasing the
PEGylation degree for a constant mPEG molecular weight resulted in a decrease in
activity. This observation can be explained by steric hindrance resulting in a decreased
accessibility of the substrate to the active site. 5 kDa and 10 kDa di-PEGylated lysozyme
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showed residual activities below 10% compared to the native protein. Due to these un-
economical residual activities, these two species were not investigated further in the
subsequent stability studies. The range of measured residual activities is in line with the
residual activities between 8 and 77% for 5 kDa PEGylated lysozyme stated by Da Silva
Freitas et al. [278].
Interestingly, 2 kDa mono-PEGylated lysozyme showed an activity increased by 31.1%
compared to the native protein, which is rather unusual for water-soluble enzymes.
Increased enzyme activities of PEGylated proteins are described in the literature for
horseradish peroxidase [286] and laccase [287] in organic surroundings. In organic sys-
tems, the attachment of hydrophilic polymers results in the formation of a protein friendly
micro-environment which decreases conformational changes of the protein structure in
comparison to the native protein. A similar activation phenomenon of trypsin upon poly-
mer modification was reported by Gaertner at al. [288] in aqueous environment. Gaertner
at al. attribute the increased activity to an increase in the concentration of the enzyme-
substrate-complex due to an altered conformational equilibrium by the attachment of a
hydrophilic chain to lysine residues. These results indicate, that the protein conformation
10 kDa−di
10 kDa−mono
5 kDa−di
5 kDa−mono
2 kDa−di
2 kDa−mono
native
relative activity [%]
0 10 25 50 75 100 125 150
Figure 6.3: Residual enzyme activity (%) of PEGylated lysozyme species towards the
substrate Micrococcus lysodeikticus. The indicated activity values refer to
native lysozyme as reference.
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is in addition to steric hindrance another important parameter influencing enzyme ac-
tivities upon PEGylation. Za´vodszky et al. state that the enzyme activity and confor-
mational flexibility are closely correlated [265]. In order to investigate the relationship
between protein conformation and enzyme activity for PEGylated lysozyme the confor-
mational properties of PEGylated lysozyme were evaluated in this work using intrinsic
protein fluorescence.
6.3.3 Conformational Stability - Influence of the Salt Concentration on the
Melting Point
To evaluate the influence of PEGylation on the conformational properties of lysozyme,
melting temperatures (Tm) were determined using intrinsic protein fluorescence measure-
ments. The influence of PEG molecular weight and PEGylation degree was studied. In
Table 6.3 the melting temperatures for all studied protein species without the addition
of salt are displayed. The measurement error bars correlate to a 95% confidence interval
(1.96 σ). All protein species revealed comparable melting temperatures between 60.04
and 62.71 ◦C. The insignificant differences in the melting temperatures indicate that all
conjugates have a similar macroscopic conformational stability as the native protein in
the absence of salt.
Table 6.3: Melting temperatures for native and PEGylated lysozyme for 0 M NaCl
Protein species Tm [
◦C] 1.96 ∗ σ
native 62.71 0.52
2 kDa-mono 60.91 0.09
2 kDa-di 60.04 0.08
5 kDa-mono 60.65 0.48
5 kDa-di 62.76 0.28
10 kDa-mono 60.23 0.44
10 kDa-di 62.00 0.45
With an increase in NaCl concentration the melting temperatures decreased for all pro-
tein species. These observations are in accordance with the studies of Hofmeister on the
destabilizing impact of certain salts on conformational and colloidal stability of proteins
[100]. In Fig. 6.4A the melting points of native, mono-PEGylated and di-PEGylated
lysozyme are displayed as a function of the NaCl concentration exemplary for the conju-
gation with 5 kDa PEG. For native lysozyme, no melting points were determined above
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Figure 6.4: A: Melting temperatures of 0,94 mmol/L native, 5 kDa mono-PEGylated and
5 kDa di-PEGylated lysozyme in dependence of NaCl concentration at pH 3.
The error bars correlate to the 95 % confidence interval (1.96 σ), B: Slope of
the linear regression of the melting points vs. NaCl concentration for native
as well as 2 kDa, 5 kDa and 10 kDa PEGylated lysozyme.
a NaCl concentration of 1.59 mol/L due to spontaneous precipitation during sample
preparation (in accordance with [79]). In a critical salt range between 0.5 und 1.5 mol/L
NaCl, the melting curves of several samples deviated markedly from the expected sig-
moidal shape. Melting points could therefore not be estimated based on sigmoidal fits and
the data points were consequently excluded from the study. In the investigated concen-
tration range, native and 5 kDa mono-PEGylated lysozyme showed comparable trends of
the melting points in dependence of the salt concentration and are hence equally destabi-
lized by the addition of salt ions. 5 kDa di-PEGylated lysozyme has the highest melting
points at all salt concentrations indicating a lower impact of salt on the conformational
stability compared to native and 5 kDa mono-PEGylated lysozyme. Analogous data sets
were determined for conjugated lysozyme with 2 kDa and 10 kDa PEG.
In order to assess the influence of different PEG molecular weights and PEGylation de-
grees on the conformational stability, a linear regression of each dataset was performed.
The slopes of these regressions are displayed in Fig. 6.4B. High absolute values of the
slope represent a large decrease in melting temperatures with increasing salt concentra-
tion. The slopes of 2 kDa mono- and-di-PEGylated lysozyme have a higher absolute value
than native lysozyme indicating a higher susceptibility to conformational changes under
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the influence of salts. 5 kDa and 10 kDa conjugates are less susceptible to conformational
changes under the influence of salts than native lysozyme. Here, no difference between
10 kDa mono- and di-PEGylated lysozyme is detectable within the 95% confidence in-
tervals.
A molecule which is prone to extensive conformational changes under the influence of
salts could be less rigid and may exhibit an increased molecular flexibility in the absence
of salt. A higher flexibility may explain the observed increase in activity for 2 kDa mono-
PEGylated lysozyme due to an improved accessibility of the substrate to the active site.
Even though the slope of 2 kDa di-PEGylated lysozyme indicates a higher molecule flex-
ibility compared to native lysozyme no increase in enzyme activity was observed. These
results support the thesis that the residual enzyme activity after polymer modification
is a combination of steric hindrance and conformational flexibility.
6.3.4 Colloidal Stability - Phase Behavior of PEGylated Lysozyme
In addition to preserving the activity after PEGylation, guaranteeing the solubility of
the protein is a fundamental requirement in order to avoid problems during storage or
application. In order to obtain information about the colloidal stability of PEGylated
lysozyme protein phase diagrams were generated for PEGylated lysozyme with 2 kDa,
5 kDa and 10 kDa PEG in microbatch format at pH 3 under the influence of NaCl.
Investigated phase transitions are displayed in Fig. 6.5B-E.
The phase diagram for native lysozyme (Fig. 6.5A) was demonstrated earlier by Baum-
gartner et al. [79]. For a comparison of the phase behavior on basis of a constant number
of molecules, the mass concentrations used by Baumgartner et al. were converted into
molar concentrations. The formation of crystals as well as precipitate was observed for na-
tive lysozyme. For NaCl concentrations above 1.82 mol/L precipitation was accompanied
by skin formation which indicates protein denaturation.
In comparison to native lysozyme, all PEGylated species showed an expansion of the
soluble area and a reduced aggregation propensity. For 2 kDa mono-PEGylated lysozyme
(Fig. 6.5B) phase transitions to crystallization and precipitation occurred. In comparison
to native lysozyme, an approximately 3 fold higher NaCl concentration was required to
induce a phase transition at the highest investigated protein concentration. With few
exceptions, the complete crystallization range of the native protein was converted into
stable protein solution. For 2 kDa mono-PEGylated lysozyme, crystallization and preci-
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Figure 6.5: Phase diagrams for native (A), 2 kDa mono-PEGylated (B), 2 kDa di-
PEGylated (C), 5 kDa mono-PEGylated (D), 10 kDa mono-PEGylated (E)
lysozyme with sodium chloride (NaCL) as precipitant at pH 3. Data for the
phase diagrams of native lysozyme was taken from Baumgartner et al. [79].
F: Solubility lines of unmodified lysozyme [254] and 2 kDa mono-PEGylated
lysozyme at pH 3. 115
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pitation occured simultaneously in most cases. Compared to the occurrence of large
three-dimensional crystals in the case of native lysozyme, only small needle-shaped crys-
tals and microcrystals were observed in case of 2 kDa mono-PEGylated lysozyme. For
2 kDa di-PEGylated lysozyme (Fig. 6.5C), 5 kDa mono-PEGylated lysozyme (Fig. 6.5D)
and 10 kDa mono-PEGylated lysozyme (Fig. 6.5E) the PEGamers were completely sol-
uble in the entire investigated protein and salt concentration range. Skin formation and
thus protein denaturation was prevented for all PEG molecular weights and PEGylation
degrees.
In Fig. 6.5F the measured solubility values for 2 kDa mono-PEGylated lysozyme are
displayed and compared to data for unmodified lysoyzme [254]. When the two curves are
compared, a considerable increase in solubility is observed. At a constant NaCl concen-
tration of 1.36 mol/L an approximately 11 fold increase in solubility was achieved. The
statement that PEGylation results in an increased protein solubility, well-documented in
the literature, has been underlined in this systematic study with experimental data.
Although 2 kDa di-PEGylated lysozyme, 5 kDa mono-PEGylated lysozyme and 10 kDa-
mono-PEGylated lysozyme show the same phase behavior in the investigated concen-
tration range, they reveal a difference in their conformational stability (Fig. 6.4). These
results indicate that the measurement of the thermal stability may not be correlated to
the phase behavior for PEGylated proteins, although the thermal stability is often used
as an indicator of the general protein stability.
In order to induce a phase transition of the PEGamers which were soluble in the entire
investigated concentration range, extreme protein and salt conditions were applied. The
influence of increased protein concentrations on the one hand and higher NaCl concen-
trations as well as an additional salt (Na2SO4) on the other hand were investigated. In
Fig. 6.6 photographs of the protein aggregates formed under the applied conditions are
displayed for all PEGamers. Native Lysozyme formed heavy precipitate under all con-
ditions. With increasing PEGylation degree and PEG molecular weight the aggregates
changed from precipitate to gelation and even liquid-liquid phase separation occurred.
This indicates that the nature of the aggregates is determined for high PEGylation de-
grees and PEG molecular weights by the properties of the polymer rather than by the
properties of the protein itself.
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Figure 6.6: Photographs of phase transitions of native and PEGylated lysozyme species
resulting from extreme protein and salt conditions (NaCl and Na2SO4).
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6.4 Conclusion
Recombinant proteins for pharmaceutical or biotechnological applications are often prone
to instabilities during production, formulation and storage. The stability attributes are
determined by the complexity of the protein molecule itself and the interplay of en-
vironmental conditions determining molecule interactions. The covalent attachment of
polyethylene glycol (PEG) to proteins is a promising approach to solve these stability
issues. In the presented work, purified samples of lysozyme PEGamers with 2 kDa, 5 kDa
and 10 kDa mPEG-aldehyde attached were examined for their functional, conformational
and colloidal stability. The automatic generation of protein phase diagrams and the mea-
surement of melting points were found to be helpful tools for understanding mechanisms
of protein stabilities. Higher molecular weight PEGs and PEGylation degree resulted in
a greater conformational and colloidal stability. However, a reduced in vitro activity was
observed. The properties of the conjugates have shown to be a mixture of protein and
polymer properties. These findings suggests that in addition to PEG, different synthetic
polymers may in future be conjugated to proteins in order to create functional conjugates
with tailor-made properties due to the multiplicity of polymers. A careful choice of PEG
molecular weight and PEGylation degree enables the fine tuning of protein properties
and should be carefully considered for the use of PEGylated proteins upon formulation
and storage.
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Abstract
Covalent attachment of synthetic polymers to proteins, known as protein-polymer conju-
gation, is currently one of the main approaches for improving the physicochemical prop-
erties of proteins. The most commonly applied polymer is polyethylene glycol (PEG),
having extensive research and clinical track records for its use in biopharmaceuticals.
However, the occurrence of allergic reactions or hypersensitivity and the formation of anti-
bodies against PEG conjugates on the one hand and the introduction of controlled radical
polymerization techniques and novel monomers on the other hand, is driving the search
for alternative polymers for protein conjugation. This study presents the synthesis, purifi-
cation and protein-conjugation of the alternative polymers, poly-(4-acryloylmorpholine)
(PNAM) and poly-(oligoethylene glycol methacrylate) (POEGMA), using lysozyme from
chicken egg white as model protein. Conjugate species with different conjugation degrees
are investigated for their aggregation behavior and solubility using a high-throughput
screening approach. All investigated conjugates show an improved protein solubility when
compared to the native protein. To achieve a comparable effect on solubility as PEG, the
conjugates required polymers with higher molecular weight or higher conjugation de-
grees.
Keywords: PNAM, POEGMA, RAFT polymerization, protein-conjugation, phase be-
havior, solubility
124
7.1 Introduction
7.1 Introduction
The development of recombinant DNA technologies has resulted in a revolution of the
biotechnological production of recombinant proteins. Today, industrially produced pro-
teins are widely applied as biocatalysts for the green synthesis of organic materials as well
as in the textile, detergent, food processing and pharmaceutical industry. For the latter,
drugs based on peptides and proteins have gained a significant share of the pharmaceu-
tical market [13]. The high potential of proteins results from their inherent specificity
for molecular targets in the human body, and thus an intervention with minimal side
effects. However, the complex molecular structure of proteins and the resulting chemical
and physical properties present a challenge for the purification, formulation, storage and
delivery of these drugs [289]. Problems that need to be addressed include limited stabil-
ity, low solubility, short in vivo circulation times, and unwanted immunogenicity [142,
289, 290]. Protein-polymer conjugation has become a central strategy to improve both
physicochemical and pharmacokinetic properties of biopharmaceuticals in non-native en-
vironments [142].
Protein-polymer conjugates are hybrid molecules generated by the covalent attachment
of a synthetic polymer to a native protein. This strategy offers the opportunity to com-
bine the structural and functional features of proteins with the versatility of synthetic
polymers to develop novel high performance biomaterials. [291, 292] Requirements for
the polymer candidates are biocompatibility, water-solubility and an existing reactive
group for the conjugation process [124]. Polyethylene glycol (PEG) is the most com-
monly applied non-ionic hydrophilic polymer in the pharmaceutical industry. PEG owes
its popularity to its FDA approval for use in pharmaceuticals, as well as the long clinical
track records and extensive research efforts on PEG conjugates [142]. Despite the positive
properties of PEGylated proteins such as increased stability [278], solubility [293] and
residence time in the blood stream [294], a series of undesirable effects are reported in
literature. These include the occurrence of allergic reactions or hypersensitivity and the
formation of antibodies against PEG conjugates (anti-PEG) [295–299]. The formation of
anti-PEG leads to an increased clearance rate through the immune system [300] which
counteracts the goal of an increased circulation time of the conjugated drug. Further-
more, it is reported that PEG conjugates are not degradable in the human body and
that PEG vacuoles are formed in organs such as liver, kidney and spleen [301, 302].
The discussed drawbacks seen in PEG intensified the search for alternative polymers
for therapeutic use. A series of synthetic polymers are being investigated and are in
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different stages of development [126, 135, 303]. Synthetic polymers owe their versatile
range of properties to the availability of different monomers with varying architectures
and functional groups [304]. Controlled radical polymerization techniques such as re-
versible addition-fragmentation chain transfer (RAFT) polymerization allow for an accu-
rate adjustment of the polymer molecular weight with a low dispersity (narrow molecular
weight distribution) [292]. The polymer functionality and size as well as the number of
the bound polymers is decisive for the physicochemical and biological properties of the
protein-polymer conjugate. Fine tuning of these parameters is crucial to optimize activity
and stability attributes of the conjugates [292]. However, the underlying physicochemi-
cal interactions between polymer and protein as well as the effect of this interaction on
the conjugate properties are still not fully understood. The development and processing
of conjugates with specific properties and functionalities hence requires the establish-
ment of standardized methods for quantifying the influence of polymer parameters on
the resulting molecular properties.
In this study, we investigated the impact of poly-(4-acryloylmorpholine) (PNAM) and
poly-(oligoethylene glycol methacrylate) (POEGMA) of different sizes on solubility, ag-
gregation (phase) behavior, and resulting biological activity of the conjugated model
protein lysozyme. PNAM is the polymer of the bisubstituted acrylamide derivative N-
acryloylmorpholine and has a number of useful properties including its solubility in water
and other polar and low-polarity solvents, and low toxicity [305, 306]. Veronese et al.
patented in 1997 the activation of PNAM with a single reactive group for the selective
monofunctional attachment of PNAM to various surfaces and molecules including bioma-
terials and bioactive substances such as enzymes and polypeptides [307]. The controlled
polymerization of POEGMA was reported by the research group of Armes [308, 309], and
it was first used to graft on proteins by Chilkoti et al.[310, 311]. Proteins modified by
PNAM and POEGMA showed an increased residence time in blood when compared to
the unmodified form [310, 312–316]. Although there are pharmacokinetic investigations
on the effect of said polymers, no detailed or systematic studies of their influence on the
physical stability of the conjugated proteins have been reported.
In this work, we examined the role of the physicochemical properties of the polymers
on the solubility and aggregation behavior of protein-polymer conjugates. We present an
automated high-throughput approach to assess the influence of monomer type, molecular
weight, and conjugation degree on the stability of protein-polymer conjugates. For the
determination of solubility and phase behavior, lysozyme was conjugated to NHS-ester
functionalized PNAM or POEGMA in a random reaction. The conjugated species with
different conjugation degrees were purified by cation exchange chromatography. Sub-
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sequently, protein phase diagrams were generated using an automated liquid handling
station. To do so, 96-batch systems with varying concentrations of conjugate and precip-
itant agent (sodium chloride) were prepared on a microtiter plate and examined for phase
behavior and solubility. The residual enzyme activity after conjugation was assessed and
compared to the native protein using the lysozyme-specific activity assay based on the
substrate M. lysodeikticus.
7.2 Materials and Methods
7.2.1 Materials
Unless otherwise specified, reagents were used as received without further purification.
4-acryloylmorpholine (Sigma, 97 %), 1,4-dioxane (Sigma, 99 %), dichloromethane (DCM;
VWR), diethyl ether (99.5 %, Roth), sinapic acid (Sigma, 98 %), 2,2’-Azobis(2-methylpro-
pionitrile) (AIBN, Aldrich, 98 %), 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid
N-succinimidyl ester (Aldrich), oligo(ethyleneglycol) methyl ether methacrylate 300 (PO-
EGMA 300, Sigma), trans-2-[3-(4-tert-Butylphenyl)-2-methyl-2-propenylidene]malononi-
trile (DCTB, 99 %), and acetonitrile (Sigma, anhydrous, 99.8 %) were used as received.
The used buffer substance were sodium citrate tribasic dihydrate (Sigma-Aldrich, USA)
for pH 3, sodium acetate trihydrate (Sigma-Aldrich, USA) for pH 5, sodium phosphate
monobasic dihydrate (Sigma-Aldrich, USA) and di-sodium hydrogen phosphate dihydrate
(Merck, Germany) for pH 7.
7.2.2 Polymer Characterization
1H nuclear magnetic resonance (NMR) spectroscopy measurements were performed on a
Bruker AM 500 spectrometer (500 MHz). All compounds were dissolved in CDCl3 and
the residual solvent peak was used for shift correction (7.26 ppm).
Matrix-assisted laser desorption ionization coupled to time-of-flight (MALDI-ToF) mass
spectra were acquired with a 4800 Proteomics Analyzer (Applied Biosystems, Foster City,
CA, USA) in positive ion linear mode and a mass range of 1000 to 40000 Da. The laser
intensity was set to 4800. The spectra obtained represent the average of laser shots taken
by an automatic scheme measuring spectra over the whole spot. The matrices used were
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sinapic acid for conjugated proteins and DCTB for the polymer samples. Peak lists were
generated using Data Explorer Software 4.0 (Applied Biosystems).
Size exclusion chromatography (SEC) measurements were performed on a TOSOH Eco-
SEC HLC-8320 GPC System, comprising an autosampler, a SDV 5 µm bead size guard
column (50Ö8 mm, PSS) followed by three SDV 5 µmm columns (300Ö7.5 mm, subse-
quently 100 A˚, 1000 A˚ and 105 A˚ pore size, polystyrene sulfonate (PSS)), and a differ-
ential refractive index (DRI) detector using THF as eluent at 30◦C with a flow rate of
1 mL/min. The SEC system was calibrated using linear polystyrene standards ranging
from 266 to 252106 g/mol. Before injection the samples were filtered using a 0.2 µm
filter.
7.2.3 RAFT Polymerization of 4-Acryloylmorpholine
In a 250 mL round-bottom flask 91.0 mg of 4-cyano-4-(phenylcarbonothioylthio)pentanoic
acid N-succinimidyl ester were mixed with 12.0 mg (0.3 eq) of AIBN and 1.129 g (68 eq) of
4-acryloylmorpholine. The mixture was then dissolved in 1,4-dioxane to a monomer final
concentration of 1.6 M, and flushed with nitrogen for 30 minutes. The polymerization
mixture was heated to 80◦C for 35 minutes. After evaporation of the solvent under
reduced pressure and dissolving the residue in DCM, the polymer was precipitated in
diethyl ether, centrifuged, separated, and dried under vacuum. The dry product was
analyzed by THF SEC, MALDI-ToF, and 1H NMR spectroscopy.
7.2.4 RAFT Polymerization of Oligo(ethyleneglycol) methyl ether
methacrylate 300
In a 250 mL round-bottom flask 361.4 mg of 4-cyano-4-(phenylcarbonothioylthio)penta-
noic acid N-succinimidyl ester were mixed with 31.53 mg (0.2 eq) of AIBN, and 12.73 g
(44 eq) of oligo(ethyleneglycol) methyl ether methacrylate (OEGMA). The mixture was
dissolved in acetonitrile to a RAFT agent final concentration of 16 mM, and flushed
with nitrogen for 30 minutes. The polymerization mixture was then heated to 70◦C
for 4 hours. After evaporation of the solvent under reduced pressure and dissolving the
residue in DCM, the polymer was precipitated in diethyl ether, separated, and dried
under vacuum. The dry product was analyzed by THF-SEC, MALDI-ToF, and 1H NMR
spectroscopy.
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7.2.5 Protein Conjugation
Conjugation experiments were performed batch-wise in 50 mL Falcon Tubes (BD Bio-
sciences, USA). For conjugation, lysozyme and the respective polymer were dissolved in
25 mM sodium phosphate buffer at pH 7.2. The concentration of lysozyme was set to
0,28 mmol/l. PNAM and POEGMA were added based on a molar polymer to protein
ratio (r =Npolymer/Nprotein with N being the concentration of moles per volume) of 2.
For the reaction, the tube was continuously shaken in an overhead shaker (LabincoLD79,
Labinco BV, Netherlands) for 1 h at room temperature.
7.2.6 Purification of Protein Conjugates
The preparative separation of protein conjugates with varying number of attached poly-
mer molecules was performed on an A¨KTA purifier system equipped with a Fraction
Collector Frac-950 (GE Healthcare, Sweden). As stationary phase, a 5 ml prepacked Toy-
opearl GigaCap S-650M cation exchange (CEX) column (TOSOH Bioscience, Germany)
was used. For column loading, the system was equilibrated in 10 mM sodium acetate
buffer (pH 5). In order to reduce the influence of unbound polymer on the binding be-
havior of the conjugates to the CEX resin, the conjugation batch was diluted 1:6 in 10 mM
sodium acetate buffer (pH 5). Injection of the diluted batch was performed using a 50 mL
super loop (GE Healthcare, Sweden). Elution was performed by applying an NaCl step
gradient with an elution buffer containing 1 M sodium chloride in 10 mM sodium acetate
buffer (pH 5). The NaCl molarities used for the step elution of the different conjugates
are displayed in Table 7.1 in dependence of the attached polymer. The flow rate for equi-
libration, binding and elution was set to 1 ml/min. For process monitoring the absorption
at wavelengths of 280 nm (for protein) and 320 nm (for polymer) as well as conductivity
were detected continuously. From each chromatographic separation, fractions of 2 mL
Table 7.1: NaCl steps in mol/L used for the elution of different conjugate species from
Toyopearl GigaCap S-650M at pH 5 in dependency of the attached polymer.
Native lysozyme mono-conjugated
lysozyme
di-conjuagted
lysozyme
PNAM3.5kDA 1 0.36 0.23
PNAM7kDA 1 0.4 0.175
POEGMA7.5kDA 1 0.24 0.12
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were collected into a 96-well deep well plate (VWR, USA). To obtain sufficient sample
for stability assessment of the different conjugate species the corresponding fractions of
multiple chromatographic runs were pooled. Peak allocation to the different conjugate
species were performed by MALDI-ToF.
7.2.7 Conditioning and Quantification of Protein Conjugates
The separation of protein-polymer conjugates led to fractions containing different NaCl
concentrations. Characterizing the isolated conjugates with regard to activity and phase
behavior thus required a sample conditioning consisting of buffer exchange (resp. pH-
change) and concentration increase. Buffer exchange was carried out using Slide-A-Lyzer
Dialysis Cassettes (Thermo Fisher Scientific, USA) with a molecular weight cut-off of
2 kDa. Concentrating of protein samples was performed by evaporation using a vacuum
concentration unit RVC 2-33CDplus (Martin Christ Gefriertrocknungsanlagen GmbH,
Germany) operated at 24 mbar.
Concentrations of unmodified lysozyme were determined by measuring the absorption at
280 nm using a NanoDrop 2000c UV-Vis spectroscopic device (Thermo Fisher Scientific,
USA) and an extinction coefficient of 1%280 nm,lysozyme = 22.00 [254]. To convert mass
concentrations into molar concentrations, a molecular weight of lysozyme of 14.3 kDa
was used [282].
Since the two polymers PNAM and POEGMA also absorb at 280 nm (Supplementary
Figure A.2), the total absorption at 280 nm (A280nm) is described for protein-polymer
conjugates by:
A280nm = A280nm,lysozyme +A280nm,polymer . (7.1)
In order to quantify the molar concentration of the protein-polymer conjugates, mea-
surements solely at 280 nm are therefore not sufficient. For the quantification of protein-
polymer conjugates, a method based on the differences in the spectra of protein and
polymer was applied. At 320 nm, the two polymers absorb light due to the RAFT group
[317], while lysozyme does not (Supplementary Figure A.2). Thus, by measuring the ab-
sorption at 320 nm and comparing it to a calibration of polymer solutions, it is possible
to quantify how much polymer is bound to a protein. For polymer calibration, absorption
spectra between 240 nm and 340 nm were recorded for polymer solutions (in conjugation
buffer) at 10 concentrations between 0,1 and 1,0 mg/ml using a NanoDrop 2000c UV-Vis
spectroscopic device (Thermo Fisher Scientific, USA). Using the respective molecular
weight of the polymer, the mass concentrations were converted to molar concentrations.
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From the recorded polymer spectra, the absorption values were extracted for 280 nm and
320 nm. By implementing the proportionality
K = A280nm,polymer/A320nm,polymer , (7.2)
it is possible to rearrange Eq. 7.1 and calculate the absorption A280nm,lysozyme as
A280nm,lysozyme = A280nm −K ·A320nm,polymer . (7.3)
For the K value, the mean value of all K values of the 10 measured polymer concentrations
was used. In order to convert the calculated absorption A280nm,lysozyme into a concen-
tration, the extinction coefficient of 1%280 nm,lysozyme = 22.00 was used as for unmodified
lysozyme. All concentration measurements were performed as triplicates.
7.2.8 Stability Assessment
7.2.8.1 Functional Atability - Activity Assay Using M. Lysodeikticus
In order to evaluate the residual activity of the protein-polymer conjugates after conju-
gation and separation, a Micrococcus lysodeikticus-based activity assay was performed
according to [293]. The kinetic assay is based on the lysis of bacterial cells by the en-
zyme. The decrease in cell density results in a decrease in turbidity over time, which was
monitored by measuring the absorbance at 450 nm. To allow a comparison for differ-
ent conjugated species, the derived activities were normalized to the activity of native
lysozyme.
7.2.8.2 Colloidal Stability - Generation of Phase Diagrams
According to [79], in total four protein phase diagrams for mono-PNAM3.5 kDaylated
lysozyme, di-PNAM3.5 kDaylated lysozyme, mono-PNAM7 kDaylated lysozyme and mono-
POEGMA7.5 kDalated lysozyme, were generated on an automated liquid handling sta-
tion (Freedom EVO®200 from Tecan, Germany). The pH value was adjusted to 3 us-
ing a buffer system of citric acid monohydrate (Merck, Germany) and sodium citrate
tribasic dihydrate (Sigma-Aldrich, USA) and a total buffer capacity of 100 mM. The
purified conjugated species were concentrated to 3.04 mmol/L ± 0.07 mmol/L (corre-
sponds to 43.5 mg/mL ± 1 mg/mL unmodified protein) dialyzed and into 100 mM citric
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buffer (pH 3) (=protein stock solution). Eight protein dilution steps between 0.35 and
3.04 mmol/L were prepared by mixing protein stock solution and 100 mM citric buffer
(pH 3) on a protein plate. As precipitant, sodium chloride was used. Twelve salt con-
centrations between 0 and 5 M were created according to [79]. Binary phase diagrams
were generated by mixing 12 µL of each diluted protein solution with 12 µL of each
prepared salt concentration on a crystallization plate (Swissci, Switzerland) resulting in
96 batch systems with varying composition. As result the protein concentrations varied
from 0.17 to 1.52 mmol/L and the salt concentrations from 0 M to 2.5 M. Evaluation
of phase states was conducted based on photographs taken by the Rock Imager 182/54
automated imaging system (Formulatrix, USA). In order to determine solubility lines
the protein concentration in the supernatant of batch systems where a phase transition
occurred was determined after 40 days using a NanoDrop 2000c UV–vis spectroscopic
device.
7.3 Results and Discussion
7.3.1 Polymer Synthesis
The disadvantages of PEG, already discussed in previous sections, increased the inter-
est in alternative polymers for use in therapeutics. Synthetic polymers, such as PNAM
and POEGMA, are some of the potential alternatives being investigated. The selected
polymers for this study can be prepared via RAFT polymerization, which allows not
only the synthesis of polymers with defined sizes and narrow dispersities, but also the
introduction of a functional group to the end chain for further modification by selecting
the appropriate RAFT agent. Its relatively simple experimental setup when compared to
PEG (e.g., no handling of gaseous monomer), and the possibility to scale up its synthesis
make these polymers attractive for potential uses in biomedical fields.
A commercially available RAFT agent with an activated NHS ester was used for the
polymer synthesis. The use of NHS esters to bind lysine residues is a well-known technique
for protein conjugation [318]. Table 7.2 summarizes the features of the polymers used for
this study. As expected, the polymers synthesized show a narrow dispersity (D<1.10),
and the survival of the activated ester group for protein conjugation is shown via UV
spectra (Supplementary Figure A.2) and 1H NMR (Supplementary Figures A.4, A.5 and
A.6).
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Table 7.2: Summary of the characterization of the three polymers synthesized for this
study.
Monomeric
units
Mn,SEC Mn,NMR D
PNAM3.5kDA 22 1900 3500 1.08
PNAM7kDA 47 3800 7100 1.09
POEGMA7.5kDA 24 6700 7600 1.10
7.3.2 Protein Conjugation and Purification
Preparative purification of lysozyme species with different number of attached polymer
molecules was performed by a single cation exchange step. In Fig 7.1 the resulting CEX
chromatograms with an NaCl step gradient for 1:6 diluted conjugation batches are dis-
played for PNAM3.5 kDa (A), PNAM7 kDa (B) and POEGMA7.5 kDa (C). The first 50 ml
of the chromatographic purification run correspond to the loading phase and are hence
not displayed here. The green line indicates the absorption at 280 nm (UV280nm) at
which both protein and polymer absorb. The red line indicates the absorption at 320 nm
(UV320nm) at which only the polymer absorbs. Conjugation species with varying degree of
conjugation were assigned to the individual peaks of the CEX chromatogram by MALDI-
ToF. The results of this fractional analysis are shown in Fig 7.2 and will be discussed
in the following. For a first estimation of the conjugation degree, however, the ratio of
UV320nm to UV280nm can be used. Fractions containing only protein but no polymer do
not absorb at 320 nm. In Fig 7.1 A und C, it can be seen that the native fractions
for PNAM3.5 kDa and POEGMA7.5 kDa contain slight impurities of the respective poly-
mer. However, these fractions were not used for further experiments within the study.
The higher the degree of conjugation, the higher the ratio of UV320nm to UV280nm. For
all three investigated polymers, native lysozyme had the highest binding affinity to the
adsorbent given that a higher salt concentration is required to elute it than for con-
jugated species. For conjugated species, a decrease in binding strength with increasing
conjugation degree was observed. These results are in accordance with the purification of
PEGylated lysozyme published earlier [293]. Modified binding strength can be explained
by weakened electrostatic interactions between protein binding site and adsorber surface
due to the attached polymer [149, 258, 319].
The successful separation of each conjugated species was proven via MALDI-ToF (Fig 7.2).
A sample of the raw mixture obtained after the conjugation experiment was taken for
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Figure 7.1: CEX chromatograms of 1:6 diluted conjugationlation batches (r = 2, pH 7.2,
1 h) loaded with a 50 mL loop for PNAM3.5 kDa (A), PNAM7 kDa (B) and
POEGMA7.5 kDa (C).
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each polymer. At this point and without any purification step, the MALDI spectra show,
in all cases, three main different distributions (Fig 7.2B, D, and F), which correspond to
a mixture of native and conjugated protein. The signal at approximately 14.3 kDa is a
narrow distribution that can be assigned to native unreacted lysozyme, while the higher
mass value species correspond to the polymer-protein conjugates obtained. Samples col-
lected after separation using CEX chromatography were then analyzed via MALDI and
assigned to a protein or polymer-protein species (Fig 7.22 B, D, and F). In the case of
conjugation experiments using either PNAM3.5 kDa or PNAM7 kDa, the spectra of the
first and second eluted species on CEX show a monomodal distribution. The maximum
of these signals add up to two and one polymer chains attached on one protein, respec-
tively. As previously mentioned, the last species to elute is lysozyme, as seen from the
signal at 14.3 kDa on the MALDI spectra for all cases. Analysis of the separation of the
POEGMA-lysozyme conjugates using MALDI show a similar pattern in the case of the
native and mono conjugated protein. Although a signal of native protein is still visible
on the spectrum of the mono conjugated species, further characterization of the sample
Figure 7.2: MALDI spectra of the synthesized polymers (top) and the conjugated frac-
tions separated using CEX chromatography (bottom).
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using high-throughput capillary gel electrophoresis (Supplementary Figure A.7) and SEC
(Supplementary Figure A.8) have proven the high purity of the mono conjugate. The
higher conjugates corresponding to the first eluted species on CEX, however, show more
than one distribution and were, therefore, not used for further experiments.
7.3.3 Stability Assessment
7.3.3.1 Functional Stability
The functional stability of the purified protein-polymer conjugates was studied using a
lysozyme specific activity assay based on the substrate M. lysodeikticus. The assay proce-
dure and calculation of the residual enzyme activities were performed according to [293].
The resulting catalytic activities of native, PNAMylated and POEGMAlated lysozyme
species are displayed in Fig. 7.3. With the exception of mono-PNAM3.5 kDaylated lysozyme,
all conjugated species had a lower in vitro activity than the native protein. For PNAM,
increasing the molecular weight of the polymer for a constant conjugation degree as well
as increasing the conjugation degree for a constant polymer molecular weight resulted in
a decreased residual activity. These results are in accordance with the activities of
0 10 25 50 75 100 125
mono-POEGMA7.5kDa
mono-PNAM7kDa
mono-PNAM3.5kDa
native
relative activity [%]
di-PNAM3.5kDa
di-PNAM7kDa
Figure 7.3: Residual lysozyme activity (%) of protein-polymer conjugates towards the
substrate M. lysodeikticus. The indicated activity values refer to native
lysozyme as reference.
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PEGylated lysozyme species published earlier [293]. For PEG, changes in enzyme ac-
tivities upon PEGylation have shown to result from a combination of steric hindrance
and molecular flexibility. It can be assumed, that similar mechanism apply for the here
studied polymers. di-PNAM7 kDaylated lysozyme showed no residual activity. When com-
paring mono-PNAM7 kDaylated and mono-POEGMA7.5 kDalated lysozyme, the PNAM-
conjugates exhibit a significantly higher residual activity of 56 % compared to 13.5 % for
the POEGMA-conjugates. The low residual activity obtained for di-POEGMA7.5 kDalated
lysozyme gives grounds to expect a residual activity of below 10 % for di-POEGMA7.5 kDa-
lated lysozyme. Due to these uneconomical residual activities, di-PNAM7 kDaylated and
di-POEGMA7.5 kDalated lysozyme were not investigated further in the subsequent sta-
bility study.
7.3.3.2 Colloidal Stability
In addition to conserving the biological functionality after the conjugation, the resulting
physicochemical properties of the hybrid molecules are of major interest. In this study,
the solubility and the phase behavior of the conjugates are investigated as an impor-
tant physicochemical property. To obtain information about the colloidal stability of the
conjugated lysozyme species, protein phase diagrams were generated for lysozyme con-
jugated with PNAM3.5 kDa, PNAM7 kDa and POEGMA7.5 kDa in microbatch format at
pH 3 under the influence of NaCl. The investigated phase transitions are displayed in
Fig 7.4B-E. The phase diagram for native lysozyme Fig 7.4A was generated earlier by
Baumgartner et al. [79]. For a comparison of the phase behavior on basis of a constant
number of molecules, the mass concentrations used by Baumgartner et al. were con-
verted into molar concentrations. The formation of crystals as well as precipitate was
observed for native lysozyme. For NaCl concentrations above 1.82 mol/L precipitation
was accompanied by skin formation which indicates protein denaturation.
Compared to native lysozyme, all conjugated species featured a reduced aggregation
propensity which manifests in an extension of the soluble area. For mono-PNAM3.5 kDa-
ylated lysozyme (Fig 7.4B), the NaCl concentration initiating a phase transition for the
highest investigated protein concentration was twice as high when compared to native
lysozyme. The visual evaluation of the phase diagrams revealed phase transitions to crys-
tallization, precipitation and gelation. For all occurring phase transitions, the formation
of precipitate was observed. For moderate salt and protein concentrations, precipitate was
accomplished by gelation and the formation of microcrystals. Except for the deficiency
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Figure 7.4: Phase diagrams for native (A), 3.5 kDa mono-PNAMylated (B), 3.5 kDa
di-PNAMylated (C), 7 kDa mono-PNAMylated (D), 7.5 kDa mono-
POEGMAlated (in preparation and therefore at day 7) (E) lysozyme with
sodium chloride (NaCl) as precipitant at pH 3. Data for the phase diagrams
of native lysozyme was taken from [79].
of microcrystals and a slight increase in the gelation area, the resulting phase diagram of
mono- and di-PNAM3.5 kDaylated lysozyme (Fig 7.4B and C, respectively) show similar
features. However, the resulting aggregates differ greatly in their appearance as shown by
the photographs in Fig 7.4 (conjugate concentration of 1,52 mmol/l and a NaCl concentra-
tion of 1,82 mol/l). In the case of mono-PNAM3.5 kDaylated lysozyme, heavy precipitation
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occurs resulting in a visible dark area. For di-PNAM3.5 kDaylated lysozyme, the phase
transition is predominated by gelation and only light precipitate is formed. For a higher
conjugation degree, the properties of the conjugates seem to be rather dominated by the
polymer properties than by those of the native protein. PNAM is a hydrophilic poly-
mer that increases the hydrodynamic radius of the protein by binding water molecules.
Thereby the interactions of salts ions and protein charges are weakened. Moreover, the
bound polymer masks hydrophobic patches on the protein surface. Since the present salt
ions have less interactions and the hydrophobic patches are less accessible, the hydropho-
bic forces are weaker and a higher precipitant agent concentration is necessary to induce
protein-based aggregation. However, these same high salt concentrations seem to lead to
physically crosslinked polymer gels. Crosslinking by ionic interactions is a known strategy
for hydrogel formation, that does not necessarily require the presence of ionic groups in
the polymer for gel formation [320, 321]. Mono-POEGMA7.5 kDaylated lysozyme shows
the largest soluble area of all investigated conjugate species. For the highest protein con-
centration used, 2.05 M NaCl was necessary to induce phase transition for the POEG-
MAlated lysozyme compared to 0.45 M NaCl for unmodified lysozyme. Precipitation and
gelation preexisted for the conjugated species. For POEGMA the outstanding reduction
of the aggregation propensity is contrasted by the already discussed extreme decrease of
the residual biological activity. This example clearly demonstrates that a careful choice
of the polymer type, molecular weight and number of bound molecules must be made
depending on the requirements of the particular application.
To quantify the impact of the polymer attachment on the solubility increase, the conju-
gate concentration in the supernatant of the batch systems with observed phase transi-
tion was measured after 40 days of incubation. In Fig. 7.5, the measured solubility curves
for mono- and di-PNAM3.5 kDaylated lysozyme as well as for mono-PNAM7 kDaylated
lysozyme are displayed. The solubility curves for native lysozyme [254] and mono-PEG2 kDa-
ylated lysozyme [293] have been published earlier. As already expected from the phase
diagrams, all conjugated species show a higher solubility under the influence of NaCl at
pH 3. Surprisingly, 3.5 kDa di-PNAMylated lysozyme exhibits a lower solubility than
3.5 kDa mono-PNAMylated lysozyme at moderate salt concentrations. For high salt
concentrations, the two solubility curves approach each other. Based on the assumption
that two attached polymer chains lead to a higher shielding effect, di-PNAM3.5 kDaylated
lysozyme was expected to be more stable than mono-PNAM3.5 kDaylated lysozyme. A
possible explanation is the higher proportion of bound water molecules by two polymer
chains compared to one polymer chain. Compared to the mono-conjugated species, the
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Figure 7.5: Solubility lines of unmodified lysozyme [254], mono-PNAM3.5 kDaylated
lysozyme, di-PNAM3.5 kDaylated lysozyme, mono-PNAM7 kDaylated
lysozyme and mono-PEG2 kDaylated lysozyme [293] at pH 3. Solubility
line for mono-POEGMA7.5 kDalated lysozyme is in preparation.
residual water necessary for a solvation of the protein conjugates is reduced which may
cause the observed decrease in solubility. The solubility line of mono-PNAM7 kDaylated
lysozyme behaves similarly to that of mono-PEG2 kDaylated lysozyme. It can be stated
that due to the difference in polymer architecture, a higher molecular weight of PNAM
is required to achieve the same stabilizing effect as by PEG.
At the point of handing in this thesis, the phase experiment for mono-POEGMA7.5 kDalated
lysozyme is in its 40 days incubation period and the solubility line is not yet measured.
Based on the optical evaluation of the phase diagrams, however, a higher solubility is
expected when compare to mono-PEG2 kDaylated lysozyme.
7.4 Conclusion
In this study, the polymers PNAM and POEGMA were synthesized by RAFT poly-
merization and conjugated to lysozyme from chicken egg white. The resulting conjugate
properties result from a combination of protein and polymer properties. By shielding the
140
7.5 Acknowledgments
protein surface, the attached polymer simultaneously led to a decrease in the in vitro
activity and an increase in the equilibrium solubility under a combined influence of ex-
treme salt concentrations and pH value. The here presented method constitutes a helpful
tool for optimizing polymer parameters for a tradeoff between enhanced physicochemical
properties and reduced in vitro activity.
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Abstract
Recent studies highlighted the potential of PEGylated proteins to improve stabilities
and pharmacokinetics of protein drugs. Ion-exchange chromatography (IEX) is among
the most frequently used purification methods for PEGylated proteins. However, the
underlying physical mechanisms allowing for a separation of different PEGamers (proteins
with a varying number of attached PEG molecules) are not yet fully understood.
In this work, mechanistic chromatography modeling was applied to gain a deeper under-
standing of the mass transfer and adsorption/desorption mechanisms of mono-PEGylated
proteins in IEX. Using a combination of the general rate model (GRM) and the steric
mass action (SMA) isotherm, simulation results in good agreement with the experimen-
tal data were achieved. During linear gradient elution of proteins attached with PEG
of different molecular weight, similar peak heights and peak shapes at constant gradient
length were observed. A superimposed effect of increased desorption rate and reduced dif-
fusion rate as a function of the hydrodynamic radius of PEGylated proteins was identified
to be the reason of this anomaly. That is why the concept of the diffusion-desorption-
compensation effect is proposed. In addition to the altered elution orders, PEGylation
resulted in a considerable decrease of maximum binding capacity. By using the SMA
model in a kinetic formulation, the adsorption behavior of PEGylated proteins in the
highly concentrated state was described mechanistically. An exponential increase in the
steric hindrance effect with increasing PEG molecular weight was observed. This suggests
the formation of multiple PEG layers in the interstitial space between bound proteins
and an associated shielding of ligands on the adsorber surface to be the cause of the
reduced maximum binding capacity. The presented in silico approach thus complements
the hitherto proposed theories on the binding mechanisms of PEGylated proteins in
IEX.
Keywords: Mechanistic modeling, ion-exchange chromatography, PEGylated proteins,
diffusion-desorption-compensation effect, shielding
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8.1 Introduction
It is estimated that in 2020 about 46% of the sales volume of the 100 highest-selling
pharmaceutical products will be achieved by biopharmaceutical products [13]. Biophar-
maceuticals contain active substances based on biological molecules, such as recombinant
proteins. Compared to conventional small molecular pharmaceuticals, proteins have a
complex three-dimensional structure allowing for a more efficient and specific interven-
tion in cellular metabolic pathways. The efficacy of systemically administered protein
drugs however, may be hampered by a low bioavailability due to a poor solubility un-
der physiological conditions, a short in vivo half-life due to a rapid elimination by the
body and proteolysis. A promising approach to overcoming these drawbacks is the co-
valent attachment of polyethylene glycol (PEG) to protein drugs [142]. As early as in
1977, the group of Abuchowski and Davis found an increased blood circulation half-life
and a reduced immunogenicity of PEGylated proteins compared to the native form [133,
294]. Additional positive effects of PEGylation are an increased thermal stability as well
as a higher solubility allowing for higher concentrated protein formulations [293]. Two
successfully approved PEGylated protein drugs are interferon α-2a (Pegasys®, Hoffman-
LaRoche) for the treatment of hepatitis C and granulocyte-colony stimulating factor
(Neulasta®, Amgen) for the treatment of leukemia.
The emergence of conjugates with varying number (PEGamers) and site of attachment
(positional isoforms) upon PEGylation reactions creates a need for a thorough purifica-
tion in order to gain regulatory approval [130, 322]. Ion-exchange chromatography (IEX)
is among the most frequently used purification methods for PEGylated proteins [129,
130]. Understanding the underlying physical mechanisms is an important prerequisite to
optimize, control, predict, and scale-up the separation of PEGamers to pilot and pro-
duction level. In this context, mechanistic modeling provides an excellent opportunity to
generate various information about mass transport and adsorption isotherm parameters
in silico.
The physico-chemical properties and thus the behavior of a protein in chromatographic
separation processes are significantly influenced by its PEGylation [130, 322]. Due to
the high hydration of the hydrophilic PEG, PEGylated proteins have a distinctly higher
hydrodynamic radius than unmodified proteins with the same molecular weight. A non-
linear correlation introduced by Fee and Van Alstine allows a reliably mathematical
prediction of the hydrodynamic radius hR,PEGprot based on the molecular weight of the
protein and the attached PEG [130, 139]. In case of chromatographic separation, the
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PEG ‘cloud’ around the protein results in an increased distance between protein bind-
ing site and adsorber surface [322]. Seely and Richey [149] observed that the elution
order of different PEGamers was the same in both cation-exchange and anion-exchange
chromatography. They proposed the ‘charge-shielding effect’ which links the weakened
electrostatic interactions to the increased distance between protein binding site and ad-
sorber surface. A deeper process understanding was achieved by Yamamoto et al. [323]
using mechanistic chromatography modeling. They applied the stoichiometric displace-
ment model (SDM) to verify the ‘charge-shielding effect’ quantitatively and associated
it with the decreased elution volume of PEGamers. Moreover, it was shown that mono-
PEGylated proteins are bound to the ion-exchange adsorber with binding sites similar
to the unmodified protein. In following studies, this model was applied to PEGylated
lysozyme and BSA [150, 324]. The aforementioned contributions demonstrated the suc-
cessful application of mechanistic modeling to understand the adsorption behavior of
PEGylated proteins in the linear region of the adsorption isotherm.
This work presents a full investigation of the behavior of mono-PEGylated proteins in
IEX based on mechanistic chromatography modeling. In contrast to previous studies,
information on the adsorption and desorption behavior in the non-linear region of the
isotherm, i.e. the overloaded state, is included by using the steric mass action (SMA)
model [155] in kinetic formulation. Compared to the equilibrium isotherm used hitherto,
the kinetic formulation is suitable for the description of protein behavior in higher con-
centrated state on adsorber surface. To further account for mass transfer effects within
the chromatography column the general rate model (GRM) [325] is employed. To best of
our knowledge, mechanistic modeling of polymer grafted proteins in IEX using a com-
bination of GRM and SMA isotherm has not been studied. By connecting these two
approaches, this study delivers supplements by the quantitative investigation on the film
diffusion, pore diffusion, charge and shielding parameters, as well as the adsorption and
desorption rate coefficients.
The model protein lysozyme from chicken egg was chosen as PEGylation target and con-
jugated to activated PEG of three different molecular weights (2 kDa, 5 kDa and 10 kDa).
The preparative isolation of the mono-PEGylated species was carried out using a single
cation-exchange (CEX) chromatography step. For each purified protein species, three
linear gradient elution (LGE) experiments with different gradient slopes were conducted
to confirm the constancy of the characteristic charge. Breakthrough experiments were
carried out to gain insight into the binding behavior of PEGylated proteins in the highly
non-linear region and to investigate whether the perceivable behavior of PEGylated pro-
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teins originates from adsorption/desorption or mass transfer. Confidence intervals at 95 %
level were calculated for parameter estimates.
8.2 Materials and Methods
8.2.1 Adsorber, Proteins, and Chemicals
All stock solutions and buffers were prepared with ultra-pure water (PURELAB Ultra
water purification system, ELGA Labwater, Germany), filtrated using a cellulose-acetate
filter with a membrane cut-off of 0.22µm (Satorius, Germany) and degassed by sonication.
The used buffer substances were sodium acetate trihydrate (Sigma-Aldrich, USA) for pH 5
and sodium phosphate monobasic dihydrate (Sigma-Aldrich, USA) as well as di-sodium
hydrogen phosphate dihydrate (Merck, Germany) for pH 7.0 and pH 7.2, respectively.
Hydrochloric acid and sodium hydroxide (NaOH) for pH adjustment were obtained from
Merck (Germany). Lysozyme from chicken egg-white (no. HR7-110) was purchased from
Hampton Research (USA). Methoxy-PEG-propionaldehyde (mPEG-aldehyde) with an
average molecular weight (MW) of 2 kDa (Sunbright®ME-020 AL), 5 kDa (Sunbright®-
ME-050 AL) and 10 kDa (Sunbright®ME-100 AL) was obtained from NOF Corpo-
ration (Japan). Sodium cyanoborohydride (NaCNBH3) and L-lysine were purchased
from Sigma-Aldrich (USA). For preparative isolation of PEGamers as well as for mod-
eling purposes, the strong cation-exchange (CEX) chromatography adsorber medium
TOYOPEARL® GigaCap S-650M (Tosoh Bioscience, Germany) was used. It is a high ca-
pacity polymer grated cation exchange resin based on hydroxylated methacrylic polymer
with a 100 nm pore size and a 75µm particle size. For preparative isolation of PEGamer
species, 5 mL pre-packed MiniChrom columns (dimension: 100 mm × 8 mm) and for mod-
eling purposes, a pre-packed 0.965 mL Toyoscreen®column (dimension: 30 mm × 6.4 mm)
were used. Between the runs, the resin media were stored in 20 % ethanol. The storage
solution was removed by prolonged equilibration with ultra-pure water and flushed with
binding and elution buffer before experimentation. Sodium chloride (NaCl) used for pro-
tein elution was purchased from Merck (Germany). 0.5 M NaOH (Merck, Germany) was
used for cleaning-in-place.
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8.2.2 Instrumentation and Software
pH adjustment of all buffers was performed using a five-point calibrated pH-meter HI-
3220 (Hanna Instruments, USA) equipped with a SenTix®62 pH electrode (Xylem Inc.,
USA). Protein concentration measurements were conducted using a NanoDrop2000c
UV–vis spectrophotometer (Thermo Fisher Scientific, USA). Purity of isolated mono-
PEGylated lysozyme was determined by high-throughput capillary gel electrophoresis
(HT-CGE) using the Caliper LabChip®GX II device (PerkinElmer, USA). For data pro-
cessing and purity determination, the LabChip®GX 3.1 software (PerkinElmer, USA)
was used.
Preparative isolation of mono-PEGylated lysozyme species was performed on an A¨KTA
purifier system equipped with a Fraction Collector Frac-950 (GE Healthcare, Sweden).
All experiments for chromatography model calibration were carried out using an Ettan
liquid chromatography (LC) system with the UV monitor UV-900 (3 mm optical path
length), pump unit P-905, dynamic single chamber mixer M-925 (90 µl mixer volumne),
and conductivity cell pH/C-900 (all GE Healthcare, Little Chalfont, Buckinghamshire,
UK). The UNICORN 5.31 software (GE Healthcare, UK) was used to control both chro-
matographic systems and to record the signals. The protein chromatography simulation
software ChromX (GoSilico, Germany) was used for the numerical simulations of the
system of partial differential equations, estimation of model parameters, as well as for
statistical analysis [158]. Other data evaluations were conducted in Matlab® R2016a
(MathWorks, USA).
8.2.3 PEGylation Reaction
As reaction buffer 25 mM sodium phosphate (pH 7.2) containing 20 mM sodium cyanoboro-
hydride (NaCNBH3) as reducing agent was used. PEGylation experiments were per-
formed batch-wise in 50 mL Falcon Tubes (BD Biosciences, USA). Lysozyme (5 mg/mL)
and mPEG-aldehyde were dissolved in the reaction buffer with a molar polymer to pro-
tein ratio of 6.67:1 [264, 281]. The tube was continuously shaken in an overhead shaker
LabincoLD79 (Labinco BV, Netherlands) for 3.5 h at 25◦C. The PEGylation reaction was
stopped by adding 200 mM of L-lysine according to [253].
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8.2.4 Preparative Purification of Mono-PEGylated Lysozyme
For preparative isolation of mono-PEGylated lysozyme, the stopped PEGylation batch
was diluted to a ratio of 1:12 in 10 mM sodium acetate buffer (pH 5) [281]. For column
loading, the system was equilibrated in 10 mM sodium acetate buffer (pH 5). Sample ap-
plication was performed using a 50 mL super loop (GE Healthcare, Sweden). Elution was
initiated by applying an NaCl step gradient with 10 mM sodium acetate buffer (pH 5)
containing 1.0 M sodium chloride. The NaCl molarities used for the step elution of the
different PEGamers are displayed in Tab. 8.1 as a function of the molecular weight of
the attached PEG molecules. The flow rate for binding and elution was set to 1 mL/min.
Fractions of 2 mL were collected into a 96-well deep well plate (VWR, USA). To ob-
tain sufficient sample volume for the linear gradient and the breakthrough experiments,
fractions containing mono-PEGylated lysozyme of multiple chromatography runs were
pooled.
Table 8.1: NaCl steps in mM used for the elution of different PEGamer species from
Toyopearl GigaCap S-650M at pH 5 as a function of the PEG molecular weight
Native lysozyme mono-PEGylated
lysozyme
di-PEGylated
lysozyme
Mw=2 kDa 1000 460 290
Mw=5 kDa 1000 350 160
Mw=10 kDa 1000 250 75
To ensure similar binding conditions for all PEG molecular weights during the calibra-
tion runs, the mono-PEGylated samples were concentrated to approximately 3.76·10−4 M.
This was accomplished by evaporation using a vacuum concentration unit RVC 2-33CDplus
(Martin Christ Gefriertrocknungsanlagen GmbH, Germany) operated at 24 mbar. After
concentrating, the protein samples were transferred to 25 mM sodium phosphate buffer
(pH 7) using Slide-A-Lyzer Dialysis Cassettes (Thermo Fisher Scientific, USA) with a
molecular weight cut-off of 2 kDa. All chromatography experiments were carried out at
25◦C.
8.2.5 Oﬄine Identification and Quantification of PEGamer Species
Purity of isolated mono-PEGylated lysozyme was determined by high-throughput capil-
lary gel electrophoresis (HT-CGE) as described in [281]. The experiments were performed
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with an HT Protein Express LabChip® and an HT Protein Express Reagent Kit (Perkin
Elmer, Hopkinton, MA, USA). The LabChip® installation, sample preparation and anal-
ysis were performed according to the manufacturer’s standard protocol [326]. Sample
preparation was performed in skirted 96-well polypropylene twin.tec® PCR plates from
Eppendorf (Hamburg, Germany). Molecular weight determination was performed accord-
ing to protein standards from the HT Protein Express Reagent Kit.
For protein quantification, absorption measurements at 280 nm were performed. Since the
bound PEG molecules do not absorb at 280 nm, the extinction coefficient of 1%280nm,lysozyme
= 22.00 was used for native as well as for mono-PEGylated lysozyme [79, 281]. Appro-
priate blanks were subtracted. Molar concentrations were calculated using a lysozyme
molecular mass of 14.6 kDa [327]. The final concentrations of native lysozyme and mono-
PEGylated species attached with 2 kDa, 5 kDa, and 10 kDa PEG used for the linear gradi-
ent and breakthrough experiments were 3.87·10−4± 7.19·10−7 M, 3.63·10−4± 1.41·10−7 M,
3.60·10−4 ±1.61 ·10−7 M, and 3.81·10−4± 1.57·10−5 M, respectively. The slight deviations
in PEGamer concentrations are due to concentrating and buffer exchange. For subsequent
modeling the exact concentrations were employed.
8.2.6 Chromatography System Characterization
Tracer pulse injections at constant flow rate of 0.33 mL/min were carried out to character-
ize the A¨KTA system and chromatography column. For determination of the interstitial
volume of the column, 25µL of 10 g/L non-interacting, non-pore-penetrating tracer blue
dextran 2000 kDa (Sigma-Aldrich, St. Louis, MO, USA) in ultra-pure water was used.
25µL of 1 %(v/v) pore-penetrating, non-interacting tracer acetone (Merck, Darmstadt,
Germany) in ultra-pure water was used to determine system and total voidage of the
column. The UV signals at 260 nm were recorded for that purpose. All measurements
were corrected with respect to system dead volumes. The ionic capacity Λ of GigaCap
S-650M was determined via acid-base titration following Huuk and coworkers [157].
8.2.7 Linear Gradient Experiments for Model Calibration
Protein solutions with lysozyme and its PEGylated species were prepared in binding
buffer (25 mM sodium phosphate buffer, pH 7.0). Before injection, the protein solutions
were filtrated with a membrane cut-off of 0.22µm.
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Linear gradient elution (LGE) experiments were used for determining model parameters
for native lysozyme, lysozyme attached with PEG 2 kDa, PEG 5 kDa, and PEG 10 kDa.
Protein solutions were injected via a 100µL loop. After a post-loading wash step of 1 CV
binding buffer, elution was carried out by increasing the salt gradient from 0 M to 1.0 M
NaCl. From low-salt and high-salt buffer, linear gradients with a gradient length of 15 CV,
20 CV, and 25 CV were mixed within the LC system. After that, the column was stripped
over 3 CV at an NaCl concentration of 1.0 M and re-equilibrated for 5 CV binding buffer.
To ensure a constant residence time, all experiments were carried out at a flow rate of
0.33 mL/min.
8.2.8 Breakthrough Experiments for Model Calibration
Breakthrough experiments were used for modeling of the SMA isotherm model in the
non-linear region. Protein solutions with native lysozyme, lysozyme attached with PEG
2 kDa, PEG 5 kDa, and PEG 10 kDa were prepared in binding buffer and injected via a
50 mL superloop (GE Healthcare, UK). The loading was carried out under strong binding
condition at 0 M NaCl until 100 % breakthrough was observed. To ensure a constant
residence time, all experiments were carried out at a flow rate of 0.33 mL/min.
8.2.9 General Rate Model
In the presented study, the general rate model (GRM) was employed to cover convection
and diffusion within a one-dimensional chromatography column of length L. Here, the
concentrations of all components i in the bulk phase c, in the pore phase cp, and adsorbed
to the stationary phase q depend on time t and axial position x. Eq. 8.1 describes the
mass transfer between the bulk phase and the pore phase depending on the flow velocity
u, axial dispersion Dax, bed porosity εb, film diffusion coefficient kfilm, particle radius
rp, and the concentrations c and cp. The chosen Danckwerts boundary conditions are
shown in Eqs. 8.2 and 8.3. In Eq. 8.4 the mass transfer between the pore phase and
the stationary phase is described to be dependent on the radial position in the pore r,
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pore diffusion coefficient Dpore, particle porosity εp, film diffusion coefficient kfilm, and
concentrations in the bulk phase c, pore phase cp, and stationary phase q.
∂ci(x, t)
∂t
= −u(t)∂ci(x, t)
∂x
+Dax
∂2c(x, t)
∂x2
(8.1)
−1− εb
εb
kfilm,i
3
rp
(ci(x, t)− cp,i(x, t))
∂ci(0, t)
∂x
=
u(t)
Dax
(ci(0, t)− cin,i(t)) (8.2)
∂ci(L, t)
∂x
= 0 (8.3)
∂cp,i(x, t)
∂t
=

1
r2
∂
∂r (r
2Dp,i
∂cp,i(x,t)
∂r )− 1−εpεp
∂qi(x,t)
∂t for r ∈ (0, rp),
kfilm,i
εpDp,i
(ci(x, t)− cp,i(x, t)) for r = rp,
0 for r = 0.
(8.4)
8.2.10 Adsorption Isotherm Model
Based on the stoichiometric displacement model (SDM) [328], Brooks and Cramer derived
the steric mass action (SMA) isotherm model by introducing the shielding factor σ, which
accounts for the sterically hindered binding sites on the adsorber surface due to protein
binding [155]. In Eq. 8.5, the kinetic formulation according to Nilsson and coworkers is
shown [156]. It describes the protein concentration in the stationary phase q as a function
of q itself, in the pore phase cp, and salt concentration cp,salt in the pore phase.
kkin,i
∂qi(x, t)
∂t
= keq,i(Λ−
k∑
j=1
(νi + σi)qj(x, t))
νicp,i(x, t) (8.5)
−cp,salt(x, t)νiqi(x, t), ∀i 6= salt
Eq. 8.6 describes the salt concentration in the stationary phase as a function of proteins
bound to the adsorber surface.
qsalt(x, t) = Λ−
k∑
j=1
νjqj(x, t) (8.6)
Instead of the adsorption rate coefficient kads and the desorption rate coefficient kdes, the
equilibrium coefficient keq=kads/kdes and the kinetic coefficient kkin = 1/kdes were used.
In this way, parameter estimation was simplified, since keq and kkin correlate mainly
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with the retention time and peak height, respectively [158]. ν is the characteristic charge,
also known as the number of binding sites directly involved in binding. Λ is the column-
specific ionic binding capacity equal to the number of potential binding sites. Here, the
SMA isotherm has been chosen to cover the overloading state in investigated break-
through experiments. For the description of low protein loading as usually applied in
the step gradient experiments for preparative separation, the SDM isotherm would be
sufficient. The kinetic formulation has been chosen out of several reasons. According to
Carta and Jungbauer, protein adsorption is often slower than small molecules because
of limitations in the binding kinetics. In addtion, a true adsorption equilibrium may not
be established since the protein may undergo molecular changes due to unfolding, aggre-
gation, or degradation before reaching equilibrium with the surface [188]. Furthermore,
Toyopearl GigaCap S-650M is a hydroxylated methacrylic polymer grafted adsorber pro-
viding high ligand density. As result, fast adsorption rates may be favored initially, but
with increasing protein binding, steric crowding and electrostatic repulsion may limit the
access to binding sites [329, 330].
8.2.11 Numerical Methods
The chromatograms resulting from LGE and breakthrough experiments were used to
estimate the parameters with the inverse method [331].The adaptive simulated anneal-
ing (ASA) [332] yielding the first guess was followed by the Levenberg-Marquardt (LM)
algorithm [333] for the fine adjustment of the parameter estimates. Subsequently, the
confidence intervals at 95 % level were calculated to verify estimation reliability. Dis-
cretization in space on a grid with equidistant nodes and θ-scheme discretization in time
were carried out by employing the finite element method and the fractional step [334],
respectively. Picard iteration was employed to approximate the solution of the non-linear
equation system [335].
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8.3 Results
8.3.1 PEGylation and Purification
In case of lysozyme, six lysine residues and the N-terminal amino group are available
as binding sites for the PEG aldehyde reaction [257]. The large number of binding
sites allows for the formation of different PEGamers. Preparative isolation of the mono-
PEGylated species was performed by a single cation-exchange step. In Fig. 8.1 the result-
ing chromatograms are shown for 1:12 diluted PEGylation batches with 2 kDa (a), 5 kDa
(b) and 10 kDa (c) PEG. After peak fractionation, HT-CGE analysis was performed
according to [281] to verify purity and PEGylation degree. As observed and discussed
by [129, 149, 258], a decrease in elution volume with increasing PEGylation degree was
observed for all PEG molecular weights. The red areas in Figs. 8.1a-c indicate the re-
spective pooling limits for the mono-PEGylated species based on purity requirements
greater than 97%. Purity was determined by HT-CGE analysis according to the ana-
lytical protocol established by [281]. The resulting fluorescence signals of HT-CGE for
the native lysozyme and the purified mono-PEGylated species with a concentration of
6.99·10−5 M showed a distinct peak broadening of PEGylated proteins compared to the
native species (Supplementary Fig. A.9). By using the calibration established by [281],
this peak broadening was taken into account in the calculation of purities.
Figure 8.1: Chromatograms of preparative CEX for 1:12 diluted PEGylation batches
(r=6.67, pH 7.2, 3.5 h) loaded with a 50 mL loop for 2 kDa PEG (a), 5 kDa
PEG (b) and 10 kDa PEG (c). The red area indicates the respective pooling
limits for the mono-PEGylated species.
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8.3.2 System Characteristics
Tracer experiments were carried out to determine the system parameters bed voidage,
particle voidage, and axial dispersion. The ionic capacity was determined by applying
acid-base titration. The results are shown in Tab. 8.2. The axial dispersion was found to
be similar to literature data [336].
Table 8.2: For the Toyoscreen column,the voidages and axial dispersion are calculated
from the retention volume and peak broadening of tracer injections. The ionic
capacity is determined by acid-base titration.
GigaCap S-650M
Particle diameter dp 75µm
Bed voidage εb 0.414
Particle voidage εp 0.779
Total voidage εt 0.871
Axial dispersion [mm2/s] Dax 6.691·10−2
Ionic capacity [M] Λ 1.389
8.3.3 Linear Gradient Elution and Breakthrough Experiments
Linear gradient experiments were carried out to generate information about proteins
in the linear region of the adsorption isotherm. The retention time of every protein
species over three different salt gradient lengths yielded information about the isotherm
parameters characteristic charge ν and equilibrium coefficient keq. The height, width,
and shape of the elution peaks provided partial information about the mass transfer
parameters film diffusion coefficient kfilm and pore diffusion coefficient Dpore. Thus, by
employing ASA and LM, ν and keq were estimated with high reliability, for kfilm and
Dpore an initial guess was delivered. As can be seen by comparing the dashed lines in
Figs. 8.2a, d, g, and j, lysozyme in its native form was the strongest binding species for all
investigated gradient lengths. Comparison of the elution peaks of native and PEGylated
species at a constant gradient length in Fig. 8.2 reveals that the elution times decreased
with increasing PEG chain length. Except for the different elution times of all protein
species, their peak heights and widths are highly similar at each salt gradient conditions.
A small shoulder peak behind the main peak can be seen in Fig. 8.2d-f, indicating a small
amount of a stronger binding protein species. Presumably this species is by unmodified
159
Chapter 8 Mechanistic Chromatography Modeling for PEGylated Lysozyme
Figure 8.2: Plots of UV signals over process run-time for bind-and-elute experiments.
Dashed lines display the UV signals measured at the column outlet and
the adjusted linear salt gradients. Solid lines represent the simulated chro-
matograms. The elution peaks of native lysozyme, lysozyme attached with
2 kDa PEG, 5 kDa PEG, and 10 kDa PEG by applying linear salt gradients
from 0.05M to 1.0M over 10CV, 15CV, and 20CV are shown in (a) - (c),
(d) - (f), (g) - (i), and (j) - (l). Similar peak heights and widths, but different
retention times can be seen for different protein species. Here, the Toyoscreen
column was employed.160
8.3 Results
lysozyme, since for the 2 kDa PEGylation no peak baseline sepearation between the
different PEGamer species could be achieved in in preparative chromatography (compare
Fig. 8.1a).
Additionally, breakthrough experiments were carried out under strong binding condition.
The 280 nm signals were highly non-linear above 2000 mAU and reached the detector sat-
uration at approximately 2500 mAU. As shown by the dashed lines in Fig. 8.3, lysozymes
with 10 kDa, 5 kDa and 2 kDa PEG attached, and the native lysozyme exhibited their
breakthrough in successive order. Based on this information, the shielding parameter σ
was estimated and the correlation between kkin and kfilm that both affect the peak height
in the linear part of the adsorption isotherm was dissolved.
Figure 8.3: Plots of normalized protein concentration over process run-time for break-
through experiments. Dashed lines display the normalized protein concentra-
tions calculated from UV Fig. 8.2 as solid lines. In all cases, a good agree-
ment between simulations and signals measured at the column outlet and the
constant salt concentration at 0.05 M. Solid lines represent the normalized
protein concentrations calculated from the simulated chromatograms. The
native lysozyme and lysozyme attached with 2 kDa PEG, 5 kDa PEG, and
10 kDa PEG are shown in purple, yellow, green, and red, respectively. Here,
the Toyoscreen column was employed.
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The final parameter estimates and the related confidence intervals at 95 % level are
summarized in Tab. 8.3. The simulated LGE for the four protein species are displayed in
measurements was found for the retention time, peak width, and peak shape. Overall, the
conformity was highest for the native lysozyme. The peak heights of PEGylated species
were slightly overestimated. The simulated breakthrough curves for all protein species
are displayed in Fig. 8.3. Here, the model accurately accounted for the overall slopes
and reflected the process relevant times at 10 % and 50 % breakthrough. The relative
offsets for the process times at 10 % breakthrough were 1.83 % for lysozyme in the native
condition, 3.53 % for lysozyme attached with 2 kDa PEG, 1.93 % for lysozyme attached
with 5 kDa, and 4.17 % for lysozyme attached with 10 kDa.
Table 8.3: Parameters of the mass transfer model and kinetic isotherm formulation esti-
mated from bind-and-elute experiments with linear salt gradient and break-
through curves using the inverse method are shown for native and mono-
PEGylated lysozyme species. Confidence intervals at 95 % level reflect the
reliability of the parameter estimates.
Parameter Native 2 kDa
PEGylated
5 kDa
PEGylated
10 kDa
PEGylated
kfilm [mm/s] 9.95·10−2
± 5.20·10−2
8.92·10−2
± 5.49·10−2
6.62·10−2
± 3.12·10−2
4.07·10−2
± 2.53·10−2
Dpore [mm
2/s] 2.85·10−4
± 2.38·10−5
1.33·10−4
± 7.56·10−6
8.42·10−5
± 2.08·10−6
5.75·10−5
± 2.28·10−6
keq [-] 4.62 ·10−2
± 9.16·10−5
5.94 ·10−3
± 2.79·10−5
1.16·10−3
± 5.13·10−6
1.92·10−5
± 1.48·10−6
kkin [sM
−ν ] 3.94 ·10−2
± 7.56·10−4
4.58 ·10−3
± 2.10·10−4
2.31·10−4
± 6.74·10−5
6.34·10−6
± 2.82·10−5
ν [-] 4.21
± 1.82 ·10−3
4.21
± 2.65·10−3
4.20
± 1.10·10−3
4.22
± 1.56·10−3
σ [-] 5.61
± 1.27·10−2
6.81
± 1.35·10−2
9.79
± 1.67·10−2
25.90
± 1.08·10−1
8.3.4 Mass Transfer and Kinetic Phenomena
The GRM assumes that the adsorbent particles have a spherical shape and a uniform
diameter. The shape of PEGylated proteins is influenced by the surrounding PEG layer
which is higlhly dynamic. Due to the high hydration of PEG, PEGylated proteins have a
significantly greater hydrodynamic radius than unmodified proteins with a comparable
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Figure 8.4: (a) - (f) the show film diffusion coefficient, pore diffusion coefficient, adsorp-
tion coefficient, desorption coefficient, characteristic charge, and shielding
factor versus the hydrodynamic radius hR,PEGprot of PEGamers. hR,PEGprot
takes into account the non-linear relationship between conjugate size and to-
tal molecular weight of attached PEG [130, 139]. Blue dots from left to right
represent the native lysozyme and lysozyme attached with 2 kDa PEG, 5 kDa
PEG, and 10 kDa PEG.
molecular weight. Fee and Van Alstine introduced a nonlinear relationship between the
degree of PEGylation in terms of total molecular weight of PEG attached and the hydro-
dynamic radius of the PEGylated protein [130, 139]. This non-linearity is the reason why
the behavior of conjugated proteins in IEX must necessarily be described as a function
of the hydrodynamic radius and not in terms of the total molecular weight of attached
polymer. According to the correlation introduced by Fee and Van Alstine [130], the hydro-
dynamic radii hR,PEGprot were calculated to be 2.00 nm, 2.37 nm, 3.08 nm, and 3.84 nm
for the four lysozyme species with increasing PEG MW.
For lysozyme, the mass transfer coefficient keff calculated according to 1/keff = 1/kpore+
1/kfilm with the internal mass transfer resistance kpore = 10Dporeεp/dp [151] was found to
be consistent with literature data [336]. An approximately linear decrease of the film diffu-
sion coefficient kfilm with increasing hR,PEGprot was determined as displayed in Fig. 8.4 a.
A comparable dependency was reported by Mej´ıa-Manzano et al. [337] for affinity chro-
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matography. As shown in Fig. 8.4 b, the pore diffusion coefficient Dpore decreased recipro-
cally with increasing hR,PEGprot according to the Stokes-Einstein equation qualitatively.
The adsorption and desorption rate coefficients kads = keq/kkin and kdes = 1/kkin were
calculated and are displayed in Figs. 8.4 c and d. With increasing PEG MW, both kads and
kdes showed an exponential increase. A similar trend has been observed by Mej´ıa-Manzano
et al. [337] for affinity chromatography. The increase of kdes exceeded the increase of kads
by more than two orders of magnitude. For native and 5 kDa mono-PEGylated lysozyme,
keq was found to be of the same magnitude as reported in the literature [150].
8.3.5 Characteristic Charge and Shielding
The characteristic charges ν of PEGylated lysozyme (4.20-4.22) were found to be equal to
the value determined for native lysozyme (4.21) as shown in Fig. 8.4 e. ν was unaffected
by PEGylation degree and PEG chain length. This finding was consistent with data
delivered by Abe and coworker [150]. A small shielding factor σ of 5.61 was found for the
native lysozyme. With increasing PEG chain length, σ increased from 6.81 for 2 kDa to
9.79 for 5 kDa, and up to 25.90 for 10 kDa PEG as displayed in Fig. 8.4 f. The dependency
of σ on the hydrodynamic radius was highly non-linear. Based on the definition of qmax
being Λ/(σ + ν), the maximal binding capacity qmax for the four protein species was
calculated to be 1.41·10−1 M for native species, 1.26·10−1 M for 2 kDa PEGylated species,
9.93·10−2 M for 5 kDa PEGylated species and 4.61·10−2 M for 10 kDa PEGylated species.
qmax was found to be reduced by 10.6 % when attached with 2 kDa PEG by 29.6 % when
attached with 5 kDa PEG, and by 67.3 % when attached with 10 kDa PEG compared to
the native lysozyme species.
8.4 Discussion
PEGylation is commonly used in biopharmaceutical industry to improve protein sta-
bilities and pharmacokinetics of protein drugs. However, the currently used reaction
mechanisms and conditions usually result in a heterogeneous product mixture of un-
reacted protein and conjugates with varying number and modification site of attached
polymers [130, 322]. For this reason, purification processes of PEGylated proteins are im-
perative. Chromatographic processes based on electrostatic interactions e.g. ion-exchange
chromatography, are among the most effective purification processes for this application
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[324]. So far, the development of ion-exchange steps for the purification of the individual
PEGamers has been driven mainly by expert-based or experimental approaches (high-
throughput process development and statistical design of experiments). These approaches
are time-consuming and cost-intensive due to the wide variety of proteins and polymers
(linear vs. branched, molecular weight etc.). Mechanistic modeling and simulations can
help to reduce the number of experiments during process optimization by in silico pre-
dictions [143]. From the perspective of process development, the parameters estimated
by mechanistic modeling can be used for process up scaling, process optimization, and
process control, meeting the demands of the Quality by Design approach (QbD) proposed
by the US food and drug administration (FDA) [338].
In our work, the SMA isotherm in kinetic formulation coupled with the GRM produced
a comprehensive description of the adsorption and desorption behavior on the adsorber
surface, steric hindrance, and the mass transfer for native lysozyme and its PEGylated
species. The model parameters kfilm, Dpore, keq, kkin, ν, and σ were determined and kads,
kdes, hR,PEGprot, and qmax were calculated to improve the mechanistic understanding
of PEGylated proteins in CEX. It should be mentioned, that the PEGylation reaction
usually delivers various PEGamer isoforms. In the presented case, the isoforms behaved
highly similar and could not be separated with the used CEX setup. Hence all isoforms
of each lysozyme species had to be modeled as lumped components, resulting in slight
overestimation of the peak heights.
As reported by many researchers, PEGylated proteins elute earlier than their native
analogs [149, 150, 324]. Based on the observation of the elution order of different PE-
Gylated species beeing the same in both cation-exchange and anion-exchange chro-
matography, Seely and Richey suggested the ‘charge-shielding effect’ to explain this
phenomenon [149]. Later, Abe and coworkers applied the equilibrium stoichiometric dis-
placement isotherm model (SDM) to describe the retention time of PEGylated proteins in
linear gradient experiments and determined similar numbers of binding sites for lysozyme
and BSA attached with PEG of different lengths. Furthermore, they reported the decrease
of a lumped parameter consisting of the equilibrium coefficient, the binding site, and the
ionic binding capacity with increasing PEG chain length [150]. In this way, the ‘charge-
shielding effect’ hypothesis was verified and the equilibrium coefficient was identified to
be responsible for the weaker binding of PEGylated proteins [150].
kfilm showed a linear dependency on hR,PEGprot as expected according to the correlation
suggested by Jungbauer and Carta [188]. Its decrease with increasing PEG chain length
was to be reflected by broader and lower elution peaks. However, the LGE under same
operating conditions showed similar peak heights and widths for all PEGylated and na-
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tive species. Considering the fact that there is a strongly exponential correlation of kdes
with hR,PEGprot, a diffusion-desorption-compensation effect is suggested to be responsible
for the uniformity in peak heights and width. The faster desorption of proteins attached
with longer PEG chain may be neutralized by the slower film diffusion. This hypothesis
is highly consistent with the widely accepted view of the ‘charge-shielding effect’, since
weaker charged proteins increasingly tend to undergo desorption. Dpore showed a recip-
rocal correlation with hR,PEGprot, as had been expected according to the Stokes-Einstein
equation [339], which is reflected by slight tailing of elution peaks in LGE.Dpore was found
to exceed the molecular diffusion coefficient for native lysozyme. As intensively studies
in literature, there are two opinions to explain this effect. Carta et al. and Rodrigues
et al. [340–342] introduced the convection-enhanced effective intra-particle diffusivity.
Many more experimental examples of intra-particle convection in protein chromatogra-
phy could be found in the literature [343–347]. However, convective mass transfer into
the bead interior was observed for large pores (> 5000 A˚)[347, 348]. For small pores up
to 700 A˚, Nash et al. assumed diffusional mass transport only. For the TOYOPEARL®
GigaCap S-650M resin having an average pore size of 1000 A˚, the observed molecular
diffusion coefficient cannot be explained completely by convective mass transport in the
pores. An additional effect observed by Dziennik et al. [349] for porous resins with high
charge density applies to TOYOPEARL® GigaCap S-650M. They found indications that
non-diffusive mechanisms of electrostatic origin could enhance protein uptake rates in ion
exchange particles, resulting in enhanced effective pore diffusivities.
The shielding factor σ showed an exponential increase with increasing PEG chain length.
In comparison to native lysozyme, approximately 12 %, 43 %, and 207 % more free binding
sites are sterically hindered by the species with 2 kDa, 5 kDa, and 10 kDa PEG attached,
respectively. In contrast to this, ν was found to be independent of PEGylation and PEG
chain length, indicating the same binding orientation for all species. Thus, the steric
hindrance of free binding sites was identified to be the main contributor to the observed
exponential decrease of molar binding capacity qmax upon PEGylation. It is indicated
that the longer PEG chains of an adsorbed protein make many more free binding sites
inaccessible than the shorter ones or equally sized unmodified proteins. Fee and Van
Alstine proposed a correlation for the average shape of the PEG-layers around a protein
over timescale [130, 322]. These layers are expected to have increasing degree of dynamics
with increasing PEG molecular weight [350]. This concept could also explain the non-
linearity in kads, kdes, and σ shown in Fig. 8.4c, d, f.
Especially in the overloading state under strong binding condition, a high density of
proteins bound could result in formation of multiple PEG chain layers covering adjacent
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Figure 8.5: Molecular picture of the adsorption of lysozymes on an adsorber surface.
Increasing PEG chain length results in the formation of multiple PEG chain
layers hindering the binding of further lysozymes. The reduction of accessible
binding sites explains the observed decrease in binding capacity upon protein
PEGylation. (Molecular graphic of lysozyme (PDB: 1LYZ) was created with
YASARA (www.yasara.org)).
free binding sites. The multiple PEG chain layers would not shield the electrostatic in-
teractions, but keep the proteins in the mobile phase distant from the adsorber surface,
so that the electrostatic attraction would become weak and binding impossible. This hy-
pothesis is schematically represented by Fig. 8.5. Along the increasing binding density,
several transitional states are supposed to exist. First, in the linear part of the adsorp-
tion isotherm, the proteins could distribute uniformly on the adsorber surface; secondly,
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unfavorable binding sites between the proteins covered by thin PEG chain layers could
be occupied, though the electrostatic attraction could already be reduced; finally, the
multiple PEG chain layers could become dominant, so that the electrostatic attraction
could disappear and binding could be suppressed. This concept is consistent with the
observation made by Blaschke and coworkers [351]. They found that adsorption was less
enthalpy-driven at higher loading states for proteins attached with longer PEG chains.
Of course, the PEG-layers around PEGylated proteins are not static, rather of dynamic
nature. Thus, the mechanistic chromatography model describes the average behavior of
lysozyme species in CEX. As suggested by Fee et al., the dynamicism of PEG-layers tend
to increase with increasing PEG chain length. This concept could be an alternative ex-
planation for the nontrivial behavior of PEGylated lysozymes observed in the presented
work.
Using mechanistic chromatography modeling and considering insights provided by former
pioneer work, the hydrodynamics and thermodynamics of PEGylated lysozymes in CEX
were investigated. The diffusion-desorption-compensation effect was introduced to explain
the anomaly of peak heights and widths remaining constant in spite of an increasing
hydrodynamic radius. Additionally, it reflects the exponential dependency of the shielding
factor on the MW of PEGylated proteins and suggests that multiple PEG chain layers
formed in the overloading state are responsible for this non-trivial phenomenon. Thus, the
model view of PEGylated proteins’ behavior in CEX was supplemented by the overloading
state.
This study clearly demonstrates that mechanistic chromatography modeling can be ap-
plied to describe PEGylated proteins with high accuracy and reliability. Thus it has
great potential for the optimization, prediction, and scale-up of purification processes
for PEGylated proteins. A future challenge is to show whether the separation of posi-
tional isoforms can be predicted by this kind of simulation. In this respect, a combination
of mechanistic chromatography modelling combined with molecular modeling could be
profitable.
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Chapter 9 High-Throughput Evaluation of Hydrogels
Abstract
Synthetic hydrogels provide an effective and convenient way to administer high molecu-
lar weight protein drugs. However, the release kinetics of these proteins from hydrogels
depend on the highly complex physical and chemical properties of the hydrogel, the sur-
rounding solution conditions and the protein itself. The objective of this work was the
development of an rapid and cost-effective tool for the investigation of the influences
of these variables on occurring interactions. The fulfillment and realization of this aim
was successfully achieved by a combination of hydrogel 3D printing and high-throughput
screening techniques. In a case study, the lysozyme uptake and release profiles of hy-
drogel structures with different compositions (polyethylene glycol-diacrylate and acrylic
acid) under the influence of varying surrounding buffer conditions was investigated. In
comparison with literature data, it was shown that the approach presented here leads
to very similar data for the used materials and thus constitutes a helpful tool for the
development of hydrogel-based drug delivery systems.
Keywords: 3D printing, photopolymerization, controlled drug delivery, protein uptake
and release, high-throughput screening
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9.1 Introduction
Advances in medical technology and the pharmaceutical sector have created a better un-
derstanding of the root cause of a variety of diseases in recent years. Biopharmaceuticals
based on recombinant proteins, such as monoclonal antibodies or therapeutic enzymes,
promise highly effective therapies with minimal side effects due to their high selectiv-
ity for certain cells or metabolic pathways in the human body. Moreover, recombinant
proteins can treat diseases resulting from insufficient or deficient production of endoge-
nous proteins [170]. The increasing use of pharmaceutical proteins has created a need
for new methods of controlled administration of these compounds [167]. In this context,
polymeric carrier systems arouse the interest of academia and industry for the controlled
spatial and temporal release of biotherapeutics [162, 163]. For use in the clinical field,
these polymers must meet the requirements of biocompatibility and immunological ac-
ceptance while integrating elements of responsive behavior to give a well-defined reaction
to external conditions [163].
Proteins are found in human tissues mainly in aqueous environments. In order to mimic
this natural environment and thus to preserve the native protein conformation, hy-
drophilic polymers are suitable to administer pharmaceutical proteins. These polymers
are capable of absorbing large amounts of water or biological fluids and can be interlinked
to three-dimensional networks. Therefore those hydrophilic networks are often referred
to as hydrogels. The presence of chemical and/or physical crosslinks renders hydrogels
insoluble in water after network formation. [161]
Hydrogels are already used as a matrix for the oral administration of small molecule
drugs [352]. Also, hydrogel-based formulations present a promising approach for the oral
administration of protein drugs since the molecule is protected from harsh conditions
and degradation by endogenous enzymes in the gastrointestinal tract [167]. Thus, for
example, considerable efforts for the development and clinical testing of oral delivery
forms for insulin have been made [353–355]. Further, hydrogels may be applied directly to
a wound or implanted near the site of action. This approach results in a depot formulation
from which the drug slowly elutes and thus maintains a high local concentration in the
surrounding tissues over an extended period of time [165].
The network structure and the thermodynamic nature of all compounds involved de-
termine the protein release profile of these networks [321]. The molecular weight and
content of the polymer as well as the addition of crosslinking agents determine the den-
sity of crosslinks in the gel matrix and thus the mesh size [167]. The mesh size of the
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swollen network affects the physical properties of the gel, such as mechanical strength,
degradation and diffusion of captured molecules [170]. By the addition of ionizable or
hydrophobic hydrogel monomers, additional interactions of the proteins with the poly-
mer network can be promoted [167]. On the protein side, mainly the molecular weight,
the composition of the amino acids and thus the distribution of charged and hydropho-
bic residues on the surface of the protein as well as the three-dimensional structure of
the protein affect the release properties from the hydrogel [167]. The interaction-based
uptake and release of biomolecules is determined by the ratio of the interaction between
the hydrogel and the protein as well as the protein and the surrounding solution [163].
There are many theoretical approaches to describe network structure, mesh size, swelling
behavior and mass transport of biomolecules in hydrogels [161]. The high number of vari-
ables, however, makes a comprehensive mechanistic understanding of protein-hydrogel
interaction difficult. Furthermore, the theoretical predictability of the uptake and release
profiles is aggravated by the multiplicity of combinable proteins and hydrogel materials
[356]. A sound experimental data base is essential for theoretical knowledge building of
the various interactions occurring between the hydrogels, proteins and the liquid envi-
ronment. In this context, high-throughput screenings (HTS) may help to understand the
complexity affecting the drug delivery result [357]. HTS offer an accurate, rapid, and
cost-saving method to study hydrogel-protein interactions and the influence of surround-
ing solution conditions while covering a high number of potential process parameters at
the same time. The standard HTS-format in biotechnology are multi-well plates, which
are handled by highly automated pipetting stations [358–361]. For hydrogels, however,
a fast and reproducible method to crosslink precursor solutions into a HTS-compatible
shape is still missing. 3D printing offers the herefore needed outstanding possibility to
polymerize precursor solutions to any shape [362]. In case of 3D bioprinting, the printing
materials, or bioinks, are composed of biocompatible matrix materials such as hydrogels
or their precursors, additives and biological components.
This study aims to implement three dimensional hydrogel structures into multi-well plates
for the investigation of hydrogel-protein interactions on liquid-handling stations. There-
fore, hollow hydrogel cylinders fitting into standard 48-well plates were produced using
3D bioprinting. This shape provides a large surface to volume ratio for the observation
of transport phenomena while ensuring a non-destructive operation of the automated
pipetting tips. Lysozyme from chicken egg white was used as a model protein to study
the drug uptake and release behavior from polyethylene glycol-diacrylate (PEG-DA)-
based hydrogels. PEG-DA was photochemically crosslinked using a DLP (digital light
processing)-based stereolithography system. Two approaches for the incorporation of pro-
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teins in hydrogels are compared. In the first approach, the hydrogel was printed without
protein and subsequently loaded with protein (PostFabLoading). This approach increases
the probability of preserving the biological activity of the protein, reduces, however, the
maximum utilization of the protein due to partitioning limitations [169]. In order to max-
imize the protein uptake different polymer contents and pH values as well as the addition
of the comonomer acrylic acid (AA) were investigated. For the second approach, the pro-
tein was part of the bioink and consequently present during the polymerization process
(PrintLoading). This apporach may result in activity loss due to potential reactions with
the hydrogel polymer, resulting radicals or the energy input necessary for crosslinking.
After hydrogel formation and protein loading, the release was examined under different
solution conditions (pH and ionic strength). In order to ensure protein integrity after the
release, an activity assay was performed.
9.2 Materials and Methods
All solutions were prepared with ultra-pure water (0.55 µS/cm) obtained from a PURE-
LAB Ultra water purification system (ELGA Labwater, Germany). The 25 mM multicom-
ponent buffer with a linear buffering range from pH 3 to pH 9 consisted of the buffer sub-
stances AMPSO (2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)amino]propane-1-sulfonic
acid) (Sigma-Aldrich), TAPSO (3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]-
2-hydroxypropane-1-sulfonic acid)(Sigma-Aldrich), MES 1-hydrate (2-morpholinoethane-
sulfonic acid) (AppliChem), sodium acetate trihydrate (Sigma-Aldrich, USA) and formic
acid (Merck Millipore). The buffer recipe is summarized in Table 9.1. Potassium chlo-
Table 9.1: Composition of 25 mM multicomponent buffer with a linear buffering range
from pH 3 to pH 9 calculated according to [363]. The used buffer substances
are displayed with the corresponding pKa value and molarity.
Buffer component pKa value [-] molarity [mM]
AMPSO 9.14 42.44
TAPSO 7.64 33.90
MES 1-hydrate 6.10 38.03
Sodium acetate trihydrate 4.76 27.56
Formic acid 3.75 37.43
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ride (KCl) and di-potassium hydrogen phosphate (K2HPO4) for the size exclusion chro-
matography running buffer were purchased from VWR. Dulbecco’s Phosphate buffered
saline (PBS) (ThermoFisher Scientific) and sodium chloride (Merck Millipore) were used
for protein release studies. pH adjustment of all buffers within a range of ± 0.05 units
was performed using a five-point calibrated pH-meter HI-3220 (Hanna Instruments, USA)
with a SenTix® 62 pH electrode (Xylem Inc., USA). For pH correction hydrochloric acid
and sodium hydroxide were obtained from Merck (Germany). All buffers were filtered
using a 0.2 µm cellulose-acetate filter (Sartorius, Germany) and degassed for chromato-
graphic purposes.
Polyethylene glycol-diacrylate (PEG-DA, average MW 575), 2,2-Dimethoxy-2-phenylace-
tophenone (DMPA) and acrylic acid for bioink preparation were obtained from Sigma-
Aldrich. Protein solutions were prepared using chicken egg-white lysozyme (subsequently
referred to as lysozyme) from Hampton Research.
9.2.1 3D Printing of PEG-DA-based Hydrogels
9.2.1.1 Preparation of Bioinks
The used mass concentrations of all components are summarized in Table 9.2 for all
studied bioinks. To prevent premature polymerization, all ink components were weighed
in and stored in lightproof centrifuge tubes (50 ml Tube Cellstar®, Greiner Bio-One).
Table 9.2: Composition of bioinks. The percentage of a component %(w/w) refers to the
total weight of all components. The lysozyme stock solution was prepared by
dissolving 6,45 %(w/w) in ultrapure water.
PEG-DA
(MW 575)
ultra-pure
water
acrylic
acid
DMPA lysozyme stock
solution
PEG-DA50 50 49 - 1 -
PEG-DA75 75 24 - 1 -
PEG-DA90 90 9 - 1 -
PEG-DA75AA7.5 75 16.5 7.5 1 -
PEG-DA75AA15 75 9 15 1 -
PEG-
DA75Lys1.55
75 - - 1 9.6
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The ink was mixed on an overhead shaker for at least 24 hours to ensure complete
dissolution of the photoinitiator.
9.2.1.2 3D Fabrication of Hydrogels
A commercially available B9Creator DLP 3D printer (version 1.2, B9Creations) equipped
with an modified projector (D912HD, vivitek) as light source was used to polymerize the
bioinks. The CAD model of the hollow cylinder was created in Solid Edge ST7 (Siemens
PLM Software) and exported as a stereolithography file (.stl) into the 3D printer software
(B9Creator). The hollow cylinders have an outer diameter of 9.45 mm, a wall thickness
of 0.82 mm and a height of 7 mm. This results in a total volume of the hollow cylinder
of 155.6 mm3 before being swollen in water. The model was sliced to layers of 200 µm
thickness and the configuration of the printer was set to an x, y resolution of 30 µm.
Before printing, calibration of the build table and automatic focusing of the projector
was performed. Depending on the ink composition printer settings were adjusted in order
to achieve complete polymerization and 3D objects free from defects. The applied settings
for the different bioinks are summarized in Table 9.3. Except the changes stated here, the
bioinks were printed with the default settings for the commercial ink B9R-1-Red from
B9Creations. Since a complete filling of the tank with bioink was too material-consuming,
the ink was gradually applied manually. The necessary time for ink application was
achieved by setting the post-release delay to 10 seconds. Four cylinders were produced
simultaneously in one printing run. The irradiation by the projector led to a clouding
Table 9.3: Adapted printing parameters for the various ink compositions (see Table 2).
Exposure
settings
base
Exposure
settings
over
Attach lay-
ers
Attach
base
Attach
Over
PEG-DA50 25 1 1 20 1
PEG-DA75 20 1 1 15 1
PEG-DA90 20 1 1 15 1
PEG-DA75AA7.5 20 1 1 30 1
PEG-DA75AA15 28 1 1 50 1
PEG-DA75Lys1.55 11 1 2 12 1
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of the silicone layer which is built-in to prevent adhesion of the printed structure to the
resin vat. This effect was amplified by increasing the content of AA in the bioinks. There-
fore, the silicone layer was exchanged at regular intervals according to the specification
of B9Creations using Elastosil® RT 601 (Wacker Chemie).
9.2.1.3 Determination of Protein Uptake and Release by 3D Printed Hydrogel
Cylinders
Loading of Hydrogels with Protein
For PrintLoading, the protein is present during the printing process. The fabrication
of the protein containing hydrogel cylinders is already described in section 9.2.1.2. The
amount of lysozyme that was entrapped within the hydrogel was determined by assuming
the same weight percent of lysozyme in the precursor solution to be also present in the
polymerized hydrogel.
To perform the PostFabLoading of the printed hydrogel cylinders, a lysozyme solution of
40 mg/ml was prepared using the 25 mM multicomponent buffer of respective pH. Pro-
tein concentration measurements were conducted using a NanoDrop2000c UV-Vis spec-
trophotometer (Thermo Fisher Scientific) and an extinction coefficient of 1%280 nm,lysozyme
= 22.00 [254]. The 3D-printed cylinders were stored in ultra-pure water for at least 24 h
in order to deplete unpolymerized bioink components. For the uptake experiments, the
cylinders were drained, patted dry and placed in the wells of a 48-well plate (48 Well Cell
Culter Cluster, Costar®). Using a fully automated pipetting station Freedom EVO® 200
(Tecan) the cylinders were equilibrated for 30 min in 400 µl multicomponent buffer of
the respective pH. After equilibration, 300 µl of the buffer were withdrawn and replaced
by the 40 mg/ml protein solution yielding a concentration of 30 mg/ml for the uptake
experiments. During incubation, the 48-well plates were covered to avoid evaporation
and shaken at 200 rpm on a Te-Shake orbital mixer (Tecan). After 0, 2, 4, 6, 8, 10 and
12 hours, the supernatant was removed from a triplet of cylinders of equal composi-
tion and examined by analytical size exclusion chromatography (SEC) for the remaining
protein concentration. For all experiments carried out, only one measurement value is
generated from the supernatant of each hydrogel cylinder of a 48-well plate. Thus, the
multiple determination of a data point as well as the different time steps within a protein
uptake series result from different cylinders.
The chromatography runs were performed using a Dionex UltiMate® 3000 liquid chro-
matography system (ThermoFisher Scientific) equipped with a HPG-3400RS pump, a
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WPS-3000TFCanalytical autosampler, a TCC3000RS column thermostat and a DAD-
3000RS detector. As stationary phase, an Acquity UPLC® BEH200 SEC 1.7 µm (4.6 x
30mm) column (Waters) was used. Analysis was performed at a flow rate of 0.2 ml/min
using a 200 mM K2HPO4 buffer at pH 7 containing 250 mM KCl. The injection volume
was set to 20 µl using double loop overfill.
Protein Release from Hydrogels
Protein release was studied using the 25 mM multicomponent buffer at three different
pH values (3, 7 and 9) and under the influence of three different sodium chloride concen-
trations (0 M, 0.15 M and 0.5 M). Furthermore, the protein release under physiological
conditions was tested using phosphate buffered saline (PBS). To study the protein release
from the loaded hydrogels, cylinders were incubated for 12 h with protein solution for
PostFabLoading as described in section 9.2.1.3. After incubation, the protein solution
was withdrawn and the hydrogels were washed with 1 ml ultra-pure water by single-
time uptake and dispensing with a pipette. The PrintLoaded cylinders were rinsed with
ultra-pure water for 10 s after the printing process.
For the protein release studies, 500 µl of the release buffer to be screened was added to
each cylinder. During incubation, the 48-well plates was shaken at 200 rpm. Kinetics were
recorded using a NanoDrop2000c UV-Vis spectrophotometer and an extinction coefficient
of 1%280 nm,lysozyme = 22.00. For each time point, 3 µl of sample were withdrawn and
analyzed. The multiple determination of a data point within one protein release series
results from three independent cylinders.
In order to evaluate biological integrity after the fabrication process, the released protein
was analyzed for residual activity using Micrococcus lysodeikticus-based activity assay
according to [293]. This method was slight modified by measuring the activities only
at a protein concentration of 0.3 mg/ml. The slope of the absorption at 450 nm over
time was used as activity and related to the activity of reference sample containing
native lysozyme at pH 7. Moreover, samples were analyzed by analytical SEC in order
to monitor the formation of aggregates (c.f. section 9.2.1.3).
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9.3 Results and Discussion
PEG-DA-based hydrogels were fabricated by photopolymerization with a DLP-based
stereolithography system using DMPA as a photoinitiator. DMPA photofragments to
highly reactive methyl radicals, which initiate photopolymerization by attacking the
carbon-carbon double (C=C) bonds present in the acrylate groups of PEG-DA and acrylic
acid [167, 364]. This radical photopolymerization leads to linear chain growth as well as
to branched and crosslinked structures forming a three-dimensional network [364]. The
two components PEG-DA and acrylic acid absorb water in an aqueous environment and
thus create an ideal environment to incorporate biomolecules in this three-dimensional
network. In this study, two methods to introduce the biomolecule into the hydrogels are
investigated. Firstly, the hydrogel is polymerized and subsequently incubated in concen-
trated drug solutions (post-fabrication equilibrium partitioning = PostFabLoading) [169]
and secondly, the protein is present in the bioink during the polymerization (PrintLoad-
ing) [167]. The hydrogels loaded in both ways are tested for their release behavior and
the residual activity of the incorporated protein.
9.3.1 3D Printing of PEG-DA-based Hydrogels
The presented setup with the B9Creator and the modified projector was well suited
to produce hydrogel structures from all prepared ink compositions. With the UV filter
removed from the projector the emission spectra and the irradiance was adequate to
polymerize hydrogel layers of 200 µm and hollow cylinders could be build up. To ensure
a proper print result, the applied printing parameters (c.f. Table 9.3) had to be adapted
for the varying bioink formulations (c.f. Table 9.2). The aim of the adaptions was the
production of hydrogel structures with a minimum of reject and waste. Furthermore,
the duration of light exposure was optimized in regard to print result, total print time,
and in the specific case preventing inadequate irradiation of the protein. Adjusting the
suitable print settings as well as the application of the ink were the most crucial steps
for a successful printing procedure. Insufficient exposure settings for the attaching layer
concluded in poor attachment and the occurring of polymerized parts in the applied ink
(see Fig. 9.1A). Also incomplete structures were developing when the freshly printed layer
had no contact to the already consisting layer. In the later printing process, air bubbles
or the lack of applied ink could disrupt the resulting hydrogel structure as shown in
Fig. 9.1B. It is in the nature of this printing technique, that unintended absence of
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polymerizeable material during the printing process inevitably causes malformations in
the resulting structure. Nonetheless, commensurate ink application in combination with
the adapted printing parameters (c.f. Table 9.3) resulted in a high repeatability in the
production of flawless hydrogel cylinders for the further use in this study (see Fig. 9.1C).
An increasing amount of PEG-DA in the bioink resulted in shorter exposure times needed
for good printing outcomes. This need for lower energy input at the given layer height
can be explained by the concentration dependent amount of possible crosslinking sites
[365]. To generate flawless hydrogel structures from bioinks containing 75 % PEG-DA
and additional acrylic acid an increase in the exposure time was required compared to
bioinks without acrylic acid. The reaction rate of this copolymerization seems to be
slowed down with increasing percentage of acrylic acid. Different reactivities of PEG-DA
and acrylic acid can be used as an explanation for this shift. The applied exposure times
could be reduced for the bioink PEG-DA75Lys1.55. This was influenced by the noticeable
turbidity (see Fig. 9.1), which was already visible before the polymerization and probably
occurred due to precipitated lysozyme in this ink. The turbidity increased the absorbance
of luminous energy which resulted in a faster polymerization process.
Figure 9.1: Photographs of printed hydrogel structures from PEG-DA75 (A-C) and PEG-
DA75Lys1.55 (D). Underexposure led to insufficient adherence of the hydrogel
at the build platform (A). Unbalanced ink application and air bubbles resulted
in partially defective structures (B) . Flawless hollow hydrogel cylinders as
they have been used in the presented study (C). PrintLoading cylinders with
noticeable turbidity due to incorporated protein (D).
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9.3.2 Protein Uptake During Post-Fabrication Equilibrium Partitioning
Post-fabrication equilibrium partitioning (PostFabLoading) of lysozyme to PEG-DA-
based hydrogels was studied using the bioinks PEG-DA50, PEG-DA75, PEG-DA90, PEG-
DA75AA7.5 and PEG-DA75AA15. The protein uptake was determined by measuring the
lysozyme concentration in the supernatant of incubated hydrogel cylinders at regular
time intervals by analytical SEC. The amount of loaded protein was calculated by the
difference between the amount of protein in the protein stock solution and in the super-
natant. The relative protein uptake was defined by Eq. 9.1, where mloaded and mstock are
the mass of the loaded protein and the mass of the total protein in the stock solution,
respectively.
Relative protein uptake =
mloaded
mstock
· 100% (9.1)
In Fig. 9.2, the relative protein uptake is displayed for different bioink compositions and
loading conditions. The error bars indicate the standard deviation of a triple determi-
nation from the supernatant of three independent hydrogel cylinders. In Fig. 9.2A, the
influence of PEG-DA mass fraction in the bioink on the relative protein uptake at pH 7
is shown. Over a time of 12 hours, the hydrogels with an initial PEG-DA mass fraction
of 50 % exhibit the highest uptake of up to 40 % of the initial applied protein mass. The
course of the protein uptake curve for the hydrogels with 75 % and 90 % PEG-DA are
very similar and achieve a maximum of approximately 20 % in the studied 12 h. These
observations are consistent with the work of Zhang and coworkers [366] who describe that
a higher PEG-DA concentration leads to a more compact hydrogel structure with higher
crosslinking density. A higher crosslinking density restricts the swelling of the hydrogel
and results in a reduced meshsize which in turn hinders protein diffusion into and out
of the hydrogel. For all three curves, the increase in protein uptake is highest during the
first 6 h and almost reaches a plateau value after 10 h. The plateau value reflects the
maximal protein absorption capacity of the hydrogel, which is denoted as protein up-
take at saturation [367]. Zaho et al. [367] have observed similar results for the uptake of
lysozyme by glycerol diglycidylether crosslinked oxidized starch microgels. They found a
absorption time of 4 h to be sufficient for the microgel to reach saturation during protein
absorption.
In Fig. 9.2B it is demonstrated, how the relative protein uptake of PEG-DA-based hy-
drogels can be increased by addition of the comonomer acrylic acid. Firstly, it can be
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Figure 9.2: PostFabLoading of PEG-DA-based hydrogels with lysozyme: Relative protein
uptake of hydrogels with varying mass fraction of PEG-DA at pH 7 (A), with
75 % PEG-DA and varying mass fraction of the comonomer acrylic acid at
pH 7 (B) and different loading pH values for 75 % PEG-DA and 15 % acrylic
acid (C). 187
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seen that the protein uptake rises more steeply in the first 4 h than without acrylic acid.
This indicates that lysozyme absorbes with higher affinity to hydrogels containing acrylic
acid. This observation can be explained by the introduction of an ionic character to the
hydrogel by the addition of acrylic acid [167]. At pH 7, acrylic acid is negatively charged
due to its pKa of 4.25 [368] while the net charge of lysozyme is positive (pI=11.3 [257]).
Therefore, electrostatic interactions occur between protein and ionized acrylic acid. Sec-
ondly, the protein uptake at saturation increases approximately linearly with increasing
mass fraction of acrylic acid. This linear increase can be explained by the introduction
of exactly one negative charge per molecule acrylic acid into the hydrogel. Doubling the
acrylic acid content therefore leads to a doubling of the binding sites for the protein.
An unlimited increase in the acrylic acid content is, however, not possible, because the
molecule has only one free double bond and thus weakens the network structure of the
hydrogel.
In Fig. 9.2C, the effect of the solution pH on the protein uptake is shown for the bioink
PEG-DA75AA15 containing 75 % PEG-DA and 15 % acrylic acid. When comparing the
three pH values, the lowest protein uptake is achieved at pH 5. The curves of pH 7
and pH 9 are identical within the error bars. Since pH 7 and pH 9 are more than two
pH-steps higher than the pKa value of acrylic acid, a complete deprotonation of all acid
groups can be assumed for both pH values. According to the calculation of the protein
charge with H ++ [369], the net charge of lysozyme is +8 at pH 7 and pH 9. These
assumptions apply to the identical protein uptake curves at pH 7 and pH 9. In contrast,
pH 5 is very close to the pKa value of the acrylic acid. Since the pKa value indicates
the pH value at which 50 % of the acid groups are deprotonated, it is possible that not
all acid groups are deprotonated at pH 5. This would result in a reduced number of
negative charges available to the protein for the interactions, and thus can explain the
lower protein uptake.
9.3.3 Protein Release from Loaded Hydrogels
To study the release profiles for the protein-loaded hydrogels, the hollow cylinders were in-
cubated in different release buffers for 150 min. During this period, samples were regularly
taken and the contained protein was quantified by means of absorption measurements.
The resulting release profiles are displayed in Fig. 9.3 for 0 M and 0.15 M NaCl in the re-
lease buffer. The results for 0.5 M NaCl in the release buffer are displayed Supplementary
Fig. A.10), since they differed only slightly from the results with 0.15 M NaCl.
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In all experiments, PBS behaves as the multicomponent buffer at pH 7 containing 0.15 M
sodium chloride. In Fig. 9.3A-D, the lysozyme release profiles for hydrogel cylinders
consisting of 75 % PEG-DA and 0 % AA (in the bioink) are displayed. These hydro-
gels are uncharged since they are formed exclusively by crosslinking uncharged PEG-DA
chains. For the two loading methods PostFabLoading (Fig. 9.3A and B) and PrintLoading
(Fig. 9.3C and D), neither the pH of the surrounding solution nor the salt concentration
has any influence on the release profile. The transport of the protein therefore appears
to be driven exclusively by diffusive processes. When comparing PostFabLoading and
PrintLoading for a given solution condition, it is noticeable that the maximum protein
released is higher for PrintLoaded hydrogels. This difference can not be attributed to
different concentration gradients since hydrogel cylinders of both loading methods con-
tain the same amount of protein after the loading process. The most probable cause for
the difference in the maximum protein release between PostFabLoaded and PrintLoaded
hydrogels is an unequal swelling state at the beginning of the release experiments. Hy-
drogel water content will affect the release profile because water in the matrix is the
medium through which proteins will diffuse [167]. The PostFabLoaded hydrogels are al-
ready completely swollen due to their storage, equilibrium and protein loading and have
thus reached their equilibrium water content (EWC) [167]. In contrast, the PrintLoaded
hydrogels were only washed for 10 s in ultra-pure water immediately after printing to
reduce uncontrolled protein release during the washing process. The addition of buffer
during the release experiments induced the swelling process and thus led to an increasing
mesh size during the release process. An increased gel mesh size allows more protein to
diffuse out of the hydrogel [366]. The generally low release rates indicate the existence
of intermolecular interactions such as hydrogen bonds or Van-der-Waals forces which
appear to be stronger between lysozyme and PEG-DA than between lysozyme and the
surrounding solution. In case of PrintLoaded hydrogels, covalent binding of the protein
to the gel is also possible by free radical addition or Michael addition between lysine
residues and acrylate groups of the polymer [167, 370]. Since being present during the
printing process, the protein may additionally be enclosed inaccessibly in closed or too
narrow pores.
In Fig. 9.3E and F, lysozyme release profiles from hydrogels containing 75 % PEG-DA and
15 % AA are shown. Comparing Fig. 9.3E and F with Fig. 9.3A and B, it can be seen that
the release of lysozyme from acrylic acid containing hydrogels is slower than from acrylic
acid-free hydrogels. These observations suggest an affinity-based mechanism of release,
as is was already discussed for the protein uptake experiments. For 0 M sodium
189
Chapter 9 High-Throughput Evaluation of Hydrogels
0 10 20 30 40 50 60 70 80 90 1001101201301401500
10
20
30
40
50
60
70
80
90
100
Time [min]
Re
la
tiv
e 
pr
ot
ei
n
 
re
le
as
e 
[%
] pH 3pH 7
pH 9
PBS
0 10 20 30 40 50 60 70 80 90 100110120130140150
0
10
20
30
40
50
60
70
80
90
100
Time [min]
Re
la
tiv
e 
pr
ot
ei
n
 
re
le
a
se
 
[%
] pH 3pH 7
pH 9
PBS
0 10 20 30 40 50 60 70 80 90 100110120130140150
0
10
20
30
40
50
60
70
80
90
100
Time [min]
Re
la
tiv
e 
pr
ot
ei
n
 
re
le
a
se
 
[%
] pH 3pH 7
pH 9
0 10 20 30 40 50 60 70 80 90 1001101201301401500
10
20
30
40
50
60
70
80
90
100
Time [min]
Re
la
tiv
e 
pr
ot
ei
n
 
re
le
as
e 
[%
] pH 3pH 7
pH 9
0 10 20 30 40 50 60 70 80 90 1001101201301401500
10
20
30
40
50
60
70
80
90
100
Time [min]
R
el
at
ive
 
pr
ot
ei
n
 
re
le
as
e 
[%
] pH 3pH 7
pH 9
PBS
0 10 20 30 40 50 60 70 80 90 1001101201301401500
10
20
30
40
50
60
70
80
90
100
Time [min]
R
el
at
ive
 
pr
ot
ei
n
 
re
le
as
e 
[%
] pH 3pH 7
pH 9
75% PEG-DA, 0M NaCl
A
75% PEG-DA, 0M NaCl
C
PostFabLoading, E
B
75% PEG-DA, 0.15M NaCl
D
75% PEG-DA, 0.15M NaCl
F
75% PEG-DA+15% AA, 0M NaCl
PostFabLoading, 
75% PEG-DA+15% AA, 0.15M NaCl
PostFabLading, PostFabLoading, 
PrintLoading, PrintLoading,
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and 15 % AA (E)) and under the influence of 0.15 M NaCl in the release buffer
(PostFabLoaded hydrogels from 75 % PEG-DA (B), PrintLoaded hydrogels
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chloride in the release buffer (Fig. 9.3E), a clear dependency of the protein release on
the pH value of the surrounding solution can be seen. At pH 3, the maximum protein
release is 10 fold greater than at pH 7 and pH 9. Since pH 3 is below the pKa of acrylic
acid, the acid groups in the hydrogel are protonated and thus uncharged. Due to the
pH change of pH 7 during the loading to pH 3 during release, the protein which was
absorbed via electrostatic attraction is released. These results are in accordance with
the work of Zhang and coworkers [366], who have described a fast initial burst release
of proteins at pH 2.0 due to a squeezing mechanism. Since there are no electrostatic
attractions between hydrogel and lysozyme at pH 3, the addition of salt ions (compare
Fig. 9.3F) also has no significant effect on the release. At pH 7 and pH 9, the acid groups
of acrylic acid, however, are deprotonated and thus negatively charged. Since lysozyme
has a net charge of +8 (calculated with H ++ [369]) at both pH 7 and pH 9, the protein
is equally retained in the hydrogel by means of electrostatic interactions. When salt is
added (compare Fig. 9.3F), the salt ions compete with the proteins for the charges of
the hydrogel and displace the proteins. This effect has been discussed by various authors
including Brooks and Cramer [155] in the context of ion exchange chromatography.
9.3.4 Activity Examination of the Released Lysozyme
Following the release studies, the gained samples were examined regarding their residual
enzyme activity compared to native lysozyme. In Fig. 9.4, the determined relative activ-
ity of all samples is shown. The way of carrying out the assay could have led to partially
pronounced standard deviations. Therefore, we defined a relative activity of 100 % ±
10 % as unimpaired preservation of activity. It can be seen, that the buffer conditions of
the release procedure also had an influence on the activity of the released lysozyme in
the diluted assay conditions. For the lysozyme released from PostFabLoading PEG-DA75
a slightly positive effect can be seen for the presence of NaCl in the release buffer but no
reliable statement can be made due to the standard deviations. The positive influence
of the salt could definitely be observed for the release at pH 3 PrintLoading and even
more clearly at pH 7 and pH 9 PostFabLoading PEG-DA75AA15. The salt significantly
alleviated the negative impact on the activity initiated by the loading into acrylic acid
containing hydrogels and the subsequent release with buffers at pH 7 and pH 9. The
lysozyme released in PBS showed a slightly smaller activity than the comparable multi-
component buffer at pH 7 with 0.15 M NaCl. Comparing the two executed approaches
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Figure 9.4: Comparison of the relative activities of released lysozyme relating to the load-
ing method and ink composition.
PostFabLoading and PrintLoading at given pH, a negative impact of the PrintLoad-
ing procedure could be determined. This impact was strongly evident for the released
lysozyme at pH 9.
In order to further investigate the reduced activity, released protein samples from Post-
FabLoaded and PrintLoaded hydrogels without acrylic acid at pH 9 and 0 M NaCl were
analyzed using analytical SEC. The results are displayed in Fig. 9.5. The protein sample
from PostFabLoading resulted in a single peak which could be attributed to a reference
sample of native lysozyme. The protein sample from PrintLoading, however, contained
larger and smaller protein species, which eluted earlier and later than native lysozyme,
respectively. The loss in activity during the PrintLoading process may therefore be at-
tributed to the formation of precipitate and fragments of lysozyme due to the bioink
composition and effects triggered by irradiation. The turbidity of the applied bioink and
resulting hydrogels could serve as a first indication of protein aggregation during the
printing process.
192
9.4 Conclusion
10 15 20 25 30
0
30
60
90
120
150
180
Retention time [min]
A
bs
or
pt
io
n 2
80
 n
m
 
[m
AU
]
 
 
PostFabLoading
PrintLoading
Figure 9.5: Analytical SEC comparing released lysozyme form PostFabLoading and
PrintLoading for PEG-DA-based hydrogels without acrylic acid at pH 9 and
0 M NaCl.
9.4 Conclusion
Protein uptake and release of hydrogels depends on the right combination of hydrogel
materials, protein and surrounding solution conditions. This study has demonstrated that
mechanisms and effects of protein adsorption and release by hydrogels already described
in the literature could be reproduced reliably by the presented combination of 3D printing
and high-throughput screening. Thus, a helpful tool was developed for the rapid and cost-
effective optimization of new hydrogel materials with regard to the physical, biological
and material transport requirements at the site of action. The development of oral delivery
products and implanted reservoir systems for biopharmaceutical proteins may profit from
the here presented approach. In order to further qualify this approach for high-throughput
studies, we are in the process of automating the printing procedure.
Furthermore, the results demonstrated that the direct incorporation of proteins into
the bioinks may lead to the formation of inactive species during the printing process.
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The development of suitable stabilization strategies for hydrogel-based biopharmaceutical
products are therefore of the utmost interest to meet this challenge.
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CHAPTER10
Conclusion and Outlook
The development and production of recombinant protein drugs is hampered by the occur-
rence of protein instabilities. Protein aggregation due to low solubility or unfolding of the
molecule is among the most frequent instabilities. The main focus of this work was the
development of processing and formulation strategies for the production of stable protein
therapeutics. The challenge of laborious empirical process optimizations and the lack of
mechanistic understanding of the underlying protein interactions was addressed by us-
ing high-throughput screening (HTS) methods in miniaturized scale and computer-based
approaches.
In this context, the following stabilization strategies were addressed:
 Addition of stabilizing solution additives
 Covalent attachment of biocompatible polymers (protein conjugation)
 Incorporation into hydrogels
As binary reference system in which aggregation occurs intensively, the model protein
lysozyme (from chicken egg white) under the influence of the salt sodium chloride was
used in all studies. For the unstabilized lysozyme, the phase transitions crystallization,
precipitation and skin formation occur. Skin formation is an indication for protein de-
naturation. [79]
In the first part of the thesis, it was shown that solution additives can alter both the
aggregation behavior and the solubility of proteins. The effect of the investigated additives
was found to depend on the stability of the protein conformation. For system conditions
in which the protein conformation in the binary system was unstable, a stabilization
of the protein conformation could be achieved by the addition of polyethylene glycol
(PEG) and glycerol. However, no change in the protein solubility was observed. For
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system conditions where the protein conformation was stable in the binary system, these
additives exhibited a significant increase in lysozyme solubility.
The ability of PEG to stabilize protein conformation and to increase solubility initiated
the investigation on how the covalent attachment of PEG to the protein (PEGylation)
influences aggregation behavior and solubility. In order to monitor PEGylation reac-
tions and to identify conjugate species with different number of attached PEG molecules
(PEGamers), an HTS-compatible analytical method based on a calibrated capillary gel
electrophoresis was developed. This method was found to be highly effective for large data
sets as it provides a low sample consumption and analysis time, a high resolution allow-
ing for peak baseline separation and a high sensitivity. For structural unstable proteins,
this method was successfully supplemented by a precipitation step for the preservation
of the sample composition. With regard to the stabilization of lysozyme, PEGylation
resulted in a complete suppression of protein denaturation and an enormous increase in
protein solubility. The presented experimental method is a valuable tool to optimize PEG
molecular weight and PEGylation degree with regard to a compromise between increased
conformational and colloid stability and residual protein activity.
While PEG remains useful for the stabilization of therapeutic proteins, some limitations
in its clinical use have begun to emerge driving the development of alternatives. For
this reason, two alternative, biocompatible polymers PNAM and POEGMA were syn-
thesized and investigated for their suitability for protein stabilization. Both polymers
induced an increased solubility compared to unmodified lysozyme. Compared to PEG,
however, higher molecular weight polymers were required to achieve a comparable effect
on solubility, which entailed a significant reduction of residual activity. Nonetheless, it
was demonstrated that the methods for analysis, purification and stability assessment
developed with PEGylated proteins are readily transferable to novel molecular systems.
The presented high-throughput approach hence facilitates and accelerates the search for
more effective and economically viable alternatives.
For the large-scale production of protein conjugates, ion exchange chromatography (IEX)
is one of the most important methods for the separation of differently conjugated species.
In order to transfer chromatographic processes from laboratory to production scale,
knowledge of the underlying mass transfer and adsorption/desorption parameters is con-
ducive. In this thesis, mechanistic chromatography modeling was applied to determine
these parameters based on a small number of experiments. This study demonstrates, that
an increase in PEG molecular weight results in slower film diffusion, faster desorption and
an exponential increase in shielded ligands. These observations help to explain decreased
retention time and binding capacities for PEGylated proteins.
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In the last part of the thesis, functionalized PEG was investigated as a hydrogel material
for the incorporation and release of lysozyme. Hydrogel-based protein delivery systems
have gained momentum in the recent past as they protect the drug from harmful environ-
ments, such as enzymes or the low pH value in the stomach of a human body. However,
chemical structure and molecular weight of the polymer, crosslinking density as well
as surrounding solution conditions influence the diffusion and adsorption of captured
molecules. The diversity of tunable features aggravates a mechanistic prediction of the
protein release from hydrogels. To address this issue, a rapid and cost-effective HTS tool
for the determination of protein release profiles from PEG-based hydrogels was devel-
oped. In order to crosslink the hydrogel precursors to high-throughput compatible struc-
tures, 3D printing was successfully applied for all studied materials. A modification of
protein-hydrogel interactions was achieved both by copolymerization of PEG-diacrylate
and acrylic acid as well as by changing the surrounding solution conditions. In comparison
with literature data, it was shown that the approach presented here leads to verisimilar
data for the used materials and thus constitutes a helpful tool for the development of
hydrogel-based drug delivery systems. During the study, however, protein precipitation
occurred when lysozyme was present during network formation.
In summary, the approaches presented in this work significantly accelerate and simplify
the experimental evaluation of protein stabilities and thus make a valuable contribution
to the development and processing of stable protein therapeutics. Prospective studies will
focus on the integration of protein conjugation and hydrogel formation via 3D printing.
An advantage could be a reduction in the observed instabilities when the protein is
present during network formation. Moreover, protein conjugation using bi-functionalized
polymers is conceivable. This approach would enable the attachment to the protein on
the one end and the incorporation into the polymeric hydrogel network with the other
end. The result would be a one-step immobilization of proteins into hydrogels and thus
the creation of novel hybrid materials having both biological and polymer properties.
In order to crosslink hydrogels to arbitrary three-dimensional geometries, 3D printing
has shown to be a promising tool. The implementation of the proposed concept using
3D printing allows to shape these functional hybrid materials into technically relevant
objects such as patient-specific implants, bioreactors or biosensors.
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Abbreviations and parameters
Abbreviations
3D three-dimensional
AA acrylic acid
Abs absorption
API active pharmaceutical ingredient
ASA adaptive simulated annealing
BCM barycentric mean fluorescence
BMBF Bundesministerium fu¨r Bildung und Forschung
= German Federal Ministry of Education and Research
CAD computer-aided design
CGE capillary gel electrophoresis
CEX cation-exchange chromatography
CMC critical micelle concentration
CQA critical quality attributes
CV column volumes
Cys cysteine
DDS drug delivery system
DLP digital light processing
DMPA 2,2-Dimethoxy-2-phenylacetophenone
DoE Design of Experiments
DSP downstream processing
EO ethylene oxide
EWC equilibrium water content
FDA Food and Drug Administration
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FT-IR Fourier-Transformed-Infrared
G-CSF granulocyte colonystimulating factor
Gln glutamine
GMO genetically modified organism
GRM general rate model
HIC hydrophobic interaction chromatography
HT-CGE high-throughput capillary gel electrophoresis
HTS high-throughput screening
IEX ion-exchange chromatography
LC liquid chromatography
LGE linear gradient elution
LM Levenberg-Marquardt
Lys lysine
mAb monoclonal antibodies
MALDI-TOF Matrix-Assisted Laser Desorption Ionization–Time of Flight
MD molecular dynamic
MIE Molecular Interaction Engineering
MS mass spectrometry
NaCl sodium chloride
NHS N-Hydroxysuccinimide
NMR Nuclear Magnetic Resonance
PBS phosphate buffered saline
PEG polyethylene glycol
PEG-DA polyethylene glycol-diacrylate
pI isoelectric point
PLA polylactic acid
PNAM poly-(N-acryloylmorpholine)
POEGMA poly-(oligo(ethylene glycol)methacrylate
PVA poly(vinyl alcohol)
PVP polyvinylpyrrolidone
QbD Quality by Design
RAFT reversible addition-fragmentation chain transfer
SDM stoichiometric displacement model
SDS sodium dodecyl sulfate
SEC size-exclusion chromatography
SLA sterolithography
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SMA steric mass action
TCA trichloroacetic acid
tPA tissue plasminogen activator
Tyr tyrosine
USP upstream processing
UV ultraviolet
vdW van-der-Waals
vis visible
Parameters
a activity (effective concentration)
c concentration
Dax axial dispersion coefficient
Dp pore diffusion coefficient
d diameter
F force
G Gibbs free energy
H enthalpy
Ha Hamaker constant
kads adsorption coefficient
kdes desorption coefficient
ke Coulomb’s constant
keq equilibrium coefficient
kfilm film diffusion coefficient
kkin reaction velocity coefficient
Q charge
q concentration on the stationary phase
R universal gas constant
r radial pore position or ratio
rp particle radius
S entropy
Sa activity-related supersaturation
Sc concentration-related supersaturation
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T temperature
Tm melting temperature
t time
u flow velocity
x distance or position
Greek symbols
γ activity coefficient
ε extinction coefficient
εb bed porosity
µ˜ molar chemical potential
ν characteristic binding charge
σ steric shielding factor or standard deviation
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Supplementary Figure A.1: Absorption spectra of native, mono-PEGylated and di-
PEGylated Lysozyme (A) and of native, mono-PEGylated
and di-PEGylated Savinase (B) normalized to 280nm.
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Supplementary Figure A.2: Absorption spectra of lysozmye, PNAM7kDa and
POEGMA7.5kDa normalized to their absorption maxi-
mum.
Supplementary Figure A.3: THF-SEC traces of the synthesized polymers PNAM3.5kDa,
PNAM7kDa, POEGMA7.5kDa.
Appendix A Supplementary Figures
Supplementary Figure A.4: 1H NMR spectrum of the purified PNAM3.5kDa.
Supplementary Figure A.5: 1H NMR spectrum of the purified PNAM7kDa.
Supplementary Figure A.6: 1H NMR spectrum of the purified POEGMA7.5kDa.
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Supplementary Figure A.7: Analysis of the purified POEGMA-lysozyme conjugates us-
ing high-throughput capillary gel electrophoresis (HT-CGE)
according to Morgenstern et al. [281].
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Supplementary Figure A.8: SEC chromatograms of the POEGMA conjugation
batch (A) and the purified species of native lysozyme
(B), mono-conjugated lysozyme (C) and di-conjugated
lysozyme (D). The separation was performed on a Su-
perdex200Increase 10/300 (GE Healthcare, Uppsala,
Sweden) using a 25 mM sodium phosphate buffer with 150
mM sodium chloride at pH 7.2.
Supplementary Figure A.9: HT-CGE fluorescence signals of native lysozyme as well as
lysozyme attached with 2 kDa PEG, 5 kDa PEG, and 10 kDa
PEG. All protein concentrations were set to 6.99·10−5 M.
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Supplementary Figure A.10: Relative protein release under the influence of 0.5 M NaCl
in the release buffer: PostFabLoaded hydrogels from 75 %
PEG-DA (A), PrintLoaded hydrogels from 75 % PEG-DA
(B) and PostFabLoaded hydrogels from 75 % PEG-DA and
15 % AA (C).
